| ![]() | |||||||||||
![]() |
|
|||||||||||
Misuse of Prescription Drugs |
51020
Drug | TIME PERIOD | ||||||||
---|---|---|---|---|---|---|---|---|---|
Lifetime | Past Year | Past Month | |||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
Numbers in Thousands | |||||||||
*Low precision; no estimate reported. -- Not available. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||||||
Nonmedical Use of Psychotherapeutics1 | 46,558 | 47,882 | 48,013 | 14,680 | 14,986 | 14,643 | 6,210 | 6,336 | 6,007 |
Pain Relievers | 29,611a | 31,207 | 31,768 | 10,992 | 11,671 | 11,256 | 4,377 | 4,693 | 4,404 |
OxyContin® | 1,924b | 2,832 | 3,072 | -- | -- | 1,213 | -- | -- | 325 |
Tranquilizers | 19,267 | 20,220 | 19,852 | 4,849 | 5,051 | 5,068 | 1,804 | 1,830 | 1,616 |
Stimulants | 21,072 | 20,798 | 19,982 | 3,181 | 2,751 | 2,918 | 1,218 | 1,191 | 1,189 |
Methamphetamine | 12,383 | 12,303 | 11,726 | 1,541 | 1,315 | 1,440 | 597 | 607 | 583 |
Sedatives | 9,960 | 9,510 | 9,891 | 981 | 831 | 737 | 436a | 294 | 265 |
Drug | Percentages | ||||||||
Nonmedical Use of Psychotherapeutics1 | 19.8 | 20.1 | 20.0 | 6.2 | 6.3 | 6.1 | 2.6 | 2.7 | 2.5 |
Pain Relievers | 12.6 | 13.1 | 13.2 | 4.7 | 4.9 | 4.7 | 1.9 | 2.0 | 1.8 |
OxyContin® | 0.8b | 1.2 | 1.3 | -- | -- | 0.5 | -- | -- | 0.1 |
Tranquilizers | 8.2 | 8.5 | 8.3 | 2.1 | 2.1 | 2.1 | 0.8 | 0.8 | 0.7 |
Stimulants | 9.0a | 8.8 | 8.3 | 1.4 | 1.2 | 1.2 | 0.5 | 0.5 | 0.5 |
Methamphetamine | 5.3 | 5.2 | 4.9 | 0.7 | 0.6 | 0.6 | 0.3 | 0.3 | 0.2 |
Sedatives | 4.2 | 4.0 | 4.1 | 0.4 | 0.3 | 0.3 | 0.2a | 0.1 | 0.1 |
51020
Drug | TIME PERIOD | ||||||||
---|---|---|---|---|---|---|---|---|---|
Lifetime | Past Year | Past Month | |||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
Numbers in Thousands | |||||||||
*Low precision; no estimate reported. -- Not available. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||||||
Nonmedical Use of Psychotherapeutics1 | 3,389 | 3,351 | 3,394 | 2,283 | 2,289 | 2,225 | 979 | 997 | 914 |
Pain Relievers | 2,775 | 2,798 | 2,879 | 1,870 | 1,917 | 1,865 | 794 | 801 | 751 |
OxyContin® | 224b | 254 | 305 | -- | -- | 194 | -- | -- | 66 |
Tranquilizers | 834 | 874 | 816 | 568 | 586 | 532 | 188 | 226a | 161 |
Stimulants | 1,074b | 1,007a | 867 | 650b | 568 | 496 | 200 | 221 | 178 |
Methamphetamine | 366 | 328 | 299 | 226a | 174 | 163 | 63 | 69 | 57 |
Sedatives | 238 | 249 | 251 | 138 | 131 | 133 | 47a | 47 | 26 |
Drug | Percentages | ||||||||
Nonmedical Use of Psychotherapeutics1 | 13.7 | 13.4 | 13.5 | 9.2 | 9.2 | 8.8 | 4.0 | 4.0 | 3.6 |
Pain Relievers | 11.2 | 11.2 | 11.4 | 7.6 | 7.7 | 7.4 | 3.2 | 3.2 | 3.0 |
OxyContin® | 0.9a | 1.0 | 1.2 | -- | -- | 0.8 | -- | -- | 0.3 |
Tranquilizers | 3.4 | 3.5 | 3.2 | 2.3 | 2.3 | 2.1 | 0.8 | 0.9a | 0.6 |
Stimulants | 4.3b | 4.0b | 3.4 | 2.6b | 2.3 | 2.0 | 0.8 | 0.9 | 0.7 |
Methamphetamine | 1.5a | 1.3 | 1.2 | 0.9a | 0.7 | 0.6 | 0.3 | 0.3 | 0.2 |
Sedatives | 1.0 | 1.0 | 1.0 | 0.6 | 0.5 | 0.5 | 0.2a | 0.2 | 0.1 |
51020
Drug | TIME PERIOD | ||||||||
---|---|---|---|---|---|---|---|---|---|
Lifetime | Past Year | Past Month | |||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
Numbers in Thousands | |||||||||
*Low precision; no estimate reported. -- Not available. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||||||
Nonmedical Use of Psychotherapeutics1 | 8,587b | 9,211 | 9,392 | 4,411a | 4,598 | 4,751 | 1,683b | 1,913 | 1,959 |
Pain Relievers | 6,854b | 7,513 | 7,813 | 3,540a | 3,803 | 3,834 | 1,262b | 1,486 | 1,504 |
OxyContin® | 820b | 1,145b | 1,376 | -- | -- | 562 | -- | -- | 142 |
Tranquilizers | 3,473b | 3,898 | 3,919 | 1,509 | 1,682 | 1,658 | 487 | 525 | 566 |
Stimulants | 3,340 | 3,420 | 3,426 | 1,144 | 1,114 | 1,181 | 386 | 400 | 446 |
Methamphetamine | 1,756 | 1,650 | 1,688 | 525 | 506 | 516 | 160 | 185 | 186 |
Sedatives | 648 | 565 | 627 | 162 | 156 | 163 | 49 | 58 | 49 |
Drug | Percentages | ||||||||
Nonmedical Use of Psychotherapeutics1 | 27.7a | 29.0 | 29.2 | 14.2 | 14.5 | 14.8 | 5.4a | 6.0 | 6.1 |
Pain Relievers | 22.1b | 23.7 | 24.3 | 11.4 | 12.0 | 11.9 | 4.1a | 4.7 | 4.7 |
OxyContin® | 2.6b | 3.6b | 4.3 | -- | -- | 1.7 | -- | -- | 0.4 |
Tranquilizers | 11.2a | 12.3 | 12.2 | 4.9 | 5.3 | 5.2 | 1.6 | 1.7 | 1.8 |
Stimulants | 10.8 | 10.8 | 10.6 | 3.7 | 3.5 | 3.7 | 1.2 | 1.3 | 1.4 |
Methamphetamine | 5.7 | 5.2 | 5.2 | 1.7 | 1.6 | 1.6 | 0.5 | 0.6 | 0.6 |
Sedatives | 2.1 | 1.8 | 1.9 | 0.5 | 0.5 | 0.5 | 0.2 | 0.2 | 0.2 |
51020
Drug | TIME PERIOD | ||||||||
---|---|---|---|---|---|---|---|---|---|
Lifetime | Past Year | Past Month | |||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
Numbers in Thousands | |||||||||
*Low precision; no estimate reported. -- Not available. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||||||
Nonmedical Use of Psychotherapeutics1 | 34,582 | 35,320 | 35,227 | 7,986 | 8,099 | 7,667 | 3,549 | 3,426 | 3,134 |
Pain Relievers | 19,983 | 20,896 | 21,076 | 5,582 | 5,950 | 5,556 | 2,321 | 2,406 | 2,149 |
OxyContin® | 881b | 1,433 | 1,392 | -- | -- | 457 | -- | -- | 118 |
Tranquilizers | 14,959 | 15,447 | 15,117 | 2,772 | 2,783 | 2,878 | 1,129 | 1,078 | 889 |
Stimulants | 16,658 | 16,371 | 15,689 | 1,387 | 1,068 | 1,241 | 631 | 570 | 565 |
Methamphetamine | 10,261 | 10,325 | 9,739 | 790 | 636 | 761 | 375 | 353 | 340 |
Sedatives | 9,075 | 8,696 | 9,012 | 681 | 544 | 441 | 340 | 189 | 190 |
Drug | Percentages | ||||||||
Nonmedical Use of Psychotherapeutics1 | 19.3 | 19.5 | 19.2 | 4.5 | 4.5 | 4.2 | 2.0 | 1.9 | 1.7 |
Pain Relievers | 11.1 | 11.5 | 11.5 | 3.1 | 3.3 | 3.0 | 1.3 | 1.3 | 1.2 |
OxyContin® | 0.5b | 0.8 | 0.8 | -- | -- | 0.2 | -- | -- | 0.1 |
Tranquilizers | 8.3 | 8.5 | 8.3 | 1.5 | 1.5 | 1.6 | 0.6 | 0.6 | 0.5 |
Stimulants | 9.3a | 9.0 | 8.6 | 0.8 | 0.6 | 0.7 | 0.4 | 0.3 | 0.3 |
Methamphetamine | 5.7 | 5.7 | 5.3 | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 |
Sedatives | 5.1 | 4.8 | 4.9 | 0.4 | 0.3 | 0.2 | 0.2a | 0.1 | 0.1 |
51020
Drug | TIME PERIOD | ||||||||
---|---|---|---|---|---|---|---|---|---|
Lifetime | Past Year | Past Month | |||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
Numbers in Thousands | |||||||||
*Low precision; no estimate reported. -- Not available. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||||||
Nonmedical Use of Psychotherapeutics1 | 24,371 | 24,844 | 25,503 | 7,472 | 7,559 | 7,460 | 3,086 | 3,123 | 3,019 |
Pain Relievers | 16,237 | 16,824 | 17,273 | 5,917 | 6,121 | 5,903 | 2,303 | 2,416 | 2,187 |
OxyContin® | 1,161b | 1,804 | 1,938 | -- | -- | 741 | -- | -- | 177 |
Tranquilizers | 10,051 | 10,159 | 10,551 | 2,390 | 2,498 | 2,399 | 829 | 818 | 810 |
Stimulants | 11,703 | 11,273 | 11,211 | 1,659 | 1,399 | 1,563 | 652 | 633 | 604 |
Methamphetamine | 7,401 | 7,363 | 6,985 | 859 | 778 | 889 | 343 | 398 | 300 |
Sedatives | 5,653 | 5,590 | 5,499 | 490 | 323 | 317 | 196 | 99 | 103 |
Drug | Percentages | ||||||||
Nonmedical Use of Psychotherapeutics1 | 21.5 | 21.6 | 21.9 | 6.6 | 6.6 | 6.4 | 2.7 | 2.7 | 2.6 |
Pain Relievers | 14.3 | 14.6 | 14.8 | 5.2 | 5.3 | 5.1 | 2.0 | 2.1 | 1.9 |
OxyContin® | 1.0b | 1.6 | 1.7 | -- | -- | 0.6 | -- | -- | 0.2 |
Tranquilizers | 8.8 | 8.8 | 9.1 | 2.1 | 2.2 | 2.1 | 0.7 | 0.7 | 0.7 |
Stimulants | 10.3 | 9.8 | 9.6 | 1.5 | 1.2 | 1.3 | 0.6 | 0.6 | 0.5 |
Methamphetamine | 6.5 | 6.4 | 6.0 | 0.8 | 0.7 | 0.8 | 0.3 | 0.3 | 0.3 |
Sedatives | 5.0 | 4.9 | 4.7 | 0.4 | 0.3 | 0.3 | 0.2a | 0.1 | 0.1 |
51020
Drug | TIME PERIOD | ||||||||
---|---|---|---|---|---|---|---|---|---|
Lifetime | Past Year | Past Month | |||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
Numbers in Thousands | |||||||||
*Low precision; no estimate reported. -- Not available. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||||||
Nonmedical Use of Psychotherapeutics1 | 22,187 | 23,038 | 22,510 | 7,208 | 7,427 | 7,183 | 3,125 | 3,213 | 2,988 |
Pain Relievers | 13,374a | 14,383 | 14,496 | 5,075 | 5,549 | 5,353 | 2,075 | 2,277 | 2,217 |
OxyContin® | 763b | 1,029 | 1,134 | -- | -- | 472 | -- | -- | 148 |
Tranquilizers | 9,216 | 10,061 | 9,302 | 2,458 | 2,553 | 2,669 | 975 | 1,012 | 806 |
Stimulants | 9,369 | 9,525 | 8,770 | 1,522 | 1,352 | 1,355 | 566 | 558 | 585 |
Methamphetamine | 4,982 | 4,941 | 4,741 | 682 | 537 | 551 | 254 | 210 | 282 |
Sedatives | 4,308 | 3,921 | 4,392 | 490 | 509 | 420 | 241 | 195 | 162 |
Drug | Percentages | ||||||||
Nonmedical Use of Psychotherapeutics1 | 18.3 | 18.8 | 18.1 | 5.9 | 6.1 | 5.8 | 2.6 | 2.6 | 2.4 |
Pain Relievers | 11.0 | 11.7 | 11.7 | 4.2 | 4.5 | 4.3 | 1.7 | 1.9 | 1.8 |
OxyContin® | 0.6b | 0.8 | 0.9 | -- | -- | 0.4 | -- | -- | 0.1 |
Tranquilizers | 7.6 | 8.2 | 7.5 | 2.0 | 2.1 | 2.2 | 0.8 | 0.8 | 0.6 |
Stimulants | 7.7 | 7.8 | 7.1 | 1.3 | 1.1 | 1.1 | 0.5 | 0.5 | 0.5 |
Methamphetamine | 4.1 | 4.0 | 3.8 | 0.6 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 |
Sedatives | 3.5 | 3.2 | 3.5 | 0.4 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 |
51020
Age Category | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 14,769 | 11,306 | 4,989 | 2,950 | 1,432 | 850 |
12 | 122 | 101 | 14 | 18 | 3 | 9 |
13 | 215 | 180 | 25 | 42 | 11 | 19 |
14 | 323 | 274 | 61 | 73 | 24 | 20 |
15 | 437 | 358 | 104 | 126 | 46 | 28 |
16 | 546 | 454 | 160 | 148 | 46 | 34 |
17 | 623 | 518 | 198 | 165 | 57 | 25 |
18 | 715 | 610 | 214 | 171 | 68 | 26 |
19 | 680 | 553 | 224 | 191 | 76 | 17 |
20 | 641 | 520 | 227 | 170 | 56 | 19 |
21 | 616 | 498 | 228 | 172 | 81 | 25 |
22 | 565 | 444 | 204 | 140 | 62 | 23 |
23 | 525 | 430 | 197 | 126 | 70 | 21 |
24 | 474 | 388 | 180 | 99 | 58 | 17 |
25 | 372 | 284 | 141 | 77 | 46 | 14 |
26-29 | 1,531 | 1,176 | 553 | 257 | 150 | 72 |
30-34 | 1,407 | 1,038 | 493 | 269 | 180 | 71 |
35-39 | 1,374 | 982 | 470 | 201 | 139 | 91 |
40-44 | 1,268 | 907 | 446 | 226 | 123 | 92 |
45-49 | 1,115 | 779 | 384 | 166 | 106 | 97 |
50-54 | 517 | 371 | 208 | 58 | 14 | 55 |
55-59 | 273 | 183 | 119 | 16 | 14 | 30 |
60-64 | 218 | 125 | 83 | 8 | 4 | 17 |
65+ | 214 | 134 | 55 | 30 | * | 31 |
51020
Age Category | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 6.2 | 4.8 | 2.1 | 1.2 | 0.6 | 0.4 |
12 | 3.0 | 2.5 | 0.4 | 0.4 | 0.1 | 0.2 |
13 | 5.0 | 4.2 | 0.6 | 1.0 | 0.3 | 0.4 |
14 | 7.5 | 6.4 | 1.4 | 1.7 | 0.5 | 0.5 |
15 | 10.5 | 8.6 | 2.5 | 3.0 | 1.1 | 0.7 |
16 | 13.3 | 11.0 | 3.9 | 3.6 | 1.1 | 0.8 |
17 | 15.4 | 12.8 | 4.9 | 4.1 | 1.4 | 0.6 |
18 | 15.8 | 13.5 | 4.7 | 3.8 | 1.5 | 0.6 |
19 | 17.1 | 13.9 | 5.7 | 4.8 | 1.9 | 0.4 |
20 | 16.0 | 13.0 | 5.7 | 4.2 | 1.4 | 0.5 |
21 | 15.3 | 12.4 | 5.7 | 4.3 | 2.0 | 0.6 |
22 | 14.2 | 11.2 | 5.1 | 3.5 | 1.6 | 0.6 |
23 | 13.4 | 11.0 | 5.0 | 3.2 | 1.8 | 0.5 |
24 | 12.7 | 10.4 | 4.8 | 2.7 | 1.5 | 0.5 |
25 | 10.6 | 8.1 | 4.0 | 2.2 | 1.3 | 0.4 |
26-29 | 10.1 | 7.8 | 3.7 | 1.7 | 1.0 | 0.5 |
30-34 | 7.1 | 5.2 | 2.5 | 1.4 | 0.9 | 0.4 |
35-39 | 6.5 | 4.6 | 2.2 | 0.9 | 0.7 | 0.4 |
40-44 | 5.7 | 4.0 | 2.0 | 1.0 | 0.5 | 0.4 |
45-49 | 5.2 | 3.6 | 1.8 | 0.8 | 0.5 | 0.5 |
50-54 | 2.7 | 1.9 | 1.1 | 0.3 | 0.1 | 0.3 |
55-59 | 1.8 | 1.2 | 0.8 | 0.1 | 0.1 | 0.2 |
60-64 | 1.8 | 1.0 | 0.7 | 0.1 | 0.0 | 0.1 |
65+ | 0.6 | 0.4 | 0.2 | 0.1 | * | 0.1 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 14,769 | 11,306 | 4,989 | 2,950 | 1,432 | 850 |
AGE | ||||||
12-17 | 2,266 | 1,884 | 562 | 571 | 187 | 134 |
18-25 | 4,587 | 3,726 | 1,616 | 1,147 | 516 | 160 |
26 or Older | 7,917 | 5,696 | 2,811 | 1,232 | 729 | 555 |
GENDER | ||||||
Male | 7,497 | 5,980 | 2,429 | 1,540 | 842 | 377 |
Female | 7,272 | 5,326 | 2,560 | 1,410 | 590 | 473 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 12,883 | 9,807 | 4,547 | 2,693 | 1,280 | 790 |
White | 11,151 | 8,395 | 4,167 | 2,424 | 1,141 | 711 |
Black or African American | 1,079 | 931 | 168 | 107 | 33 | 48 |
American Indian or Alaska Native | 109 | 75 | 44 | 32 | 22 | 6 |
Native Hawaiian or Other Pacific Islander | 66 | 47 | 8 | 21 | 14 | 5 |
Asian | 287 | 216 | 80 | 38 | 20 | 7 |
Two or More Races | 192 | 143 | 80 | 71 | 49 | 14 |
Hispanic or Latino | 1,886 | 1,499 | 443 | 257 | 151 | 59 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 6.2 | 4.8 | 2.1 | 1.2 | 0.6 | 0.4 |
AGE | ||||||
12-17 | 9.1 | 7.5 | 2.2 | 2.3 | 0.7 | 0.5 |
18-25 | 14.5 | 11.8 | 5.1 | 3.6 | 1.6 | 0.5 |
26 or Older | 4.4 | 3.1 | 1.6 | 0.7 | 0.4 | 0.3 |
GENDER | ||||||
Male | 6.5 | 5.2 | 2.1 | 1.3 | 0.7 | 0.3 |
Female | 5.9 | 4.3 | 2.1 | 1.1 | 0.5 | 0.4 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 6.2 | 4.7 | 2.2 | 1.3 | 0.6 | 0.4 |
White | 6.7 | 5.1 | 2.5 | 1.5 | 0.7 | 0.4 |
Black or African American | 3.9 | 3.4 | 0.6 | 0.4 | 0.1 | 0.2 |
American Indian or Alaska Native | 8.1 | 5.6 | 3.3 | 2.4 | 1.7 | 0.4 |
Native Hawaiian or Other Pacific Islander | 10.1 | 7.2 | 1.2 | 3.3 | 2.2 | 0.8 |
Asian | 3.0 | 2.3 | 0.8 | 0.4 | 0.2 | 0.1 |
Two or More Races | 7.5 | 5.6 | 3.1 | 2.8 | 1.9 | 0.5 |
Hispanic or Latino | 6.3 | 5.0 | 1.5 | 0.9 | 0.5 | 0.2 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 2,266 | 1,884 | 562 | 571 | 187 | 134 |
GENDER | ||||||
Male | 1,051 | 893 | 244 | 249 | 78 | 57 |
Female | 1,214 | 991 | 318 | 323 | 110 | 77 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 1,923 | 1,598 | 483 | 509 | 155 | 117 |
White | 1,580 | 1,300 | 439 | 456 | 138 | 92 |
Black or African American | 229 | 206 | 15 | 24 | 4 | 16 |
American Indian or Alaska Native | 27 | 22 | 8 | 8 | 6 | 2 |
Native Hawaiian or Other Pacific Islander | 7 | 6 | * | 4 | 1 | * |
Asian | 40 | 32 | 9 | 7 | 3 | 2 |
Two or More Races | 39 | 33 | 11 | 10 | 3 | 3 |
Hispanic or Latino | 342 | 286 | 79 | 62 | 32 | 17 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 9.1 | 7.5 | 2.2 | 2.3 | 0.7 | 0.5 |
GENDER | ||||||
Male | 8.2 | 7.0 | 1.9 | 1.9 | 0.6 | 0.4 |
Female | 9.9 | 8.1 | 2.6 | 2.6 | 0.9 | 0.6 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 9.2 | 7.6 | 2.3 | 2.4 | 0.7 | 0.6 |
White | 10.2 | 8.4 | 2.8 | 2.9 | 0.9 | 0.6 |
Black or African American | 6.2 | 5.5 | 0.4 | 0.6 | 0.1 | 0.4 |
American Indian or Alaska Native | 15.2 | 12.2 | 4.6 | 4.5 | 3.6 | 1.3 |
Native Hawaiian or Other Pacific Islander | 9.9 | 7.9 | * | 5.2 | 0.8 | * |
Asian | 4.1 | 3.3 | 0.9 | 0.7 | 0.3 | 0.2 |
Two or More Races | 9.6 | 8.1 | 2.6 | 2.4 | 0.6 | 0.7 |
Hispanic or Latino | 8.4 | 7.0 | 1.9 | 1.5 | 0.8 | 0.4 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Retired persons, disabled persons, homemakers, students, or other persons not in the labor force are included in the Other Employment category. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 4,587 | 3,726 | 1,616 | 1,147 | 516 | 160 |
GENDER | ||||||
Male | 2,481 | 2,084 | 854 | 616 | 290 | 82 |
Female | 2,106 | 1,641 | 762 | 530 | 225 | 78 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 4,004 | 3,263 | 1,456 | 1,029 | 447 | 139 |
White | 3,500 | 2,839 | 1,344 | 933 | 403 | 127 |
Black or African American | 292 | 262 | 53 | 34 | 8 | 5 |
American Indian or Alaska Native | 36 | 25 | 13 | 16 | 12 | 1 |
Native Hawaiian or Other Pacific Islander | 17 | 14 | 2 | 4 | 3 | 0 |
Asian | 87 | 69 | 18 | 20 | 6 | 3 |
Two or More Races | 72 | 54 | 26 | 23 | 15 | 3 |
Hispanic or Latino | 583 | 463 | 160 | 117 | 69 | 22 |
EDUCATION | ||||||
< High School | 1,097 | 920 | 385 | 239 | 154 | 33 |
High School Graduate | 1,526 | 1,248 | 520 | 368 | 206 | 56 |
Some College | 1,533 | 1,221 | 552 | 432 | 132 | 53 |
College Graduate | 430 | 337 | 159 | 107 | 23 | 19 |
CURRENT EMPLOYMENT | ||||||
Full-Time | 2,056 | 1,699 | 736 | 446 | 222 | 66 |
Part-Time | 1,200 | 971 | 398 | 318 | 105 | 45 |
Unemployed | 486 | 388 | 197 | 145 | 92 | 19 |
Other1 | 845 | 668 | 285 | 237 | 97 | 31 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Retired persons, disabled persons, homemakers, students, or other persons not in the labor force are included in the Other Employment category. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 14.5 | 11.8 | 5.1 | 3.6 | 1.6 | 0.5 |
GENDER | ||||||
Male | 15.6 | 13.1 | 5.4 | 3.9 | 1.8 | 0.5 |
Female | 13.3 | 10.4 | 4.8 | 3.4 | 1.4 | 0.5 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 15.4 | 12.5 | 5.6 | 4.0 | 1.7 | 0.5 |
White | 17.8 | 14.5 | 6.8 | 4.8 | 2.1 | 0.6 |
Black or African American | 6.9 | 6.2 | 1.2 | 0.8 | 0.2 | 0.1 |
American Indian or Alaska Native | 18.9 | 13.1 | 7.0 | 8.7 | 6.5 | 0.6 |
Native Hawaiian or Other Pacific Islander | 11.4 | 9.1 | 1.5 | 2.5 | 2.0 | 0.1 |
Asian | 6.0 | 4.7 | 1.3 | 1.4 | 0.4 | 0.2 |
Two or More Races | 19.3 | 14.5 | 7.0 | 6.1 | 3.9 | 0.8 |
Hispanic or Latino | 10.4 | 8.2 | 2.8 | 2.1 | 1.2 | 0.4 |
EDUCATION | ||||||
< High School | 16.1 | 13.5 | 5.6 | 3.5 | 2.3 | 0.5 |
High School Graduate | 14.0 | 11.5 | 4.8 | 3.4 | 1.9 | 0.5 |
Some College | 15.3 | 12.2 | 5.5 | 4.3 | 1.3 | 0.5 |
College Graduate | 10.8 | 8.5 | 4.0 | 2.7 | 0.6 | 0.5 |
CURRENT EMPLOYMENT | ||||||
Full-Time | 14.0 | 11.5 | 5.0 | 3.0 | 1.5 | 0.4 |
Part-Time | 14.9 | 12.0 | 4.9 | 3.9 | 1.3 | 0.6 |
Unemployed | 18.9 | 15.1 | 7.7 | 5.6 | 3.6 | 0.7 |
Other1 | 13.5 | 10.6 | 4.5 | 3.8 | 1.5 | 0.5 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Retired persons, disabled persons, homemakers, students, or other persons not in the labor force are included in the Other Employment category. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 7,917 | 5,696 | 2,811 | 1,232 | 729 | 555 |
GENDER | ||||||
Male | 3,965 | 3,003 | 1,331 | 675 | 474 | 237 |
Female | 3,952 | 2,694 | 1,480 | 557 | 255 | 318 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 6,956 | 4,946 | 2,607 | 1,155 | 678 | 534 |
White | 6,071 | 4,257 | 2,384 | 1,035 | 600 | 492 |
Black or African American | 557 | 463 | 101 | 49 | 21 | 27 |
American Indian or Alaska Native | 46 | 29 | 22 | 8 | 4 | 2 |
Native Hawaiian or Other Pacific Islander | 41 | 27 | 4 | 14 | * | * |
Asian | 160 | 115 | 53 | 11 | 11 | 2 |
Two or More Races | 81 | 56 | 43 | 38 | 32 | 8 |
Hispanic or Latino | 962 | 750 | 204 | 77 | 50 | 21 |
EDUCATION | ||||||
< High School | 1,356 | 1,067 | 436 | 221 | 152 | 77 |
High School Graduate | 2,499 | 1,802 | 876 | 453 | 287 | 163 |
Some College | 2,201 | 1,600 | 768 | 365 | 221 | 151 |
College Graduate | 1,860 | 1,227 | 731 | 193 | 69 | 164 |
CURRENT EMPLOYMENT | ||||||
Full-Time | 5,061 | 3,714 | 1,711 | 712 | 425 | 316 |
Part-Time | 982 | 627 | 362 | 183 | 103 | 56 |
Unemployed | 478 | 378 | 209 | 123 | 79 | 72 |
Other1 | 1,397 | 978 | 528 | 215 | 121 | 111 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Retired persons, disabled persons, homemakers, students, or other persons not in the labor force are included in the Other Employment category. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 4.4 | 3.1 | 1.6 | 0.7 | 0.4 | 0.3 |
GENDER | ||||||
Male | 4.6 | 3.5 | 1.5 | 0.8 | 0.5 | 0.3 |
Female | 4.2 | 2.8 | 1.6 | 0.6 | 0.3 | 0.3 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 4.3 | 3.1 | 1.6 | 0.7 | 0.4 | 0.3 |
White | 4.6 | 3.2 | 1.8 | 0.8 | 0.5 | 0.4 |
Black or African American | 2.9 | 2.4 | 0.5 | 0.3 | 0.1 | 0.1 |
American Indian or Alaska Native | 4.7 | 2.9 | 2.3 | 0.8 | 0.4 | 0.2 |
Native Hawaiian or Other Pacific Islander | 9.8 | 6.4 | 1.0 | 3.3 | * | * |
Asian | 2.2 | 1.6 | 0.7 | 0.1 | 0.1 | 0.0 |
Two or More Races | 4.6 | 3.2 | 2.4 | 2.2 | 1.8 | 0.4 |
Hispanic or Latino | 4.7 | 3.7 | 1.0 | 0.4 | 0.2 | 0.1 |
EDUCATION | ||||||
< High School | 4.5 | 3.5 | 1.4 | 0.7 | 0.5 | 0.3 |
High School Graduate | 4.4 | 3.2 | 1.5 | 0.8 | 0.5 | 0.3 |
Some College | 5.1 | 3.7 | 1.8 | 0.8 | 0.5 | 0.3 |
College Graduate | 3.7 | 2.4 | 1.4 | 0.4 | 0.1 | 0.3 |
CURRENT EMPLOYMENT | ||||||
Full-Time | 4.9 | 3.6 | 1.7 | 0.7 | 0.4 | 0.3 |
Part-Time | 5.0 | 3.2 | 1.8 | 0.9 | 0.5 | 0.3 |
Unemployed | 9.4 | 7.4 | 4.1 | 2.4 | 1.6 | 1.4 |
Other1 | 2.6 | 1.8 | 1.0 | 0.4 | 0.2 | 0.2 |
51128
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Retired persons, disabled persons, homemakers, students, or other persons not in the labor force are included in the Other Employment category. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 12,504 | 9,422 | 4,427 | 2,379 | 1,244 | 716 |
GENDER | ||||||
Male | 6,446 | 5,087 | 2,185 | 1,291 | 764 | 320 |
Female | 6,058 | 4,335 | 2,243 | 1,087 | 480 | 396 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 10,960 | 8,209 | 4,064 | 2,184 | 1,125 | 673 |
White | 9,571 | 7,096 | 3,728 | 1,968 | 1,003 | 619 |
Black or African American | 849 | 726 | 153 | 83 | 29 | 31 |
American Indian or Alaska Native | 82 | 54 | 36 | 24 | 16 | 3 |
Native Hawaiian or Other Pacific Islander | 58 | 41 | 6 | 17 | 13 | * |
Asian | 247 | 184 | 71 | 30 | 17 | 5 |
Two or More Races | 152 | 110 | 69 | 61 | 46 | 11 |
Hispanic or Latino | 1,544 | 1,213 | 364 | 194 | 119 | 43 |
EDUCATION | ||||||
< High School | 2,453 | 1,987 | 821 | 460 | 307 | 109 |
High School Graduate | 4,026 | 3,050 | 1,396 | 821 | 492 | 219 |
Some College | 3,735 | 2,821 | 1,320 | 797 | 354 | 204 |
College Graduate | 2,290 | 1,564 | 890 | 300 | 92 | 184 |
CURRENT EMPLOYMENT | ||||||
Full-Time | 7,117 | 5,413 | 2,447 | 1,158 | 647 | 382 |
Part-Time | 2,182 | 1,598 | 760 | 501 | 208 | 101 |
Unemployed | 964 | 765 | 406 | 268 | 171 | 91 |
Other1 | 2,242 | 1,646 | 814 | 451 | 218 | 142 |
51020
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Retired persons, disabled persons, homemakers, students, or other persons not in the labor force are included in the Other Employment category. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 5.9 | 4.4 | 2.1 | 1.1 | 0.6 | 0.3 |
GENDER | ||||||
Male | 6.3 | 5.0 | 2.1 | 1.3 | 0.7 | 0.3 |
Female | 5.5 | 3.9 | 2.0 | 1.0 | 0.4 | 0.4 |
HISPANIC ORIGIN AND RACE | ||||||
Not Hispanic or Latino | 5.9 | 4.4 | 2.2 | 1.2 | 0.6 | 0.4 |
White | 6.4 | 4.7 | 2.5 | 1.3 | 0.7 | 0.4 |
Black or African American | 3.6 | 3.1 | 0.6 | 0.4 | 0.1 | 0.1 |
American Indian or Alaska Native | 7.0 | 4.6 | 3.0 | 2.1 | 1.4 | 0.3 |
Native Hawaiian or Other Pacific Islander | 10.2 | 7.1 | 1.1 | 3.1 | 2.3 | * |
Asian | 2.9 | 2.1 | 0.8 | 0.4 | 0.2 | 0.1 |
Two or More Races | 7.1 | 5.1 | 3.2 | 2.8 | 2.2 | 0.5 |
Hispanic or Latino | 6.0 | 4.7 | 1.4 | 0.8 | 0.5 | 0.2 |
EDUCATION | ||||||
< High School | 6.6 | 5.3 | 2.2 | 1.2 | 0.8 | 0.3 |
High School Graduate | 5.9 | 4.5 | 2.1 | 1.2 | 0.7 | 0.3 |
Some College | 7.0 | 5.3 | 2.5 | 1.5 | 0.7 | 0.4 |
College Graduate | 4.2 | 2.9 | 1.6 | 0.6 | 0.2 | 0.3 |
CURRENT EMPLOYMENT | ||||||
Full-Time | 6.1 | 4.6 | 2.1 | 1.0 | 0.6 | 0.3 |
Part-Time | 7.8 | 5.7 | 2.7 | 1.8 | 0.7 | 0.4 |
Unemployed | 12.5 | 10.0 | 5.3 | 3.5 | 2.2 | 1.2 |
Other1 | 3.8 | 2.8 | 1.4 | 0.8 | 0.4 | 0.2 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 14,769 | 11,306 | 4,989 | 2,950 | 1,432 | 850 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 2,366 | 1,823 | 831 | 410 | 58 | 184 |
New England | 789 | 557 | 275 | 172 | 16 | 89 |
Middle Atlantic | 1,578 | 1,266 | 556 | 238 | 41 | 96 |
Midwest | 3,123 | 2,416 | 956 | 676 | 300 | 168 |
East North Central | 2,238 | 1,791 | 712 | 404 | 136 | 101 |
West North Central | 886 | 624 | 244 | 272 | 165 | 67 |
South | 5,363 | 4,100 | 2,178 | 962 | 426 | 300 |
South Atlantic | 2,703 | 2,098 | 1,111 | 388 | 145 | 164 |
East South Central | 967 | 737 | 464 | 192 | 94 | 58 |
West South Central | 1,693 | 1,264 | 603 | 381 | 187 | 78 |
West | 3,916 | 2,967 | 1,024 | 903 | 648 | 197 |
Mountain | 1,193 | 927 | 343 | 273 | 207 | 56 |
Pacific | 2,723 | 2,040 | 682 | 629 | 441 | 141 |
COUNTY TYPE | ||||||
Large Metro | 7,581 | 5,828 | 2,571 | 1,351 | 600 | 419 |
Small Metro | 4,844 | 3,670 | 1,668 | 1,033 | 493 | 298 |
250K – 1 Mil. Pop. | 3,130 | 2,356 | 1,042 | 630 | 308 | 161 |
< 250K Pop. | 1,714 | 1,314 | 626 | 403 | 185 | 137 |
Nonmetro | 2,345 | 1,808 | 751 | 566 | 338 | 133 |
Urbanized | 1,060 | 848 | 333 | 247 | 144 | 42 |
Less Urbanized | 1,092 | 818 | 349 | 266 | 167 | 82 |
Completely Rural | 193 | 142 | 69 | 53 | 27 | 9 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 6.2 | 4.8 | 2.1 | 1.2 | 0.6 | 0.4 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 5.2 | 4.0 | 1.8 | 0.9 | 0.1 | 0.4 |
New England | 6.6 | 4.7 | 2.3 | 1.4 | 0.1 | 0.7 |
Middle Atlantic | 4.7 | 3.8 | 1.7 | 0.7 | 0.1 | 0.3 |
Midwest | 5.8 | 4.5 | 1.8 | 1.3 | 0.6 | 0.3 |
East North Central | 5.9 | 4.8 | 1.9 | 1.1 | 0.4 | 0.3 |
West North Central | 5.5 | 3.9 | 1.5 | 1.7 | 1.0 | 0.4 |
South | 6.3 | 4.8 | 2.6 | 1.1 | 0.5 | 0.4 |
South Atlantic | 6.1 | 4.7 | 2.5 | 0.9 | 0.3 | 0.4 |
East South Central | 6.8 | 5.2 | 3.3 | 1.3 | 0.7 | 0.4 |
West South Central | 6.5 | 4.8 | 2.3 | 1.5 | 0.7 | 0.3 |
West | 7.3 | 5.5 | 1.9 | 1.7 | 1.2 | 0.4 |
Mountain | 7.6 | 5.9 | 2.2 | 1.7 | 1.3 | 0.4 |
Pacific | 7.1 | 5.3 | 1.8 | 1.6 | 1.2 | 0.4 |
COUNTY TYPE | ||||||
Large Metro | 6.0 | 4.6 | 2.0 | 1.1 | 0.5 | 0.3 |
Small Metro | 6.8 | 5.2 | 2.4 | 1.5 | 0.7 | 0.4 |
250K – 1 Mil. Pop. | 6.7 | 5.1 | 2.2 | 1.4 | 0.7 | 0.3 |
< 250K Pop. | 7.1 | 5.4 | 2.6 | 1.7 | 0.8 | 0.6 |
Nonmetro | 5.8 | 4.5 | 1.9 | 1.4 | 0.8 | 0.3 |
Urbanized | 6.3 | 5.0 | 2.0 | 1.5 | 0.9 | 0.2 |
Less Urbanized | 5.6 | 4.2 | 1.8 | 1.4 | 0.9 | 0.4 |
Completely Rural | 4.8 | 3.5 | 1.7 | 1.3 | 0.7 | 0.2 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 2,266 | 1,884 | 562 | 571 | 187 | 134 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 350 | 294 | 74 | 89 | 13 | 23 |
New England | 108 | 89 | 25 | 32 | 5 | 8 |
Middle Atlantic | 241 | 205 | 48 | 57 | 8 | 15 |
Midwest | 508 | 416 | 101 | 147 | 40 | 28 |
East North Central | 364 | 309 | 71 | 99 | 23 | 20 |
West North Central | 144 | 108 | 30 | 49 | 17 | 9 |
South | 834 | 682 | 271 | 202 | 69 | 54 |
South Atlantic | 408 | 332 | 129 | 94 | 33 | 26 |
East South Central | 155 | 129 | 53 | 35 | 11 | 10 |
West South Central | 271 | 222 | 90 | 74 | 26 | 18 |
West | 574 | 491 | 116 | 132 | 64 | 28 |
Mountain | 171 | 143 | 36 | 47 | 21 | 8 |
Pacific | 404 | 348 | 80 | 86 | 43 | 20 |
COUNTY TYPE | ||||||
Large Metro | 1,102 | 920 | 260 | 272 | 78 | 67 |
Small Metro | 728 | 600 | 198 | 180 | 67 | 46 |
250K – 1 Mil. Pop. | 480 | 389 | 130 | 116 | 40 | 32 |
< 250K Pop. | 248 | 211 | 68 | 65 | 27 | 13 |
Nonmetro | 435 | 364 | 103 | 119 | 42 | 22 |
Urbanized | 185 | 158 | 42 | 44 | 15 | 7 |
Less Urbanized | 213 | 175 | 52 | 62 | 24 | 12 |
Completely Rural | 37 | 31 | 9 | 13 | 3 | 2 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 9.1 | 7.5 | 2.2 | 2.3 | 0.7 | 0.5 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 7.8 | 6.5 | 1.6 | 2.0 | 0.3 | 0.5 |
New England | 9.3 | 7.7 | 2.2 | 2.8 | 0.4 | 0.7 |
Middle Atlantic | 7.3 | 6.2 | 1.4 | 1.7 | 0.2 | 0.5 |
Midwest | 8.9 | 7.3 | 1.8 | 2.6 | 0.7 | 0.5 |
East North Central | 9.1 | 7.7 | 1.8 | 2.5 | 0.6 | 0.5 |
West North Central | 8.5 | 6.4 | 1.8 | 2.9 | 1.0 | 0.5 |
South | 9.4 | 7.7 | 3.0 | 2.3 | 0.8 | 0.6 |
South Atlantic | 9.1 | 7.4 | 2.9 | 2.1 | 0.7 | 0.6 |
East South Central | 10.7 | 8.9 | 3.6 | 2.4 | 0.8 | 0.7 |
West South Central | 9.1 | 7.5 | 3.0 | 2.5 | 0.9 | 0.6 |
West | 9.7 | 8.3 | 2.0 | 2.2 | 1.1 | 0.5 |
Mountain | 9.9 | 8.3 | 2.1 | 2.7 | 1.2 | 0.5 |
Pacific | 9.7 | 8.3 | 1.9 | 2.1 | 1.0 | 0.5 |
COUNTY TYPE | ||||||
Large Metro | 8.3 | 6.9 | 2.0 | 2.0 | 0.6 | 0.5 |
Small Metro | 9.8 | 8.1 | 2.7 | 2.4 | 0.9 | 0.6 |
250K – 1 Mil. Pop. | 9.6 | 7.8 | 2.6 | 2.3 | 0.8 | 0.6 |
< 250K Pop. | 10.2 | 8.7 | 2.8 | 2.7 | 1.1 | 0.6 |
Nonmetro | 10.2 | 8.5 | 2.4 | 2.8 | 1.0 | 0.5 |
Urbanized | 10.5 | 9.0 | 2.4 | 2.5 | 0.8 | 0.4 |
Less Urbanized | 10.2 | 8.4 | 2.5 | 3.0 | 1.2 | 0.6 |
Completely Rural | 8.7 | 7.1 | 2.0 | 3.1 | 0.8 | 0.5 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 4,587 | 3,726 | 1,616 | 1,147 | 516 | 160 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 800 | 655 | 255 | 214 | 28 | 29 |
New England | 262 | 214 | 83 | 89 | 10 | 8 |
Middle Atlantic | 538 | 441 | 172 | 124 | 19 | 22 |
Midwest | 1,035 | 851 | 324 | 264 | 118 | 33 |
East North Central | 747 | 636 | 238 | 162 | 54 | 23 |
West North Central | 288 | 215 | 86 | 103 | 64 | 10 |
South | 1,703 | 1,369 | 749 | 391 | 166 | 63 |
South Atlantic | 792 | 653 | 324 | 162 | 50 | 31 |
East South Central | 314 | 255 | 169 | 69 | 34 | 11 |
West South Central | 598 | 461 | 255 | 160 | 82 | 22 |
West | 1,048 | 851 | 288 | 278 | 203 | 35 |
Mountain | 357 | 287 | 113 | 90 | 65 | 17 |
Pacific | 691 | 564 | 175 | 188 | 138 | 18 |
COUNTY TYPE | ||||||
Large Metro | 2,210 | 1,801 | 763 | 512 | 218 | 84 |
Small Metro | 1,617 | 1,305 | 586 | 430 | 178 | 54 |
250K – 1 Mil. Pop. | 1,009 | 808 | 352 | 254 | 104 | 33 |
< 250K Pop. | 608 | 496 | 235 | 176 | 74 | 21 |
Nonmetro | 759 | 620 | 267 | 205 | 119 | 23 |
Urbanized | 367 | 306 | 130 | 92 | 46 | 11 |
Less Urbanized | 339 | 274 | 119 | 99 | 65 | 11 |
Completely Rural | 54 | 41 | 18 | 14 | 8 | 1 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 14.5 | 11.8 | 5.1 | 3.6 | 1.6 | 0.5 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 14.3 | 11.7 | 4.6 | 3.8 | 0.5 | 0.5 |
New England | 17.9 | 14.6 | 5.7 | 6.1 | 0.7 | 0.5 |
Middle Atlantic | 13.0 | 10.6 | 4.2 | 3.0 | 0.5 | 0.5 |
Midwest | 14.1 | 11.6 | 4.4 | 3.6 | 1.6 | 0.5 |
East North Central | 14.8 | 12.6 | 4.7 | 3.2 | 1.1 | 0.5 |
West North Central | 12.7 | 9.5 | 3.8 | 4.5 | 2.8 | 0.4 |
South | 15.1 | 12.1 | 6.6 | 3.5 | 1.5 | 0.6 |
South Atlantic | 14.2 | 11.7 | 5.8 | 2.9 | 0.9 | 0.6 |
East South Central | 16.3 | 13.2 | 8.8 | 3.6 | 1.8 | 0.5 |
West South Central | 15.7 | 12.1 | 6.7 | 4.2 | 2.2 | 0.6 |
West | 14.1 | 11.5 | 3.9 | 3.8 | 2.7 | 0.5 |
Mountain | 16.0 | 12.9 | 5.1 | 4.0 | 2.9 | 0.7 |
Pacific | 13.3 | 10.9 | 3.4 | 3.6 | 2.7 | 0.3 |
COUNTY TYPE | ||||||
Large Metro | 13.5 | 11.0 | 4.7 | 3.1 | 1.3 | 0.5 |
Small Metro | 15.7 | 12.6 | 5.7 | 4.2 | 1.7 | 0.5 |
250K – 1 Mil. Pop. | 15.2 | 12.1 | 5.3 | 3.8 | 1.6 | 0.5 |
< 250K Pop. | 16.6 | 13.5 | 6.4 | 4.8 | 2.0 | 0.6 |
Nonmetro | 15.4 | 12.5 | 5.4 | 4.1 | 2.4 | 0.5 |
Urbanized | 15.9 | 13.3 | 5.6 | 4.0 | 2.0 | 0.5 |
Less Urbanized | 15.0 | 12.1 | 5.3 | 4.4 | 2.9 | 0.5 |
Completely Rural | 14.0 | 10.6 | 4.8 | 3.7 | 2.2 | 0.3 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 7,917 | 5,696 | 2,811 | 1,232 | 729 | 555 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 1,217 | 874 | 502 | 107 | 16 | 132 |
New England | 418 | 254 | 167 | 50 | 2 | 73 |
Middle Atlantic | 798 | 620 | 335 | 57 | 14 | 59 |
Midwest | 1,581 | 1,148 | 531 | 264 | 142 | 107 |
East North Central | 1,127 | 847 | 404 | 143 | 59 | 58 |
West North Central | 454 | 302 | 127 | 121 | 83 | 49 |
South | 2,826 | 2,049 | 1,158 | 369 | 191 | 182 |
South Atlantic | 1,503 | 1,114 | 658 | 133 | 63 | 107 |
East South Central | 499 | 354 | 242 | 89 | 49 | 37 |
West South Central | 824 | 581 | 258 | 147 | 79 | 38 |
West | 2,294 | 1,625 | 620 | 492 | 380 | 134 |
Mountain | 666 | 497 | 193 | 137 | 120 | 31 |
Pacific | 1,628 | 1,128 | 427 | 355 | 260 | 103 |
COUNTY TYPE | ||||||
Large Metro | 4,268 | 3,107 | 1,548 | 567 | 304 | 268 |
Small Metro | 2,498 | 1,765 | 883 | 423 | 248 | 198 |
250K – 1 Mil. Pop. | 1,640 | 1,159 | 560 | 261 | 164 | 96 |
< 250K Pop. | 858 | 606 | 323 | 162 | 84 | 102 |
Nonmetro | 1,151 | 824 | 380 | 242 | 177 | 89 |
Urbanized | 508 | 384 | 161 | 111 | 83 | 24 |
Less Urbanized | 541 | 369 | 178 | 105 | 78 | 59 |
Completely Rural | 102 | 71 | 42 | 26 | 15 | 6 |
51021
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 4.4 | 3.1 | 1.6 | 0.7 | 0.4 | 0.3 |
GEOGRAPHIC DIVISION | ||||||
Northeast | 3.5 | 2.5 | 1.4 | 0.3 | 0.0 | 0.4 |
New England | 4.5 | 2.7 | 1.8 | 0.5 | 0.0 | 0.8 |
Middle Atlantic | 3.1 | 2.4 | 1.3 | 0.2 | 0.1 | 0.2 |
Midwest | 3.9 | 2.8 | 1.3 | 0.6 | 0.3 | 0.3 |
East North Central | 3.9 | 3.0 | 1.4 | 0.5 | 0.2 | 0.2 |
West North Central | 3.7 | 2.5 | 1.0 | 1.0 | 0.7 | 0.4 |
South | 4.4 | 3.2 | 1.8 | 0.6 | 0.3 | 0.3 |
South Atlantic | 4.4 | 3.2 | 1.9 | 0.4 | 0.2 | 0.3 |
East South Central | 4.6 | 3.3 | 2.2 | 0.8 | 0.4 | 0.3 |
West South Central | 4.2 | 3.0 | 1.3 | 0.8 | 0.4 | 0.2 |
West | 5.7 | 4.0 | 1.5 | 1.2 | 0.9 | 0.3 |
Mountain | 5.7 | 4.3 | 1.7 | 1.2 | 1.0 | 0.3 |
Pacific | 5.7 | 3.9 | 1.5 | 1.2 | 0.9 | 0.4 |
COUNTY TYPE | ||||||
Large Metro | 4.4 | 3.2 | 1.6 | 0.6 | 0.3 | 0.3 |
Small Metro | 4.7 | 3.3 | 1.7 | 0.8 | 0.5 | 0.4 |
250K – 1 Mil. Pop. | 4.7 | 3.3 | 1.6 | 0.7 | 0.5 | 0.3 |
< 250K Pop. | 4.7 | 3.3 | 1.8 | 0.9 | 0.5 | 0.6 |
Nonmetro | 3.7 | 2.7 | 1.2 | 0.8 | 0.6 | 0.3 |
Urbanized | 4.0 | 3.0 | 1.3 | 0.9 | 0.7 | 0.2 |
Less Urbanized | 3.6 | 2.5 | 1.2 | 0.7 | 0.5 | 0.4 |
Completely Rural | 3.2 | 2.2 | 1.3 | 0.8 | 0.5 | 0.2 |
51031
Age at First Use | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
Past Year Use among Lifetime Users Aged 18 or Older | ||||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 12,504 | 9,422 | 4,427 | 2,379 | 1,244 | 716 |
Under 16 Years | 2,232 | 1,388 | 440 | 372 | 150 | 109 |
16 Years or Older | 10,271 | 8,034 | 3,988 | 2,006 | 1,095 | 606 |
16 to 20 Years | 5,423 | 3,882 | 1,697 | 1,148 | 574 | 235 |
21 to 25 Years | 2,221 | 1,807 | 901 | 438 | 268 | 92 |
26 Years or Older | 2,627 | 2,345 | 1,390 | 421 | 253 | 279 |
Age at First Use | Past Year Use among Lifetime Users Aged 18 to 25 | |||||
TOTAL | 4,587 | 3,726 | 1,616 | 1,147 | 516 | 160 |
Under 16 Years | 1,028 | 683 | 232 | 206 | 86 | 36 |
16 Years or Older | 3,558 | 3,042 | 1,385 | 941 | 430 | 125 |
16 to 20 Years | 2,966 | 2,483 | 1,057 | 796 | 348 | 91 |
21 to 25 Years | 592 | 559 | 328 | 145 | 82 | 34 |
Age at First Use | Past Year Use among Lifetime Users Aged 26 or Older | |||||
TOTAL | 7,917 | 5,696 | 2,811 | 1,232 | 729 | 555 |
Under 16 Years | 1,204 | 704 | 208 | 166 | 64 | 73 |
16 Years or Older | 6,713 | 4,992 | 2,603 | 1,066 | 665 | 482 |
16 to 20 Years | 2,457 | 1,398 | 640 | 353 | 226 | 144 |
21 to 25 Years | 1,629 | 1,248 | 573 | 293 | 186 | 59 |
26 Years or Older | 2,627 | 2,345 | 1,390 | 421 | 253 | 279 |
51031
Age at First Use | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
Past Year Use among Lifetime Users Aged 18 or Older | ||||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL | 28.3 | 33.6 | 23.4 | 12.1 | 10.5 | 7.5 |
Under 16 Years | 33.4 | 38.0 | 22.6 | 12.4 | 9.1 | 7.6 |
16 Years or Older | 27.4 | 32.9 | 23.5 | 12.1 | 10.8 | 7.5 |
16 to 20 Years | 27.8 | 34.9 | 23.6 | 11.4 | 9.2 | 4.9 |
21 to 25 Years | 24.7 | 29.5 | 20.0 | 10.8 | 10.5 | 5.1 |
26 Years or Older | 29.5 | 32.7 | 26.2 | 16.9 | 18.6 | 19.3 |
Age at First Use | Past Year Use among Lifetime Users Aged 18 to 25 | |||||
TOTAL | 50.6 | 50.4 | 43.0 | 33.8 | 30.4 | 26.2 |
Under 16 Years | 51.3 | 49.8 | 39.8 | 26.0 | 23.0 | 26.2 |
16 Years or Older | 50.4 | 50.5 | 43.5 | 36.1 | 32.4 | 26.2 |
16 to 20 Years | 49.3 | 49.1 | 40.7 | 34.7 | 30.1 | 22.8 |
21 to 25 Years | 56.8 | 57.7 | 55.8 | 47.0 | 48.9 | 43.7 |
Age at First Use | Past Year Use among Lifetime Users Aged 26 or Older | |||||
TOTAL | 22.6 | 27.6 | 18.5 | 7.6 | 7.2 | 6.2 |
Under 16 Years | 25.7 | 30.9 | 15.3 | 7.5 | 5.1 | 5.6 |
16 Years or Older | 22.1 | 27.2 | 18.8 | 7.6 | 7.5 | 6.3 |
16 to 20 Years | 18.2 | 23.1 | 13.9 | 4.5 | 4.4 | 3.2 |
21 to 25 Years | 20.5 | 24.2 | 14.6 | 7.9 | 7.8 | 3.4 |
26 Years or Older | 29.5 | 32.7 | 26.2 | 16.9 | 18.6 | 19.3 |
51024
Number of Days Used in Past Year | PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
Any Stimulant | Metham- phetamine |
||||
Past Year Nonmedical Users Aged 12 or Older | |||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
1-11 Days | 5,741 | 2,637 | 1,257 | 550 | 399 |
12-49 Days | 2,744 | 1,201 | 657 | 306 | 239 |
50-99 Days | 1,224 | 549 | 331 | 176 | 85 |
100-299 Days | 1,404 | 550 | 597 | 336 | 114 |
300 or More Days | 193 | 53 | 108 | 64 | 12 |
Number of Days Used in Past Year | Past Year Nonmedical Users Aged 12 to 17 | ||||
1-11 Days | 899 | 295 | 276 | 91 | 61 |
12-49 Days | 489 | 139 | 134 | 46 | 34 |
50-99 Days | 232 | 58 | 58 | 17 | 22 |
100-299 Days | 235 | 67 | 90 | 29 | 14 |
300 or More Days | 28 | 3 | 12 | 3 | 3 |
Number of Days Used in Past Year | Past Year Nonmedical Users Aged 18 to 25 | ||||
1-11 Days | 1,911 | 862 | 518 | 203 | 82 |
12-49 Days | 951 | 393 | 281 | 121 | 38 |
50-99 Days | 396 | 176 | 125 | 62 | 23 |
100-299 Days | 420 | 172 | 200 | 118 | 16 |
300 or More Days | 48 | 13 | 23 | 12 | 2 |
Number of Days Used in Past Year | Past Year Nonmedical Users Aged 26 or Older | ||||
1-11 Days | 2,931 | 1,479 | 463 | 256 | 256 |
12-49 Days | 1,304 | 669 | 242 | 138 | 168 |
50-99 Days | 596 | 315 | 148 | 97 | 40 |
100-299 Days | 749 | 311 | 306 | 190 | 84 |
300 or More Days | 116 | 37 | 72 | 49 | 8 |
51024
Number of Days Used in Past Year | PRESCRIPTION DRUG TYPE | |||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
Past Year Nonmedical Users Aged 12 or Older | ||||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
1-11 Days | 50.8 | 52.8 | 42.6 | 38.4 | 46.9 | |
12-49 Days | 24.3 | 24.1 | 22.3 | 21.4 | 28.2 | |
50-99 Days | 10.8 | 11.0 | 11.2 | 12.3 | 10.0 | |
100-299 Days | 12.4 | 11.0 | 20.2 | 23.5 | 13.4 | |
300 or More Days | 1.7 | 1.1 | 3.7 | 4.5 | 1.5 | |
Number of Days Used in Past Year | Past Year Nonmedical Users Aged 12 to 17 | |||||
1-11 Days | 47.7 | 52.5 | 48.3 | 48.8 | 45.4 | |
12-49 Days | 25.9 | 24.7 | 23.5 | 24.8 | 25.5 | |
50-99 Days | 12.3 | 10.3 | 10.1 | 9.3 | 16.6 | |
100-299 Days | 12.5 | 11.9 | 15.8 | 15.3 | 10.4 | |
300 or More Days | 1.5 | 0.5 | 2.2 | 1.8 | 2.1 | |
Number of Days Used in Past Year | Past Year Nonmedical Users Aged 18 to 25 | |||||
1-11 Days | 51.3 | 53.3 | 45.2 | 39.3 | 50.8 | |
12-49 Days | 25.5 | 24.3 | 24.5 | 23.6 | 23.6 | |
50-99 Days | 10.6 | 10.9 | 10.9 | 12.0 | 14.4 | |
100-299 Days | 11.3 | 10.6 | 17.5 | 22.8 | 10.2 | |
300 or More Days | 1.3 | 0.8 | 2.0 | 2.3 | 1.0 | |
Number of Days Used in Past Year | Past Year Nonmedical Users Aged 26 or Older | |||||
1-11 Days | 51.5 | 52.6 | 37.6 | 35.2 | 46.1 | |
12-49 Days | 22.9 | 23.8 | 19.6 | 18.9 | 30.2 | |
50-99 Days | 10.5 | 11.2 | 12.0 | 13.3 | 7.2 | |
100-299 Days | 13.2 | 11.1 | 24.9 | 26.0 | 15.1 | |
300 or More Days | 2.0 | 1.3 | 5.9 | 6.7 | 1.4 |
51024
Gender and College Enrollment Status | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetmaine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Estimates include those with unknown enrollment status. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
ALL PERSONS AGED 18 TO 221 | 3,216 | 2,625 | 1,097 | 844 | 343 | 109 |
Enrolled as Undergraduate | 1,374 | 1,105 | 434 | 403 | 82 | 43 |
Full Time | 1,154 | 918 | 355 | 356 | 62 | 37 |
Part Time | 219 | 188 | 79 | 48 | 21 | 6 |
Not Enrolled as Undergraduate | 1,552 | 1,268 | 583 | 378 | 237 | 59 |
MALES AGED 18 TO 221 | 1,744 | 1,475 | 580 | 435 | 186 | 57 |
Enrolled as Undergraduate | 671 | 559 | 205 | 193 | 39 | 18 |
Full Time | 568 | 470 | 168 | 171 | 33 | 16 |
Part Time | 102 | 89 | 36 | 22 | 7 | 2 |
Not Enrolled as Undergraduate | 891 | 756 | 326 | 204 | 134 | 34 |
FEMALES AGED 18 TO 221 | 1,472 | 1,150 | 517 | 409 | 157 | 52 |
Enrolled as Undergraduate | 703 | 546 | 230 | 210 | 43 | 25 |
Full Time | 586 | 447 | 187 | 184 | 29 | 21 |
Part Time | 117 | 99 | 43 | 26 | 14 | 4 |
Not Enrolled as Undergraduate | 661 | 512 | 257 | 174 | 103 | 24 |
51024
Gender and College Enrollment Status | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetmaine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Estimates include those with unknown enrollment status. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
ALL PERSONS AGED 18 TO 221 | 15.7 | 12.8 | 5.4 | 4.1 | 1.7 | 0.5 |
Enrolled as Undergraduate | 14.8 | 11.9 | 4.7 | 4.3 | 0.9 | 0.5 |
Full Time | 14.6 | 11.6 | 4.5 | 4.5 | 0.8 | 0.5 |
Part Time | 15.7 | 13.4 | 5.7 | 3.4 | 1.5 | 0.4 |
Not Enrolled as Undergraduate | 17.0 | 13.9 | 6.4 | 4.1 | 2.6 | 0.6 |
MALES AGED 18 TO 221 | 16.8 | 14.2 | 5.6 | 4.2 | 1.8 | 0.6 |
Enrolled as Undergraduate | 15.6 | 13.0 | 4.7 | 4.5 | 0.9 | 0.4 |
Full Time | 15.5 | 12.8 | 4.6 | 4.7 | 0.9 | 0.4 |
Part Time | 15.8 | 13.8 | 5.6 | 3.4 | 1.0 | 0.3 |
Not Enrolled as Undergraduate | 18.2 | 15.5 | 6.7 | 4.2 | 2.7 | 0.7 |
FEMALES AGED 18 TO 221 | 14.6 | 11.4 | 5.1 | 4.1 | 1.6 | 0.5 |
Enrolled as Undergraduate | 14.2 | 11.0 | 4.6 | 4.2 | 0.9 | 0.5 |
Full Time | 13.9 | 10.6 | 4.4 | 4.4 | 0.7 | 0.5 |
Part Time | 15.6 | 13.1 | 5.8 | 3.4 | 1.9 | 0.5 |
Not Enrolled as Undergraduate | 15.5 | 12.0 | 6.0 | 4.1 | 2.4 | 0.6 |
51024
Age and Pregnancy Status | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetmaine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Estimates include those with unknown pregnancy status. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
ALL FEMALES AGED 15 TO 441 | 5,653 | 4,226 | 2,024 | 1,231 | 529 | 304 |
Pregnant | 148 | 109 | 49 | 32 | 19 | 7 |
Not Pregnant | 5,481 | 4,097 | 1,966 | 1,191 | 507 | 296 |
FEMALES AGED 15 TO 171 | 838 | 676 | 256 | 246 | 86 | 47 |
Pregnant | 17 | 14 | 3 | 6 | 3 | 2 |
Not Pregnant | 815 | 657 | 252 | 239 | 83 | 45 |
FEMALES AGED 18 TO 251 | 2,106 | 1,641 | 762 | 530 | 225 | 78 |
Pregnant | 89 | 67 | 31 | 19 | 16 | 4 |
Not Pregnant | 1,999 | 1,559 | 723 | 505 | 207 | 73 |
FEMALES AGED 26 TO 441 | 2,709 | 1,909 | 1,006 | 454 | 218 | 179 |
Pregnant | 42 | 28 | 15 | 7 | * | 1 |
Not Pregnant | 2,667 | 1,881 | 990 | 447 | 218 | 178 |
51024
Age and Pregnancy Status | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetmaine |
|||||
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 1 Estimates include those with unknown pregnancy status. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
ALL FEMALES AGED 15 TO 441 | 9.1 | 6.8 | 3.3 | 2.0 | 0.9 | 0.5 |
Pregnant | 6.0 | 4.4 | 2.0 | 1.3 | 0.8 | 0.3 |
Not Pregnant | 9.3 | 6.9 | 3.3 | 2.0 | 0.9 | 0.5 |
FEMALES AGED 15 TO 171 | 13.9 | 11.2 | 4.2 | 4.1 | 1.4 | 0.8 |
Pregnant | 18.2 | 15.0 | 3.3 | 6.4 | 3.2 | 1.7 |
Not Pregnant | 13.8 | 11.1 | 4.3 | 4.0 | 1.4 | 0.8 |
FEMALES AGED 18 TO 251 | 13.3 | 10.4 | 4.8 | 3.4 | 1.4 | 0.5 |
Pregnant | 9.6 | 7.3 | 3.3 | 2.1 | 1.7 | 0.5 |
Not Pregnant | 13.5 | 10.6 | 4.9 | 3.4 | 1.4 | 0.5 |
FEMALES AGED 26 TO 441 | 6.8 | 4.8 | 2.5 | 1.1 | 0.5 | 0.4 |
Pregnant | 2.9 | 1.9 | 1.0 | 0.5 | * | 0.1 |
Not Pregnant | 7.0 | 4.9 | 2.6 | 1.2 | 0.6 | 0.5 |
51020
Pain Reliever | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Darvocet®, Darvon®, or Tylenol® with Codeine | 18,912 | 19,672 | 19,514 | 1,508 | 1,458 | 1,504 | 3,800b | 4,020 | 4,202 | 13,603 | 14,193 | 13,808 |
Percocet®, Percodan®, or Tylox® | 9,659b | 10,811 | 10,950 | 407b | 473 | 529 | 2,285b | 2,471b | 2,796 | 6,967 | 7,867 | 7,626 |
Vicodin®, Lortab®, or Lorcet® | 13,093b | 15,717 | 16,707 | 1,116a | 1,129a | 1,274 | 4,126b | 4,773b | 5,309 | 7,852b | 9,815 | 10,124 |
Codeine | 6,897 | 6,985 | 6,693 | 513 | 526 | 523 | 1,878 | 2,074 | 2,062 | 4,506 | 4,385 | 4,108 |
Demerol® | 2,917a | 2,986b | 2,461 | 116 | 109 | 126 | 657 | 686 | 624 | 2,144a | 2,191a | 1,711 |
Dilaudid® | 1,116 | 914 | 859 | 7 | 13 | 17 | 101 | 80 | 97 | 1,008 | 821 | 745 |
Fioricet® | 445 | 466 | 454 | 13 | 17 | 20 | 64 | 49 | 65 | 368 | 401 | 369 |
Fiorinal® | 579 | 525 | 372 | 24 | 18 | 11 | 40 | 43 | 33 | 515 | 465 | 327 |
Hydrocodone | 4,529b | 5,716 | 5,949 | 333b | 410 | 425 | 1,540b | 2,088 | 2,161 | 2,656b | 3,218 | 3,363 |
Methadone | 928b | 1,159 | 1,306 | 116 | 109 | 123 | 306b | 396 | 456 | 506 | 655 | 727 |
Morphine | 2,073 | 2,060 | 2,068 | 256 | 215 | 218 | 648b | 737 | 818 | 1,170 | 1,107 | 1,031 |
OxyContin® | 1,924b | 2,832 | 3,072 | 224b | 254 | 305 | 820b | 1,145b | 1,376 | 881b | 1,433 | 1,392 |
Phenaphen® with Codeine | 873a | 857b | 586 | 69 | 67a | 40 | 194 | 236 | 177 | 610a | 554 | 369 |
Propoxyphene | 282 | 290 | 390 | 31 | 33 | 22 | 45b | 68 | 101 | 206 | 189 | 267 |
SK-65® | 42 | 48 | 37 | 13 | 16 | 9 | 10 | 14 | 15 | 19 | 18 | 13 |
Stadol® | 133 | 157 | 154 | 6 | 5 | 4 | 23a | 16b | 49 | 103 | 136 | 101 |
Talacen® | 55 | 43 | 116 | 14 | 7 | 10 | 13 | 13 | 25 | 28 | 23 | 81 |
Talwin® | 643b | 425 | 302 | 10 | 6 | 17 | 20 | 22 | 19 | 613b | 397 | 267 |
Talwin® NX | 105 | 53 | 100 | 10 | 8 | 8 | 9 | 12 | 15 | 86 | 33 | 77 |
Tramadol | 52b | 186a | 328 | 11 | 14 | 20 | 20b | 68 | 99 | 21b | 103 | 209 |
Ultram® | 962 | 1,105 | 1,113 | 98b | 66 | 51 | 300 | 330 | 318 | 564 | 709 | 744 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Propoxyphene or Codeine Products1,2 | 20,653 | 21,428 | 21,066 | 1,696 | 1,693 | 1,702 | 4,337a | 4,611 | 4,692 | 14,620 | 15,124 | 14,672 |
Oxycodone Products1,3 | 10,151b | 11,538 | 11,921 | 523b | 605 | 693 | 2,551b | 2,831b | 3,237 | 7,076a | 8,102 | 7,991 |
Hydrocodone Products1,4 | 13,952b | 16,808 | 17,734 | 1,222b | 1,260a | 1,407 | 4,385b | 5,157a | 5,595 | 8,345b | 10,391 | 10,732 |
Tramadol Products1,5 | 994a | 1,221 | 1,280 | 102 | 76 | 67 | 313 | 375 | 372 | 579a | 770 | 840 |
51020
Pain Reliever | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Darvocet®, Darvon®, or Tylenol® with Codeine | 8.0 | 8.3 | 8.1 | 6.1 | 5.8 | 6.0 | 12.2 | 12.7 | 13.1 | 7.6 | 7.8 | 7.5 |
Percocet®, Percodan®, or Tylox® | 4.1a | 4.5 | 4.6 | 1.6b | 1.9 | 2.1 | 7.4b | 7.8a | 8.7 | 3.9 | 4.3 | 4.2 |
Vicodin®, Lortab®, or Lorcet® | 5.6b | 6.6 | 6.9 | 4.5a | 4.5a | 5.1 | 13.3b | 15.0b | 16.5 | 4.4b | 5.4 | 5.5 |
Codeine | 2.9 | 2.9 | 2.8 | 2.1 | 2.1 | 2.1 | 6.1 | 6.5 | 6.4 | 2.5 | 2.4 | 2.2 |
Demerol® | 1.2a | 1.3b | 1.0 | 0.5 | 0.4 | 0.5 | 2.1 | 2.2 | 1.9 | 1.2a | 1.2b | 0.9 |
Dilaudid® | 0.5 | 0.4 | 0.4 | 0.0 | 0.1 | 0.1 | 0.3 | 0.3 | 0.3 | 0.6 | 0.5 | 0.4 |
Fioricet® | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
Fiorinal® | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.2 |
Hydrocodone | 1.9b | 2.4 | 2.5 | 1.3a | 1.6 | 1.7 | 5.0b | 6.6 | 6.7 | 1.5b | 1.8 | 1.8 |
Methadone | 0.4b | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 1.0b | 1.2 | 1.4 | 0.3 | 0.4 | 0.4 |
Morphine | 0.9 | 0.9 | 0.9 | 1.0 | 0.9 | 0.9 | 2.1a | 2.3 | 2.5 | 0.7 | 0.6 | 0.6 |
OxyContin® | 0.8b | 1.2 | 1.3 | 0.9a | 1.0 | 1.2 | 2.6b | 3.6b | 4.3 | 0.5b | 0.8 | 0.8 |
Phenaphen® with Codeine | 0.4a | 0.4b | 0.2 | 0.3a | 0.3a | 0.2 | 0.6 | 0.7 | 0.6 | 0.3a | 0.3a | 0.2 |
Propoxyphene | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1b | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 |
SK-65® | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Stadol® | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1a | 0.1b | 0.2 | 0.1 | 0.1 | 0.1 |
Talacen® | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Talwin® | 0.3b | 0.2 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3b | 0.2 | 0.1 |
Talwin® NX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tramadol | 0.0b | 0.1a | 0.1 | 0.0 | 0.1 | 0.1 | 0.1b | 0.2 | 0.3 | 0.0b | 0.1 | 0.1 |
Ultram® | 0.4 | 0.5 | 0.5 | 0.4b | 0.3 | 0.2 | 1.0 | 1.0 | 1.0 | 0.3 | 0.4 | 0.4 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Propoxyphene or Codeine Products1,2 | 8.8 | 9.0 | 8.8 | 6.9 | 6.8 | 6.7 | 14.0 | 14.5 | 14.6 | 8.2 | 8.4 | 8.0 |
Oxycodone Products1,3 | 4.3b | 4.9 | 5.0 | 2.1b | 2.4 | 2.7 | 8.2b | 8.9b | 10.1 | 3.9 | 4.5 | 4.4 |
Hydrocodone Products1,4 | 5.9b | 7.1 | 7.4 | 4.9a | 5.0 | 5.6 | 14.1b | 16.3a | 17.4 | 4.7b | 5.7 | 5.9 |
Tramadol Products1,5 | 0.4a | 0.5 | 0.5 | 0.4a | 0.3 | 0.3 | 1.0 | 1.2 | 1.2 | 0.3a | 0.4 | 0.5 |
51020
Tranquilizer | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Klonopin® or Clonazepam | 2,374 | 2,851 | 2,746 | 180 | 160 | 164 | 724b | 964 | 1,048 | 1,470 | 1,727 | 1,533 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 8,208b | 9,500 | 9,369 | 429 | 437 | 449 | 2,091b | 2,379 | 2,495 | 5,688 | 6,684 | 6,425 |
Valium® or Diazepam | 14,386 | 14,671 | 14,607 | 427 | 424 | 380 | 2,312 | 2,473 | 2,434 | 11,648 | 11,773 | 11,794 |
Atarax® | 371a | 292 | 186 | 26 | 17 | 22 | 45 | 42 | 42 | 301a | 233 | 122 |
BuSpar® | 693 | 587 | 702 | 51 | 53 | 42 | 220 | 205 | 260 | 421 | 329 | 401 |
Equanil® | 75 | 128 | 78 | 14 | 13 | 10 | 12 | 14 | 21 | 49 | 101 | 47 |
Flexeril® | 1,781 | 1,994 | 1,968 | 47 | 49 | 34 | 295b | 377 | 461 | 1,439 | 1,569 | 1,473 |
Librium® | 1,454a | 1,121 | 981 | 17 | 20 | 29 | 79 | 84 | 61 | 1,358a | 1,017 | 891 |
Limbitrol® | 115 | 41a | 96 | 9 | 7 | 14 | 32 | 11 | 24 | 73 | 23 | 58 |
Meprobamate | 161 | 170 | 129 | 9 | 12 | 17 | 21 | 11 | 13 | 131 | 148 | 98 |
Miltown® | 169 | 98 | 73 | 12 | 8 | 14 | 6 | 8 | 6 | 151 | 82 | 52 |
Rohypnol® | 375 | 408 | 346 | 40 | 46 | 24 | 160 | 189 | 140 | 175 | 173 | 181 |
Serax® | 215 | 170 | 114 | 17 | 9 | 11 | 29 | 17 | 31 | 169 | 144 | 72 |
Soma® | 2,276 | 2,572 | 2,616 | 142 | 152 | 138 | 729b | 793b | 975 | 1,405 | 1,626 | 1,503 |
Tranxene® | 214 | 189 | 143 | 10 | 13 | 10 | 16 | 23 | 31 | 188 | 153 | 103 |
Vistaril® | 356 | 258 | 275 | 21 | 11 | 20 | 64 | 35 | 54 | 271 | 212 | 201 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Benzodiazepines1,2 | 18,132 | 18,930 | 18,643 | 729 | 732 | 704 | 3,223b | 3,645 | 3,602 | 14,180 | 14,553 | 14,337 |
Meprobamate Products1,3 | 388 | 307 | 246 | 33 | 27 | 34 | 39 | 27 | 39 | 316 | 253 | 173 |
Muscle Relaxants1,4 | 3,360a | 3,718 | 3,907 | 170 | 182 | 160 | 866b | 998b | 1,227 | 2,325 | 2,538 | 2,520 |
51020
Tranquilizer | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Klonopin® or Clonazepam | 1.0 | 1.2 | 1.1 | 0.7 | 0.6 | 0.7 | 2.3b | 3.0 | 3.3 | 0.8 | 1.0 | 0.8 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 3.5a | 4.0 | 3.9 | 1.7 | 1.7 | 1.8 | 6.7b | 7.5 | 7.7 | 3.2 | 3.7 | 3.5 |
Valium® or Diazepam | 6.1 | 6.2 | 6.1 | 1.7 | 1.7 | 1.5 | 7.5 | 7.8 | 7.6 | 6.5 | 6.5 | 6.4 |
Atarax® | 0.2a | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2a | 0.1 | 0.1 |
BuSpar® | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.7 | 0.6 | 0.8 | 0.2 | 0.2 | 0.2 |
Equanil® | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 |
Flexeril® | 0.8 | 0.8 | 0.8 | 0.2 | 0.2 | 0.1 | 0.9b | 1.2 | 1.4 | 0.8 | 0.9 | 0.8 |
Librium® | 0.6a | 0.5 | 0.4 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.2 | 0.8a | 0.6 | 0.5 |
Limbitrol® | 0.0 | 0.0a | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Meprobamate | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
Miltown® | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Rohypnol® | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | 0.5 | 0.6 | 0.4 | 0.1 | 0.1 | 0.1 |
Serax® | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
Soma® | 1.0 | 1.1 | 1.1 | 0.6 | 0.6 | 0.5 | 2.3b | 2.5a | 3.0 | 0.8 | 0.9 | 0.8 |
Tranxene® | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Vistaril® | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Benzodiazepines1,2 | 7.7 | 8.0 | 7.8 | 2.9 | 2.9 | 2.8 | 10.4 | 11.5 | 11.2 | 7.9 | 8.0 | 7.8 |
Meprobamate Products1,3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 |
Muscle Relaxants1,4 | 1.4 | 1.6 | 1.6 | 0.7 | 0.7 | 0.6 | 2.8b | 3.1b | 3.8 | 1.3 | 1.4 | 1.4 |
51020
Stimulant | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Methamphetamine,1 Desoxyn®, or Methedrine® | 12,383 | 12,303 | 11,726 | 366 | 328 | 299 | 1,756 | 1,650 | 1,688 | 10,261 | 10,325 | 9,739 |
Prescription Diet Pills2 | 8,980 | 8,671 | 8,104 | 267 | 251 | 236 | 692 | 743 | 689 | 8,021 | 7,677 | 7,179 |
Ritalin® or Methylphenidate | 4,528 | 4,168 | 4,182 | 587b | 547a | 445 | 1,662 | 1,806 | 1,729 | 2,280 | 1,816 | 2,008 |
Cylert® | 196 | 198 | 232 | 18 | 23 | 26 | 39 | 36 | 32 | 139 | 140 | 173 |
Dexedrine® | 3,274b | 2,553 | 2,580 | 70 | 69 | 62 | 318 | 291 | 318 | 2,887b | 2,193 | 2,200 |
Dextroamphetamine | 553 | 498 | 675 | 22 | 31 | 29 | 78 | 80 | 83 | 453 | 387 | 563 |
Didrex® | 177 | 196 | 184 | 21 | 19 | 13 | 31 | 25 | 33 | 124 | 152 | 138 |
Eskatrol® | 302 | 89a | 289 | 10 | 4 | 15 | 15 | 4 | 13 | 276 | 81a | 261 |
Ionamin® | 491 | 583 | 459 | 19 | 26 | 12 | 28 | 23 | 13 | 445 | 535 | 433 |
Mazanor® | 65 | 30 | 65 | 16 | 10 | 13 | 3 | 8 | 8 | 45 | 13 | 44 |
Obedrin-LA® | 79 | 18 | * | 6 | 13 | * | 6 | 5 | * | 68 | * | * |
Plegine® | 68 | 45 | 25 | 12 | 5 | 13 | 8 | 2 | 3 | 48 | 37 | 9 |
Preludin® | 856a | 705 | 529 | 10 | 13 | 13 | 35 | 52a | 23 | 811a | 640 | 493 |
Sanorex® | 137 | 105 | 106 | 12 | 20 | 23 | 23 | 17 | 33 | 102 | 68 | 50 |
Tenuate® | 275 | 146 | 221 | 10 | 13 | 10 | 10 | 17 | 14 | 255 | 116 | 196 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Amphetamine, Dextroamphetamine and Phentermine Products3,4 | 10,589a | 10,080 | 9,509 | 367 | 385 | 357 | 1,069 | 1,117 | 1,177 | 9,153a | 8,578 | 7,974 |
Mazindol Products3,5 | 187 | 127 | 156 | 24 | 26 | 32 | 25 | 21 | 34 | 138 | 80 | 90 |
51020
Stimulant | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Methamphetamine,1 Desoxyn®, or Methedrine® | 5.3 | 5.2 | 4.9 | 1.5a | 1.3 | 1.2 | 5.7 | 5.2 | 5.2 | 5.7 | 5.7 | 5.3 |
Prescription Diet Pills2 | 3.8a | 3.6 | 3.4 | 1.1 | 1.0 | 0.9 | 2.2 | 2.3 | 2.1 | 4.5a | 4.2 | 3.9 |
Ritalin® or Methylphenidate | 1.9 | 1.8 | 1.7 | 2.4b | 2.2b | 1.8 | 5.4 | 5.7 | 5.4 | 1.3 | 1.0 | 1.1 |
Cylert® | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Dexedrine® | 1.4b | 1.1 | 1.1 | 0.3 | 0.3 | 0.2 | 1.0 | 0.9 | 1.0 | 1.6b | 1.2 | 1.2 |
Dextroamphetamine | 0.2 | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 |
Didrex® | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Eskatrol® | 0.1 | 0.0a | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0a | 0.1 |
Ionamin® | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 | 0.3 | 0.2 |
Mazanor® | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Obedrin-LA® | 0.0 | 0.0 | * | 0.0 | 0.1 | * | 0.0 | 0.0 | * | 0.0 | * | * |
Plegine® | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Preludin® | 0.4a | 0.3 | 0.2 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2a | 0.1 | 0.5a | 0.4 | 0.3 |
Sanorex® | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
Tenuate® | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Amphetamine, Dextroamphetamine and Phentermine Products3,4 | 4.5b | 4.2 | 4.0 | 1.5 | 1.5 | 1.4 | 3.4 | 3.5 | 3.7 | 5.1b | 4.7 | 4.4 |
Mazindol Products3,5 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
51020
Sedative | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Methaqualone, Sopor®, or Quaalude® | 7,320 | 6,997 | 7,114 | 60 | 64 | 54 | 305 | 258 | 254 | 6,955 | 6,676 | 6,805 |
Barbiturates1 | 3,375b | 3,301b | 2,603 | 29 | 44 | 37 | 121 | 101 | 118 | 3,226b | 3,156b | 2,447 |
Restoril® or Temazepam | 1,003 | 923 | 779 | 48 | 50 | 42 | 108 | 90 | 119 | 847 | 783 | 617 |
Amytal® | 274 | 209 | 249 | 4a | 26 | 21 | 21 | 19 | 23 | 249 | 164 | 204 |
Butisol® | 109 | 103 | 69 | 8 | 15 | 17 | 14 | 12 | 22 | 87 | 76 | 30 |
Chloral Hydrate | 214 | 149 | 220 | 7 | 11 | 19 | 9 | 25 | 11 | 198 | 114 | 190 |
Dalmane® | 638 | 435 | 440 | 22 | 23 | 40 | 16 | 19 | 14 | 600 | 393 | 386 |
Halcion® | 939 | 668 | 674 | 17 | 23 | 34 | 64 | 53 | 55 | 857a | 592 | 585 |
Phenobarbital | 1,568a | 1,300 | 1,132 | 37 | 29 | 25 | 105 | 91 | 82 | 1,426a | 1,180 | 1,025 |
Placidyl® | 1,045 | 783 | 885 | 12 | 12 | 4 | 34a | 14 | 13 | 998 | 758 | 868 |
Tuinal® | 1,393a | 1,077 | 1,021 | 8 | 14 | 8 | 17 | 10 | 11 | 1,368a | 1,053 | 1,002 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Temazepam, Flurazepam, or Triazolam2,3 | 2,101b | 1,662 | 1,492 | 82 | 75 | 95 | 175 | 143 | 173 | 1,844b | 1,443 | 1,224 |
Any Barbiturates2,4 | 4,058a | 4,031a | 3,359 | 73 | 98 | 82 | 209 | 181 | 196 | 3,775a | 3,753a | 3,081 |
51020
Sedative | Total | AGE GROUP | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |
*Low precision; no estimate reported. a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
Methaqualone, Sopor®, or Quaalude® | 3.1 | 2.9 | 3.0 | 0.2 | 0.3 | 0.2 | 1.0 | 0.8 | 0.8 | 3.9 | 3.7 | 3.7 |
Barbiturates1 | 1.4b | 1.4b | 1.1 | 0.1 | 0.2 | 0.1 | 0.4 | 0.3 | 0.4 | 1.8b | 1.7b | 1.3 |
Restoril® or Temazepam | 0.4a | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.5a | 0.4 | 0.3 |
Amytal® | 0.1 | 0.1 | 0.1 | 0.0a | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Butisol® | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Chloral Hydrate | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 |
Dalmane® | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.0 | 0.3 | 0.2 | 0.2 |
Halcion® | 0.4a | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.5a | 0.3 | 0.3 |
Phenobarbital | 0.7a | 0.5 | 0.5 | 0.2 | 0.1 | 0.1 | 0.3 | 0.3 | 0.3 | 0.8a | 0.7 | 0.6 |
Placidyl® | 0.4 | 0.3 | 0.4 | 0.1 | 0.0 | 0.0 | 0.1a | 0.0 | 0.0 | 0.6 | 0.4 | 0.5 |
Tuinal® | 0.6a | 0.5 | 0.4 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.8a | 0.6 | 0.5 |
SELECTED GROUPS OF DRUGS | ||||||||||||
Temazepam, Flurazepam, or Triazolam2,3 | 0.9b | 0.7 | 0.6 | 0.3 | 0.3 | 0.4 | 0.6 | 0.4 | 0.5 | 1.0b | 0.8 | 0.7 |
Any Barbiturates2,4 | 1.7a | 1.7a | 1.4 | 0.3 | 0.4 | 0.3 | 0.7 | 0.6 | 0.6 | 2.1a | 2.1a | 1.7 |
51215
Pain Reliever | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
Darvocet®, Darvon®, or Tylenol® with Codeine | 19,366 | 10,711 | 8,655 | 1,490 | 4,007 | 13,868 |
Percocet®, Percodan®, or Tylox® | 10,473 | 6,201 | 4,272 | 469 | 2,517 | 7,487 |
Vicodin®, Lortab®, or Lorcet® | 15,172 | 8,417 | 6,756 | 1,173 | 4,736 | 9,264 |
Codeine | 6,859 | 4,219 | 2,640 | 521 | 2,005 | 4,333 |
Demerol® | 2,788 | 1,744 | 1,044 | 117 | 656 | 2,015 |
Dilaudid® | 963 | 667 | 296 | 12 | 93 | 858 |
Fioricet® | 455 | 216 | 239 | 17 | 59 | 379 |
Fiorinal® | 492 | 205 | 287 | 18 | 38 | 436 |
Hydrocodone | 5,398 | 3,055 | 2,343 | 389 | 1,930 | 3,079 |
Methadone | 1,131 | 712 | 419 | 116 | 386 | 629 |
Morphine | 2,067 | 1,315 | 752 | 230 | 734 | 1,103 |
OxyContin® | 2,609 | 1,634 | 975 | 261 | 1,114 | 1,235 |
Phenaphen® with Codeine | 772 | 477 | 294 | 59 | 202 | 511 |
Propoxyphene | 321 | 160 | 161 | 29 | 71 | 221 |
SK-65® | 42 | 27 | 15 | 12 | 13 | 16 |
Stadol® | 148 | 82 | 66 | 5 | 29 | 113 |
Talacen® | 71 | 45 | 26 | 10 | 17 | 44 |
Talwin® | 457 | 285 | 172 | 11 | 20 | 425 |
Talwin® NX | 86 | 44 | 42 | 9 | 12 | 65 |
Tramadol | 188 | 124 | 64 | 15 | 62 | 111 |
Ultram® | 1,060 | 530 | 530 | 72 | 316 | 672 |
SELECTED GROUPS OF DRUGS | ||||||
Propoxyphene or Codeine Products1,2 | 21,049 | 11,725 | 9,325 | 1,697 | 4,547 | 14,805 |
Oxycodone Products1,3 | 11,203 | 6,637 | 4,566 | 607 | 2,873 | 7,723 |
Hydrocodone Products1,4 | 16,165 | 8,932 | 7,233 | 1,296 | 5,046 | 9,823 |
Tramadol Products1,5 | 1,165 | 594 | 571 | 82 | 353 | 730 |
51215
Pain Reliever | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
Darvocet®, Darvon®, or Tylenol® with Codeine | 8.1 | 9.3 | 7.1 | 6.0 | 12.7 | 7.7 |
Percocet®, Percodan®, or Tylox® | 4.4 | 5.4 | 3.5 | 1.9 | 8.0 | 4.1 |
Vicodin®, Lortab®, or Lorcet® | 6.4 | 7.3 | 5.5 | 4.7 | 15.0 | 5.1 |
Codeine | 2.9 | 3.7 | 2.2 | 2.1 | 6.3 | 2.4 |
Demerol® | 1.2 | 1.5 | 0.9 | 0.5 | 2.1 | 1.1 |
Dilaudid® | 0.4 | 0.6 | 0.2 | 0.0 | 0.3 | 0.5 |
Fioricet® | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 |
Fiorinal® | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 |
Hydrocodone | 2.3 | 2.7 | 1.9 | 1.6 | 6.1 | 1.7 |
Methadone | 0.5 | 0.6 | 0.3 | 0.5 | 1.2 | 0.3 |
Morphine | 0.9 | 1.1 | 0.6 | 0.9 | 2.3 | 0.6 |
OxyContin® | 1.1 | 1.4 | 0.8 | 1.0 | 3.5 | 0.7 |
Phenaphen® with Codeine | 0.3 | 0.4 | 0.2 | 0.2 | 0.6 | 0.3 |
Propoxyphene | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 |
SK-65® | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Stadol® | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 |
Talacen® | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
Talwin® | 0.2 | 0.2 | 0.1 | 0.0 | 0.1 | 0.2 |
Talwin® NX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tramadol | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 |
Ultram® | 0.4 | 0.5 | 0.4 | 0.3 | 1.0 | 0.4 |
SELECTED GROUPS OF DRUGS | ||||||
Propoxyphene or Codeine Products1,2 | 8.9 | 10.2 | 7.6 | 6.8 | 14.4 | 8.2 |
Oxycodone Products1,3 | 4.7 | 5.8 | 3.7 | 2.4 | 9.1 | 4.3 |
Hydrocodone Products1,4 | 6.8 | 7.8 | 5.9 | 5.2 | 15.9 | 5.4 |
Tramadol Products1,5 | 0.5 | 0.5 | 0.5 | 0.3 | 1.1 | 0.4 |
51215
Tranquilizer | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
Klonopin® or Clonazepam | 2,657 | 1,412 | 1,244 | 168 | 912 | 1,577 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 9,025 | 4,417 | 4,608 | 438 | 2,321 | 6,266 |
Valium® or Diazepam | 14,555 | 8,046 | 6,509 | 410 | 2,406 | 11,738 |
Atarax® | 283 | 171 | 112 | 22 | 43 | 219 |
BuSpar® | 661 | 333 | 328 | 49 | 228 | 383 |
Equanil® | 94 | 45 | 49 | 12 | 16 | 66 |
Flexeril® | 1,914 | 913 | 1,002 | 43 | 377 | 1,494 |
Librium® | 1,185 | 643 | 543 | 22 | 75 | 1,089 |
Limbitrol® | 84 | 41 | 43 | 10 | 22 | 51 |
Meprobamate | 153 | 98 | 55 | 13 | 15 | 126 |
Miltown® | 113 | 68 | 45 | 11 | 7 | 95 |
Rohypnol® | 376 | 243 | 134 | 37 | 163 | 176 |
Serax® | 167 | 91 | 75 | 12 | 26 | 129 |
Soma® | 2,488 | 1,332 | 1,156 | 144 | 832 | 1,512 |
Tranxene® | 182 | 99 | 83 | 11 | 23 | 148 |
Vistaril® | 296 | 130 | 166 | 17 | 51 | 228 |
SELECTED GROUPS OF DRUGS | ||||||
Benzodiazepines1,2 | 18,569 | 9,646 | 8,922 | 722 | 3,490 | 14,357 |
Meprobamate Products1,3 | 314 | 183 | 131 | 31 | 35 | 247 |
Muscle Relaxants1,4 | 3,662 | 1,876 | 1,786 | 171 | 1,030 | 2,461 |
51215
Tranquilizer | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
Klonopin® or Clonazepam | 1.1 | 1.2 | 1.0 | 0.7 | 2.9 | 0.9 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 3.8 | 3.8 | 3.8 | 1.8 | 7.3 | 3.5 |
Valium® or Diazepam | 6.1 | 7.0 | 5.3 | 1.6 | 7.6 | 6.5 |
Atarax® | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
BuSpar® | 0.3 | 0.3 | 0.3 | 0.2 | 0.7 | 0.2 |
Equanil® | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Flexeril® | 0.8 | 0.8 | 0.8 | 0.2 | 1.2 | 0.8 |
Librium® | 0.5 | 0.6 | 0.4 | 0.1 | 0.2 | 0.6 |
Limbitrol® | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
Meprobamate | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 |
Miltown® | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 |
Rohypnol® | 0.2 | 0.2 | 0.1 | 0.1 | 0.5 | 0.1 |
Serax® | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 |
Soma® | 1.0 | 1.2 | 0.9 | 0.6 | 2.6 | 0.8 |
Tranxene® | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 |
Vistaril® | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 |
SELECTED GROUPS OF DRUGS | ||||||
Benzodiazepines1,2 | 7.8 | 8.4 | 7.3 | 2.9 | 11.0 | 7.9 |
Meprobamate Products1,3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
Muscle Relaxants1,4 | 1.5 | 1.6 | 1.5 | 0.7 | 3.3 | 1.4 |
51215
Stimulants | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
Methamphetamine,1 Desoxyn®, or Methedrine® | 12,138 | 7,250 | 4,888 | 331 | 1,698 | 10,109 |
Prescription Diet Pills2 | 8,585 | 4,505 | 4,080 | 251 | 708 | 7,626 |
Ritalin® or Methylphenidate | 4,293 | 2,577 | 1,716 | 526 | 1,732 | 2,035 |
Cylert® | 209 | 137 | 72 | 22 | 36 | 151 |
Dexedrine® | 2,803 | 1,587 | 1,216 | 67 | 309 | 2,427 |
Dextroamphetamine | 575 | 334 | 241 | 28 | 80 | 467 |
Didrex® | 186 | 95 | 91 | 18 | 30 | 138 |
Eskatrol® | 227 | 138 | 89 | 10 | 11 | 206 |
Ionamin® | 511 | 291 | 220 | 19 | 21 | 471 |
Mazanor® | 54 | 20 | 34 | 13 | 6 | 34 |
Obedrin-LA® | 33 | 8 | 24 | 7 | 4 | 23 |
Plegine® | 46 | 31 | 15 | 10 | 4 | 31 |
Preludin® | 697 | 447 | 250 | 12 | 37 | 648 |
Sanorex® | 116 | 73 | 44 | 18 | 24 | 73 |
Tenuate® | 214 | 77 | 137 | 11 | 14 | 189 |
SELECTED GROUPS OF DRUGS | ||||||
Amphetamine, Dextroamphetamine, and Phentermine Products3,4 | 10,059 | 5,260 | 4,799 | 370 | 1,121 | 8,568 |
Mazindol Products3,5 | 157 | 90 | 66 | 27 | 27 | 103 |
51215
Stimulants | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
Methamphetamine,1 Desoxyn®, or Methedrine® | 5.1 | 6.3 | 4.0 | 1.3 | 5.4 | 5.6 |
Prescription Diet Pills2 | 3.6 | 3.9 | 3.3 | 1.0 | 2.2 | 4.2 |
Ritalin® or Methylphenidate | 1.8 | 2.2 | 1.4 | 2.1 | 5.5 | 1.1 |
Cylert® | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Dexedrine® | 1.2 | 1.4 | 1.0 | 0.3 | 1.0 | 1.3 |
Dextroamphetamine | 0.2 | 0.3 | 0.2 | 0.1 | 0.3 | 0.3 |
Didrex® | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Eskatrol® | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
Ionamin® | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.3 |
Mazanor® | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Obedrin-LA® | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Plegine® | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Preludin® | 0.3 | 0.4 | 0.2 | 0.0 | 0.1 | 0.4 |
Sanorex® | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 |
Tenuate® | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
SELECTED GROUPS OF DRUGS | ||||||
Amphetamine, Dextroamphetamine, and Phentermine Products3,4 | 4.2 | 4.6 | 3.9 | 1.5 | 3.5 | 4.7 |
Mazindol Products3,5 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
51215
Sedative | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003 and 2004. |
||||||
Methaqualone, Sopor®, or Quaalude® | 7,144 | 4,325 | 2,818 | 59 | 272 | 6,812 |
Barbiturates1 | 3,093 | 1,985 | 1,108 | 37 | 113 | 2,943 |
Restoril® or Temazepam | 901 | 440 | 462 | 47 | 106 | 749 |
Amytal® | 244 | 185 | 59 | 17 | 21 | 206 |
Butisol® | 94 | 68 | 26 | 13 | 16 | 64 |
Chloral Hydrate | 194 | 98 | 96 | 12 | 15 | 167 |
Dalmane® | 504 | 293 | 211 | 28 | 17 | 459 |
Halcion® | 760 | 370 | 390 | 25 | 57 | 678 |
Phenobarbital | 1,333 | 776 | 557 | 30 | 93 | 1,210 |
Placidyl® | 905 | 611 | 293 | 9 | 20 | 875 |
Tuinal® | 1,164 | 721 | 443 | 10 | 13 | 1,141 |
SELECTED GROUPS OF DRUGS | ||||||
Temazepam, Flurazepam, or Triazolam2,3 | 1,751 | 898 | 853 | 84 | 164 | 1,504 |
Any Barbiturates2,4 | 3,816 | 2,360 | 1,456 | 84 | 195 | 3,537 |
51215
Sedative | Total | GENDER | AGE GROUP | |||
---|---|---|---|---|---|---|
Male | Female | 12 to 17 | 18 to 25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003 and 2004. |
||||||
Methaqualone, Sopor®, or Quaalude® | 3.0 | 3.8 | 2.3 | 0.2 | 0.9 | 3.8 |
Barbiturates1 | 1.3 | 1.7 | 0.9 | 0.1 | 0.4 | 1.6 |
Restoril® or Temazepam | 0.4 | 0.4 | 0.4 | 0.2 | 0.3 | 0.4 |
Amytal® | 0.1 | 0.2 | 0.0 | 0.1 | 0.1 | 0.1 |
Butisol® | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 |
Chloral Hydrate | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
Dalmane® | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.3 |
Halcion® | 0.3 | 0.3 | 0.3 | 0.1 | 0.2 | 0.4 |
Phenobarbital | 0.6 | 0.7 | 0.5 | 0.1 | 0.3 | 0.7 |
Placidyl® | 0.4 | 0.5 | 0.2 | 0.0 | 0.1 | 0.5 |
Tuinal® | 0.5 | 0.6 | 0.4 | 0.0 | 0.0 | 0.6 |
SELECTED GROUPS OF DRUGS | ||||||
Temazepam, Flurazepam, or Triazolam2,3 | 0.7 | 0.8 | 0.7 | 0.3 | 0.5 | 0.8 |
Any Barbiturates2,4 | 1.6 | 2.1 | 1.2 | 0.3 | 0.6 | 2.0 |
51117
Pain Reliever | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY PAIN RELIEVER | 30,862 | 2,817 | 7,393 | 20,652 |
Darvocet®, Darvon®, or Tylenol® with Codeine | 19,366 | 1,490 | 4,007 | 13,868 |
Percocet®, Percodan®, or Tylox® | 10,473 | 469 | 2,517 | 7,487 |
Vicodin®, Lortab®, or Lorcet® | 15,172 | 1,173 | 4,736 | 9,264 |
Codeine | 6,859 | 521 | 2,005 | 4,333 |
Demerol® | 2,788 | 117 | 656 | 2,015 |
Dilaudid® | 963 | 12 | 93 | 858 |
Fioricet® | 455 | 17 | 59 | 379 |
Fiorinal® | 492 | 18 | 38 | 436 |
Hydrocodone | 5,398 | 389 | 1,930 | 3,079 |
Methadone | 1,131 | 116 | 386 | 629 |
Morphine | 2,067 | 230 | 734 | 1,103 |
OxyContin® | 2,609 | 261 | 1,114 | 1,235 |
Phenaphen® with Codeine | 772 | 59 | 202 | 511 |
Propoxyphene | 321 | 29 | 71 | 221 |
SK-65® | 42 | 12 | 13 | 16 |
Stadol® | 148 | 5 | 29 | 113 |
Talacen® | 71 | 10 | 17 | 44 |
Talwin® | 457 | 11 | 20 | 425 |
Talwin® NX | 86 | 9 | 12 | 65 |
Tramadol | 188 | 15 | 62 | 111 |
Ultram® | 1,060 | 72 | 316 | 672 |
SELECTED GROUPS OF DRUGS | ||||
Propoxyphene or Codeine Products1,2 | 21,049 | 1,697 | 4,547 | 14,805 |
Oxycodone Products1,3 | 11,203 | 607 | 2,873 | 7,723 |
Hydrocodone Products1,4 | 16,165 | 1,296 | 5,046 | 9,823 |
Tramadol Products1,5 | 1,165 | 82 | 353 | 730 |
51117
Pain Reliever | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of lifetime nonmedical users of any prescription pain reliever. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY PAIN RELIEVER | 100.0 | 100.0 | 100.0 | 100.0 |
Darvocet®, Darvon®, or Tylenol® with Codeine | 62.7 | 52.9 | 54.2 | 67.2 |
Percocet®, Percodan®, or Tylox® | 33.9 | 16.7 | 34.0 | 36.3 |
Vicodin®, Lortab®, or Lorcet® | 49.2 | 41.6 | 64.1 | 44.9 |
Codeine | 22.2 | 18.5 | 27.1 | 21.0 |
Demerol® | 9.0 | 4.2 | 8.9 | 9.8 |
Dilaudid® | 3.1 | 0.4 | 1.3 | 4.2 |
Fioricet® | 1.5 | 0.6 | 0.8 | 1.8 |
Fiorinal® | 1.6 | 0.6 | 0.5 | 2.1 |
Hydrocodone | 17.5 | 13.8 | 26.1 | 14.9 |
Methadone | 3.7 | 4.1 | 5.2 | 3.0 |
Morphine | 6.7 | 8.2 | 9.9 | 5.3 |
OxyContin® | 8.5 | 9.3 | 15.1 | 6.0 |
Phenaphen® with Codeine | 2.5 | 2.1 | 2.7 | 2.5 |
Propoxyphene | 1.0 | 1.0 | 1.0 | 1.1 |
SK-65® | 0.1 | 0.4 | 0.2 | 0.1 |
Stadol® | 0.5 | 0.2 | 0.4 | 0.5 |
Talacen® | 0.2 | 0.4 | 0.2 | 0.2 |
Talwin® | 1.5 | 0.4 | 0.3 | 2.1 |
Talwin® NX | 0.3 | 0.3 | 0.2 | 0.3 |
Tramadol | 0.6 | 0.5 | 0.8 | 0.5 |
Ultram® | 3.4 | 2.5 | 4.3 | 3.3 |
SELECTED GROUPS OF DRUGS | ||||
Propoxyphene or Codeine Products1,2 | 68.2 | 60.2 | 61.5 | 71.7 |
Oxycodone Products1,3 | 36.3 | 21.5 | 38.9 | 37.4 |
Hydrocodone Products1,4 | 52.4 | 46.0 | 68.2 | 47.6 |
Tramadol Products1,5 | 3.8 | 2.9 | 4.8 | 3.5 |
51117
Pain Reliever | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY PAIN RELIEVER | 2,399 | 902 | 881 | 615 |
Darvocet®, Darvon®, or Tylenol® with Codeine | 822 | 362 | 255 | 205 |
Percocet®, Percodan®, or Tylox® | 426 | 143 | 190 | 93 |
Vicodin®, Lortab®, or Lorcet® | 1,207 | 433 | 499 | 274 |
Codeine | 328 | 163 | 141 | 25 |
Demerol® | 69 | 21 | 35 | 13 |
Dilaudid® | 8 | 3 | 2 | * |
Fioricet® | 8 | 3 | 5 | 0 |
Fiorinal® | 10 | 6 | 1 | 3 |
Hydrocodone | 369 | 134 | 146 | 89 |
Methadone | 52 | 29 | 14 | 9 |
Morphine | 109 | 63 | 34 | 12 |
OxyContin® | 170 | 78 | 78 | 14 |
Phenaphen® with Codeine | 23 | 15 | 8 | 1 |
Propoxyphene | 10 | 5 | 2 | 3 |
SK-65® | 4 | 3 | 1 | * |
Stadol® | 1 | * | 0 | 1 |
Talacen® | 6 | 4 | 2 | * |
Talwin® | 2 | 1 | 1 | * |
Talwin® NX | 3 | 2 | 0 | * |
Tramadol | 12 | 2 | 6 | * |
Ultram® | 55 | 18 | 18 | * |
SELECTED GROUPS OF DRUGS | ||||
Propoxyphene or Codeine Products1,2 | 997 | 443 | 332 | 222 |
Oxycodone Products1,3 | 528 | 188 | 239 | 101 |
Hydrocodone Products1,4 | 1,368 | 486 | 556 | 326 |
Tramadol Products1,5 | 67 | 21 | 23 | 23 |
51117
Pain Reliever | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of persons who initiated nonmedical use of any prescription pain reliever in the past 12 months. 1 Includes other-specify drug responses that are not asked about explicitly in the pain relievers module but fall into this category. 2 Includes Darvocet®, Darvon® or Tylenol® with Codeine, codeine, Phenaphen® with Codeine, propoxyphene, and SK-65®. 3 Includes Percocet®, Percodan® or Tylox®, and OxyContin®. 4 Includes Vicodin®, Lortab®, or Lorcet®, and hydrocodone. 5 Includes tramadol and Ultram®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY PAIN RELIEVER | 100.0 | 100.0 | 100.0 | 100.0 |
Darvocet®, Darvon®, or Tylenol® with Codeine | 34.3 | 40.1 | 28.9 | 33.3 |
Percocet®, Percodan®, or Tylox® | 17.8 | 15.9 | 21.5 | 15.2 |
Vicodin®, Lortab®, or Lorcet® | 50.3 | 48.0 | 56.6 | 44.6 |
Codeine | 13.7 | 18.0 | 16.0 | 4.0 |
Demerol® | 2.9 | 2.3 | 4.0 | 2.1 |
Dilaudid® | 0.3 | 0.4 | 0.3 | * |
Fioricet® | 0.3 | 0.4 | 0.5 | 0.0 |
Fiorinal® | 0.4 | 0.7 | 0.1 | 0.5 |
Hydrocodone | 15.4 | 14.9 | 16.5 | 14.5 |
Methadone | 2.2 | 3.2 | 1.6 | 1.5 |
Morphine | 4.5 | 6.9 | 3.9 | 2.0 |
OxyContin® | 7.1 | 8.7 | 8.8 | 2.3 |
Phenaphen® with Codeine | 1.0 | 1.6 | 0.9 | 0.1 |
Propoxyphene | 0.4 | 0.6 | 0.3 | 0.5 |
SK-65® | 0.2 | 0.3 | 0.1 | * |
Stadol® | 0.0 | * | 0.0 | 0.1 |
Talacen® | 0.2 | 0.5 | 0.2 | * |
Talwin® | 0.1 | 0.1 | 0.1 | * |
Talwin® NX | 0.1 | 0.3 | 0.0 | * |
Tramadol | 0.5 | 0.3 | 0.7 | * |
Ultram® | 2.3 | 2.0 | 2.1 | * |
SELECTED GROUPS OF DRUGS | ||||
Propoxyphene or Codeine Products1,2 | 41.6 | 49.1 | 37.6 | 36.1 |
Oxycodone Products1,3 | 22.0 | 20.8 | 27.1 | 16.4 |
Hydrocodone Products1,4 | 57.0 | 53.9 | 63.1 | 53.0 |
Tramadol Products1,5 | 2.8 | 2.3 | 2.7 | 3.8 |
51117
Tranquilizer | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY TRANQUILIZER | 19,780 | 842 | 3,763 | 15,175 |
Klonopin® or Clonazepam | 2,657 | 168 | 912 | 1,577 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 9,025 | 438 | 2,321 | 6,266 |
Valium® or Diazepam | 14,555 | 410 | 2,406 | 11,738 |
Atarax® | 283 | 22 | 43 | 219 |
BuSpar® | 661 | 49 | 228 | 383 |
Equanil® | 94 | 12 | 16 | 66 |
Flexeril® | 1,914 | 43 | 377 | 1,494 |
Librium® | 1,185 | 22 | 75 | 1,089 |
Limbitrol® | 84 | 10 | 22 | 51 |
Meprobamate | 153 | 13 | 15 | 126 |
Miltown® | 113 | 11 | 7 | 95 |
Rohypnol® | 376 | 37 | 163 | 176 |
Serax® | 167 | 12 | 26 | 129 |
Soma® | 2,488 | 144 | 832 | 1,512 |
Tranxene® | 182 | 11 | 23 | 148 |
Vistaril® | 296 | 17 | 51 | 228 |
SELECTED GROUPS OF DRUGS | ||||
Benzodiazepines1,2 | 18,569 | 722 | 3,490 | 14,357 |
Meprobamate Products1,3 | 314 | 31 | 35 | 247 |
Muscle Relaxants1,4 | 3,662 | 171 | 1,030 | 2,461 |
51117
Tranquilizer | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of lifetime nonmedical users of any prescription tranquilizer. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY TRANQUILIZER | 100.0 | 100.0 | 100.0 | 100.0 |
Klonopin® or Clonazepam | 13.4 | 19.9 | 24.2 | 10.4 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 45.6 | 52.1 | 61.7 | 41.3 |
Valium® or Diazepam | 73.6 | 48.7 | 63.9 | 77.4 |
Atarax® | 1.4 | 2.6 | 1.1 | 1.4 |
BuSpar® | 3.3 | 5.8 | 6.1 | 2.5 |
Equanil® | 0.5 | 1.4 | 0.4 | 0.4 |
Flexeril® | 9.7 | 5.1 | 10.0 | 9.8 |
Librium® | 6.0 | 2.6 | 2.0 | 7.2 |
Limbitrol® | 0.4 | 1.2 | 0.6 | 0.3 |
Meprobamate | 0.8 | 1.5 | 0.4 | 0.8 |
Miltown® | 0.6 | 1.3 | 0.2 | 0.6 |
Rohypnol® | 1.9 | 4.4 | 4.3 | 1.2 |
Serax® | 0.8 | 1.4 | 0.7 | 0.8 |
Soma® | 12.6 | 17.1 | 22.1 | 10.0 |
Tranxene® | 0.9 | 1.3 | 0.6 | 1.0 |
Vistaril® | 1.5 | 2.1 | 1.4 | 1.5 |
SELECTED GROUPS OF DRUGS | ||||
Benzodiazepines1,2 | 93.9 | 85.8 | 92.7 | 94.6 |
Meprobamate Products1,3 | 1.6 | 3.7 | 0.9 | 1.6 |
Muscle Relaxants1,4 | 18.5 | 20.3 | 27.4 | 16.2 |
51117
Tranquilizer | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY TRANQUILIZER | 1,145 | 315 | 431 | 400 |
Klonopin® or Clonazepam | 167 | 48 | 68 | 50 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 583 | 155 | 230 | 198 |
Valium® or Diazepam | 481 | 134 | 194 | 154 |
Atarax® | 13 | 7 | 6 | * |
BuSpar® | 37 | 16 | 13 | 8 |
Equanil® | 7 | 5 | 1 | * |
Flexeril® | 80 | 14 | 20 | 45 |
Librium® | 15 | 10 | 4 | * |
Limbitrol® | 2 | 0 | 1 | * |
Meprobamate | 6 | 4 | 0 | * |
Miltown® | 4 | 4 | * | * |
Rohypnol® | 14 | 11 | 3 | * |
Serax® | 4 | 4 | * | * |
Soma® | 147 | 45 | 66 | 36 |
Tranxene® | 7 | 2 | 3 | * |
Vistaril® | 13 | 7 | 4 | * |
SELECTED GROUPS OF DRUGS | ||||
Benzodiazepines1,2 | 979 | 262 | 378 | 339 |
Meprobamate Products1,3 | 15 | 12 | 2 | * |
Muscle Relaxants1,4 | 211 | 59 | 78 | 75 |
51117
Tranquilizer | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of persons who initiated nonmedical use of any prescription tranquilizer in the past 12 months. 1 Includes other-specify drug responses that are not asked about explicitly in the tranquilizers module but fall into this category. 2 Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan®, or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®. 3 Includes Equanil®, meprobamate, and Miltown®. 4 Includes Flexeril® and Soma®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY TRANQUILIZER | 100.0 | 100.0 | 100.0 | 100.0 |
Klonopin® or Clonazepam | 14.5 | 15.3 | 15.9 | 12.5 |
Xanax®, Alprazolam, Ativan®, or Lorazepam | 50.9 | 49.4 | 53.3 | 49.4 |
Valium® or Diazepam | 42.0 | 42.6 | 44.9 | 38.5 |
Atarax® | 1.1 | 2.1 | 1.4 | * |
BuSpar® | 3.2 | 5.0 | 3.1 | 2.0 |
Equanil® | 0.6 | 1.6 | 0.3 | * |
Flexeril® | 7.0 | 4.5 | 4.7 | 11.3 |
Librium® | 1.3 | 3.3 | 0.8 | * |
Limbitrol® | 0.1 | 0.1 | 0.3 | * |
Meprobamate | 0.5 | 1.3 | 0.1 | * |
Miltown® | 0.4 | 1.4 | * | * |
Rohypnol® | 1.2 | 3.4 | 0.7 | * |
Serax® | 0.3 | 1.1 | * | * |
Soma® | 12.8 | 14.2 | 15.4 | 9.0 |
Tranxene® | 0.6 | 0.6 | 0.6 | * |
Vistaril® | 1.1 | 2.2 | 0.9 | * |
SELECTED GROUPS OF DRUGS | ||||
Benzodiazepines1,2 | 85.5 | 83.3 | 87.7 | 84.8 |
Meprobamate Products1,3 | 1.3 | 3.8 | 0.5 | * |
Muscle Relaxants1,4 | 18.5 | 18.6 | 18.1 | 18.7 |
51117
Stimulant | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY STIMULANT | 20,617 | 983 | 3,395 | 16,239 |
Methamphetamine,1 Desoxyn®, or Methedrine® | 12,138 | 331 | 1,698 | 10,109 |
Prescription Diet Pills2 | 8,585 | 251 | 708 | 7,626 |
Ritalin® or Methylphenidate | 4,293 | 526 | 1,732 | 2,035 |
Cylert® | 209 | 22 | 36 | 151 |
Dexedrine® | 2,803 | 67 | 309 | 2,427 |
Dextroamphetamine | 575 | 28 | 80 | 467 |
Didrex® | 186 | 18 | 30 | 138 |
Eskatrol® | 227 | 10 | 11 | 206 |
Ionamin® | 511 | 19 | 21 | 471 |
Mazanor® | 54 | 13 | 6 | 34 |
Obedrin-LA® | 33 | 7 | 4 | 23 |
Plegine® | 46 | 10 | 4 | 31 |
Preludin® | 697 | 12 | 37 | 648 |
Sanorex® | 116 | 18 | 24 | 73 |
Tenuate® | 214 | 11 | 14 | 189 |
SELECTED GROUPS OF DRUGS | ||||
Amphetamine, Dextroamphetamine, and Phentermine Products3,4 | 10,059 | 370 | 1,121 | 8,568 |
Mazindol Products3,5 | 157 | 27 | 27 | 103 |
51117
Stimulant | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of lifetime nonmedical users of any prescription stimulant or methamphetamine. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY STIMULANT | 100.0 | 100.0 | 100.0 | 100.0 |
Methamphetamine,1 Desoxyn®, or Methedrine® | 58.9 | 33.7 | 50.0 | 62.2 |
Prescription Diet Pills2 | 41.6 | 25.6 | 20.9 | 47.0 |
Ritalin® or Methylphenidate | 20.8 | 53.6 | 51.0 | 12.5 |
Cylert® | 1.0 | 2.3 | 1.1 | 0.9 |
Dexedrine® | 13.6 | 6.8 | 9.1 | 14.9 |
Dextroamphetamine | 2.8 | 2.8 | 2.4 | 2.9 |
Didrex® | 0.9 | 1.8 | 0.9 | 0.8 |
Eskatrol® | 1.1 | 1.0 | 0.3 | 1.3 |
Ionamin® | 2.5 | 1.9 | 0.6 | 2.9 |
Mazanor® | 0.3 | 1.4 | 0.2 | 0.2 |
Obedrin-LA® | 0.2 | 0.7 | 0.1 | 0.1 |
Plegine® | 0.2 | 1.0 | 0.1 | 0.2 |
Preludin® | 3.4 | 1.2 | 1.1 | 4.0 |
Sanorex® | 0.6 | 1.9 | 0.7 | 0.5 |
Tenuate® | 1.0 | 1.1 | 0.4 | 1.2 |
SELECTED GROUPS OF DRUGS | ||||
Amphetamine, Dextroamphetamine, and Phentermine Products3,4 | 48.8 | 37.6 | 33.0 | 52.8 |
Mazindol Products3,5 | 0.8 | 2.8 | 0.8 | 0.6 |
51117
Stimulant | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY STIMULANT | 764 | 301 | 307 | * |
Methamphetamine,1 Desoxyn®, or Methedrine® | 240 | 94 | 97 | * |
Prescription Diet Pills2 | 157 | 70 | 53 | * |
Ritalin® or Methylphenidate | 323 | 143 | 125 | * |
Cylert® | 5 | 3 | 1 | * |
Dexedrine® | 38 | 16 | 18 | * |
Dextroamphetamine | 10 | 4 | 3 | * |
Didrex® | 10 | 4 | 1 | * |
Eskatrol® | 6 | 3 | 1 | * |
Ionamin® | 6 | 4 | 3 | * |
Mazanor® | 2 | 2 | * | * |
Obedrin-LA® | 1 | 1 | * | * |
Plegine® | 3 | 3 | 0 | * |
Preludin® | 2 | 2 | 0 | * |
Sanorex® | 5 | 4 | 1 | * |
Tenuate® | 2 | 2 | 0 | * |
SELECTED GROUPS OF DRUGS | ||||
Amphetamine, Dextroamphetamine, and Phentermine Products3,4 | 283 | 112 | 121 | * |
Mazindol Products3,5 | 7 | 6 | 1 | * |
51117
Stimulant | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of persons who initiated nonmedical use of any prescription stimulant or methamphetamine reliever in the past 12 months. 1 Also known as crank, crystal, ice, or speed. 2 Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine®, Biphetamine®, Fastin®, or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills. 3 Includes other-specify drug responses that are not asked about explicitly in the stimulants module but fall into this category. 4 Includes prescription diet pills, Dexedrine®, dextroamphetamine, and Ionamin®. 5 Includes Mazanor® and Sanorex®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY STIMULANT | 100.0 | 100.0 | 100.0 | * |
Methamphetamine,1 Desoxyn®, or Methedrine® | 31.5 | 31.3 | 31.5 | * |
Prescription Diet Pills2 | 20.6 | 23.2 | 17.2 | * |
Ritalin® or Methylphenidate | 42.3 | 47.5 | 40.8 | * |
Cylert® | 0.7 | 0.9 | 0.2 | * |
Dexedrine® | 4.9 | 5.4 | 6.0 | * |
Dextroamphetamine | 1.3 | 1.3 | 1.0 | * |
Didrex® | 1.3 | 1.5 | 0.3 | * |
Eskatrol® | 0.7 | 0.8 | 0.3 | * |
Ionamin® | 0.8 | 1.2 | 0.9 | * |
Mazanor® | 0.3 | 0.8 | * | * |
Obedrin-LA® | 0.1 | 0.2 | * | * |
Plegine® | 0.4 | 0.9 | 0.1 | * |
Preludin® | 0.3 | 0.5 | 0.1 | * |
Sanorex® | 0.6 | 1.2 | 0.3 | * |
Tenuate® | 0.3 | 0.6 | 0.2 | * |
SELECTED GROUPS OF DRUGS | ||||
Amphetamine, Dextroamphetamine, and Phentermine Products3,4 | 37.0 | 37.0 | 39.3 | * |
Mazindol Products3,5 | 0.9 | 1.9 | 0.3 | * |
51117
Sedative | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY SEDATIVE | 9,787 | 246 | 613 | 8,928 |
Methaqualone, Sopor®, or Quaalude® | 7,144 | 59 | 272 | 6,812 |
Barbiturates1 | 3,093 | 37 | 113 | 2,943 |
Restoril® or Temazepam | 901 | 47 | 106 | 749 |
Amytal® | 244 | 17 | 21 | 206 |
Butisol® | 94 | 13 | 16 | 64 |
Chloral Hydrate | 194 | 12 | 15 | 167 |
Dalmane® | 504 | 28 | 17 | 459 |
Halcion® | 760 | 25 | 57 | 678 |
Phenobarbital | 1,333 | 30 | 93 | 1,210 |
Placidyl® | 905 | 9 | 20 | 875 |
Tuinal® | 1,164 | 10 | 13 | 1,141 |
SELECTED GROUPS OF DRUGS | ||||
Temazepam, Flurazepam, or Triazolam2,3 | 1,751 | 84 | 164 | 1,504 |
Any Barbiturates2,4 | 3,816 | 84 | 195 | 3,537 |
51117
Sedative | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of lifetime nonmedical users of any prescription sedative. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY SEDATIVE | 100.0 | 100.0 | 100.0 | 100.0 |
Methaqualone, Sopor®, or Quaalude® | 73.0 | 24.1 | 44.4 | 76.3 |
Barbiturates1 | 31.6 | 14.9 | 18.5 | 33.0 |
Restoril® or Temazepam | 9.2 | 18.9 | 17.2 | 8.4 |
Amytal® | 2.5 | 6.9 | 3.4 | 2.3 |
Butisol® | 1.0 | 5.4 | 2.6 | 0.7 |
Chloral Hydrate | 2.0 | 4.9 | 2.4 | 1.9 |
Dalmane® | 5.2 | 11.6 | 2.7 | 5.1 |
Halcion® | 7.8 | 10.0 | 9.4 | 7.6 |
Phenobarbital | 13.6 | 12.3 | 15.1 | 13.6 |
Placidyl® | 9.2 | 3.8 | 3.3 | 9.8 |
Tuinal® | 11.9 | 4.0 | 2.1 | 12.8 |
SELECTED GROUPS OF DRUGS | ||||
Temazepam, Flurazepam, or Triazolam2,3 | 17.9 | 34.1 | 26.7 | 16.8 |
Any Barbiturates2,4 | 39.0 | 34.2 | 31.9 | 39.6 |
51117
Sedative | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY SEDATIVE | 214 | 65 | 49 | * |
Methaqualone, Sopor®, or Quaalude® | 23 | 15 | 5 | * |
Barbiturates1 | 23 | 7 | 4 | * |
Restoril® or Temazepam | 37 | 12 | * | * |
Amytal® | 2 | 2 | * | * |
Butisol® | 6 | 4 | 2 | * |
Chloral Hydrate | 4 | 3 | * | * |
Dalmane® | 9 | 7 | * | * |
Halcion® | 16 | 4 | 4 | * |
Phenobarbital | 17 | 8 | 4 | * |
Placidyl® | 1 | 1 | * | * |
Tuinal® | 0 | * | * | * |
SELECTED GROUPS OF DRUGS | ||||
Temazepam, Flurazepam, or Triazolam2,3 | 58 | 20 | 13 | * |
Any Barbiturates2,4 | 45 | 18 | 9 | * |
51117
Sedative | TOTAL | AGE GROUP | ||
---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||
*Low precision; no estimate reported. NOTE: The denominator for percentages is the total number of persons who initiated nonmedical use of any prescription sedative in the past 12 months. 1 Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal®, pentobarbital, Seconal®, secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates. 2 Includes other-specify drug responses that are not asked about explicitly in the sedatives module but fall into this category. 3 Includes Restoril®, temazepam, Dalmane®, or Halcion®. 4 Includes barbiturates, Amytal®, Butisol®, phenobarbital, and Tuinal®. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
ANY SEDATIVE | 100.0 | 100.0 | 100.0 | * |
Methaqualone, Sopor®, or Quaalude® | 11.0 | 23.4 | 10.3 | * |
Barbiturates1 | 10.8 | 10.8 | 7.1 | * |
Restoril® or Temazepam | 17.4 | 18.2 | * | * |
Amytal® | 1.2 | 3.4 | * | * |
Butisol® | 2.6 | 5.7 | 3.7 | * |
Chloral Hydrate | 1.6 | 4.4 | * | * |
Dalmane® | 4.1 | 10.9 | * | * |
Halcion® | 7.6 | 6.2 | 8.8 | * |
Phenobarbital | 8.1 | 13.0 | 7.9 | * |
Placidyl® | 0.3 | 1.1 | * | * |
Tuinal® | 0.1 | * | * | * |
SELECTED GROUPS OF DRUGS | ||||
Temazepam, Flurazepam, or Triazolam2,3 | 27.2 | 30.5 | 26.6 | * |
Any Barbiturates2,4 | 21.2 | 28.4 | 19.0 | * |
51122
Drug | NUMBER OF PAST YEAR INITIATES (1,000s)1 | PERCENTAGE OF PAST YEAR INITIATES AMONG TOTAL POPULATION1 | PERCENTAGE OF PAST YEAR INITIATES AMONG PERSONS AT RISK FOR INITIATION1,2 | PERCENTAGE OF PAST YEAR INITIATES AMONG PAST YEAR USERS1 |
---|---|---|---|---|
Aged 12 or Older | ||||
*Low precision; no estimate reported. 1 Past Year Initiates are defined as persons who used the substance(s) for the first time in the 12 months prior to date of interview. 2 At Risk for Initiation is defined as persons who did not use the substance(s) in their lifetime or used the substance(s) for the first time in the past year. 3 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 4 Estimates for OxyContin® are based on 2004 data only. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
Nonmedical Use of Any Psychotherapeutics3 | 2,657 | 1.1 | 1.4 | 18.0 |
Pain Relievers | 2,399 | 1.0 | 1.1 | 21.2 |
OxyContin®4 | 615 | 0.3 | 0.3 | 50.7 |
Tranquilizers | 1,145 | 0.5 | 0.5 | 23.0 |
Stimulants | 764 | 0.3 | 0.4 | 25.9 |
Methamphetamine | 292 | 0.1 | 0.1 | 20.4 |
Sedatives | 214 | 0.1 | 0.1 | 25.2 |
Drug | Aged 12 to 17 | |||
Nonmedical Use of Any Psychotherapeutics3 | 959 | 3.8 | 4.3 | 42.3 |
Pain Relievers | 902 | 3.6 | 3.9 | 47.8 |
OxyContin®4 | 141 | 0.6 | 0.6 | 72.8 |
Tranquilizers | 315 | 1.3 | 1.3 | 56.0 |
Stimulants | 301 | 1.2 | 1.2 | 52.8 |
Methamphetamine | 112 | 0.4 | 0.5 | 60.0 |
Sedatives | 65 | 0.3 | 0.3 | 48.4 |
Drug | Aged 18 to 25 | |||
Nonmedical Use of Any Psychotherapeutics3 | 948 | 3.0 | 4.0 | 20.6 |
Pain Relievers | 881 | 2.8 | 3.5 | 23.6 |
OxyContin®4 | 290 | 0.9 | 0.9 | 51.6 |
Tranquilizers | 431 | 1.4 | 1.5 | 26.7 |
Stimulants | 307 | 1.0 | 1.1 | 26.8 |
Methamphetamine | 121 | 0.4 | 0.4 | 23.5 |
Sedatives | 49 | 0.2 | 0.2 | 30.7 |
Drug | Aged 26 or Older | |||
Nonmedical Use of Any Psychotherapeutics3 | 750 | 0.4 | 0.5 | 9.5 |
Pain Relievers | 615 | 0.3 | 0.4 | 10.8 |
OxyContin®4 | 183 | 0.1 | 0.1 | * |
Tranquilizers | 400 | 0.2 | 0.2 | 14.2 |
Stimulants | 155 | 0.1 | 0.1 | 12.6 |
Methamphetamine | 59 | 0.0 | 0.0 | 8.1 |
Sedatives | 100 | 0.1 | 0.1 | 18.0 |
51122
Drug | NUMBER OF PAST YEAR INITIATES (1,000s)1 | PERCENTAGE OF PAST YEAR INITIATES AMONG TOTAL POPULATION1 | PERCENTAGE OF PAST YEAR INITIATES AMONG PERSONS AT RISK FOR INITIATION1,2 | PERCENTAGE OF PAST YEAR INITIATES AMONG PAST YEAR USERS1 |
---|---|---|---|---|
Males | ||||
*Low precision; no estimate reported. 1 Past Year Initiates are defined as persons who used the substance(s) for the first time in the 12 months prior to date of interview. 2 At Risk for Initiation is defined as persons who did not use the substance(s) in their lifetime or used the substance(s) for the first time in the past year. 3 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 4 Estimates for OxyContin® are based on 2004 data only. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
Nonmedical Use of Any Psychotherapeutics3 | 1,111 | 1.0 | 1.2 | 14.8 |
Pain Relievers | 1,063 | 0.9 | 1.1 | 17.8 |
OxyContin®4 | 339 | 0.3 | 0.3 | 45.7 |
Tranquilizers | 444 | 0.4 | 0.4 | 18.3 |
Stimulants | 328 | 0.3 | 0.3 | 21.3 |
Methamphetamine | 137 | 0.1 | 0.1 | 16.3 |
Sedatives | 68 | 0.1 | 0.1 | 17.9 |
Drug | Females | |||
Nonmedical Use of Any Psychotherapeutics3 | 1,546 | 1.3 | 1.5 | 21.2 |
Pain Relievers | 1,336 | 1.1 | 1.2 | 25.0 |
OxyContin®4 | 276 | 0.2 | 0.2 | 58.4 |
Tranquilizers | 702 | 0.6 | 0.6 | 27.4 |
Stimulants | 436 | 0.4 | 0.4 | 30.9 |
Methamphetamine | 155 | 0.1 | 0.1 | 26.2 |
Sedatives | 147 | 0.1 | 0.1 | 31.0 |
51122
Drug | NUMBER OF PAST YEAR INITIATES (1,000s)1 | PERCENTAGE OF PAST YEAR INITIATES AMONG TOTAL POPULATION1 | PERCENTAGE OF PAST YEAR INITIATES AMONG PERSONS AT RISK FOR INITIATION1,2 | PERCENTAGE OF PAST YEAR INITIATES AMONG PAST YEAR USERS1 |
---|---|---|---|---|
Northeast | ||||
*Low precision; no estimate reported. 1 Past Year Initiates are defined as persons who used the substance(s) for the first time in the 12 months prior to date of interview. 2 At Risk for Initiation is defined as persons who did not use the substance(s) in their lifetime or used the substance(s) for the first time in the past year. 3 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 4 Estimates for OxyContin® are based on 2004 data only. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||
Nonmedical Use of Any Psychotherapeutics3 | 463 | 1.0 | 1.2 | 19.4 |
Pain Relievers | 396 | 0.9 | 1.0 | 21.5 |
OxyContin®4 | 122 | 0.3 | 0.3 | * |
Tranquilizers | 209 | 0.5 | 0.5 | 25.1 |
Stimulants | 134 | 0.3 | 0.3 | 32.8 |
Methamphetamine | 22 | 0.0 | 0.1 | * |
Sedatives | 49 | 0.1 | 0.1 | * |
Drug | Midwest | |||
Nonmedical Use of Any Psychotherapeutics3 | 616 | 1.1 | 1.4 | 19.7 |
Pain Relievers | 568 | 1.1 | 1.2 | 23.5 |
OxyContin®4 | 139 | 0.3 | 0.3 | 50.2 |
Tranquilizers | 232 | 0.4 | 0.5 | 24.3 |
Stimulants | 186 | 0.3 | 0.4 | 27.5 |
Methamphetamine | 62 | 0.1 | 0.1 | 20.8 |
Sedatives | 51 | 0.1 | 0.1 | 30.2 |
Drug | South | |||
Nonmedical Use of Any Psychotherapeutics3 | 941 | 1.1 | 1.4 | 17.6 |
Pain Relievers | 860 | 1.0 | 1.1 | 21.0 |
OxyContin®4 | 202 | 0.2 | 0.2 | 50.8 |
Tranquilizers | 473 | 0.6 | 0.6 | 21.7 |
Stimulants | 262 | 0.3 | 0.3 | 27.3 |
Methamphetamine | 108 | 0.1 | 0.1 | 25.5 |
Sedatives | 69 | 0.1 | 0.1 | 22.8 |
Drug | West | |||
Nonmedical Use of Any Psychotherapeutics3 | 637 | 1.2 | 1.5 | 16.3 |
Pain Relievers | 575 | 1.1 | 1.2 | 19.4 |
OxyContin®4 | 151 | 0.3 | 0.3 | * |
Tranquilizers | 231 | 0.4 | 0.5 | 22.6 |
Stimulants | 182 | 0.3 | 0.4 | 20.1 |
Methamphetamine | 99 | 0.2 | 0.2 | 15.3 |
Sedatives | 46 | 0.1 | 0.1 | 23.4 |
51122
Drug | PAST YEAR INITIATES AT ANY AGE1 | PAST YEAR INITIATES WHO FIRST USED PRIOR TO AGE 181 | PAST YEAR INITIATES WHO FIRST USED PRIOR TO AGE 211 |
---|---|---|---|
Mean Age among All Persons | |||
*Low precision; no estimate reported. 1 Past Year Initiates are defined as persons who used the substance(s) for the first time in the 12 months prior to date of interview. 2 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 3 Estimates for OxyContin® are based on 2004 data only. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||
Nonmedical Use of Any Psychotherapeutics2 | 23.4 | 15.1 | 16.3 |
Pain Relievers | 22.8 | 15.1 | 16.3 |
OxyContin®3 | 24.5 | 15.7 | 17.3 |
Tranquilizers | 24.5 | 15.5 | 16.8 |
Stimulants | 21.8 | 15.1 | 16.5 |
Methamphetamine | 20.5 | 15.2 | 16.4 |
Sedatives | 29.5 | 14.6 | 15.6 |
Drug | Mean Age among Males | ||
Nonmedical Use of Any Psychotherapeutics2 | 21.6 | 15.3 | 16.5 |
Pain Relievers | 21.2 | 15.4 | 16.5 |
OxyContin®3 | 25.2 | 16.0 | 17.4 |
Tranquilizers | 22.4 | 15.7 | 17.0 |
Stimulants | 21.8 | 15.2 | 16.6 |
Methamphetamine | 19.9 | 15.3 | 16.8 |
Sedatives | 20.9 | 14.9 | 16.1 |
Drug | Mean Age among Females | ||
Nonmedical Use of Any Psychotherapeutics2 | 24.7 | 14.9 | 16.2 |
Pain Relievers | 24.1 | 14.9 | 16.1 |
OxyContin®3 | 23.6 | 15.4 | 17.0 |
Tranquilizers | 25.7 | 15.4 | 16.6 |
Stimulants | 21.8 | 15.1 | 16.4 |
Methamphetamine | 21.0 | 15.1 | 16.0 |
Sedatives | 33.5 | 14.4 | 15.2 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 47,484 | 30,862 | 19,780 | 20,617 | 12,138 | 9,787 |
NO OTHER ILLICIT DRUG USE3 | 8,621 | 4,955 | 1,209 | 921 | 159 | 289 |
ANY OTHER ILLICIT DRUG USE4 | 38,863 | 25,907 | 18,571 | 19,697 | 11,979 | 9,498 |
ANY NONPSYCHOTHERAPEUTIC5 | 38,863 | 24,821 | 17,693 | 19,250 | 11,893 | 9,240 |
Marijuana or Hashish | 37,458 | 23,763 | 17,283 | 18,909 | 11,764 | 9,081 |
Cocaine | 21,736 | 13,727 | 11,832 | 13,302 | 9,466 | 7,272 |
Crack | 5,993 | 4,444 | 3,901 | 3,998 | 3,261 | 2,205 |
Heroin | 2,898 | 2,308 | 2,130 | 2,051 | 1,607 | 1,599 |
Hallucinogens | 22,940 | 15,119 | 12,403 | 13,549 | 9,283 | 7,377 |
LSD | 17,347 | 11,458 | 9,924 | 10,983 | 7,853 | 6,371 |
PCP | 5,688 | 3,924 | 3,698 | 4,069 | 3,089 | 3,077 |
Ecstasy | 7,723 | 6,089 | 4,831 | 4,189 | 2,796 | 1,649 |
Inhalants | 14,830 | 10,438 | 8,262 | 8,660 | 5,694 | 4,868 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 17,111 | 15,556 | 13,539 | 8,259 | 8,265 |
Pain Relievers | N/A | N/A | 12,839 | 10,456 | 6,447 | 5,750 |
Tranquilizers | N/A | 12,839 | N/A | 8,723 | 5,581 | 5,967 |
Any Stimulants | N/A | 10,456 | 8,723 | N/A | N/A | 5,883 |
Methamphetamine | N/A | 6,447 | 5,581 | N/A | N/A | 3,953 |
Sedatives | N/A | 5,750 | 5,967 | 5,883 | 3,953 | N/A |
ALCOHOL | 45,482 | 29,322 | 19,367 | 20,351 | 12,057 | 9,652 |
CIGARETTES | 41,525 | 26,638 | 18,249 | 19,208 | 11,571 | 9,170 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 20.0 | 13.0 | 8.3 | 8.7 | 5.1 | 4.1 |
NO OTHER ILLICIT DRUG USE3 | 3.6 | 2.1 | 0.5 | 0.4 | 0.1 | 0.1 |
ANY OTHER ILLICIT DRUG USE4 | 16.3 | 10.9 | 7.8 | 8.3 | 5.0 | 4.0 |
ANY NONPSYCHOTHERAPEUTIC5 | 16.3 | 10.4 | 7.4 | 8.1 | 5.0 | 3.9 |
Marijuana or Hashish | 15.8 | 10.0 | 7.3 | 8.0 | 4.9 | 3.8 |
Cocaine | 9.1 | 5.8 | 5.0 | 5.6 | 4.0 | 3.1 |
Crack | 2.5 | 1.9 | 1.6 | 1.7 | 1.4 | 0.9 |
Heroin | 1.2 | 1.0 | 0.9 | 0.9 | 0.7 | 0.7 |
Hallucinogens | 9.6 | 6.4 | 5.2 | 5.7 | 3.9 | 3.1 |
LSD | 7.3 | 4.8 | 4.2 | 4.6 | 3.3 | 2.7 |
PCP | 2.4 | 1.7 | 1.6 | 1.7 | 1.3 | 1.3 |
Ecstasy | 3.2 | 2.6 | 2.0 | 1.8 | 1.2 | 0.7 |
Inhalants | 6.2 | 4.4 | 3.5 | 3.6 | 2.4 | 2.0 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 7.2 | 6.5 | 5.7 | 3.5 | 3.5 |
Pain Relievers | N/A | N/A | 5.4 | 4.4 | 2.7 | 2.4 |
Tranquilizers | N/A | 5.4 | N/A | 3.7 | 2.3 | 2.5 |
Any Stimulants | N/A | 4.4 | 3.7 | N/A | N/A | 2.5 |
Methamphetamine | N/A | 2.7 | 2.3 | N/A | N/A | 1.7 |
Sedatives | N/A | 2.4 | 2.5 | 2.5 | 1.7 | N/A |
ALCOHOL | 19.1 | 12.3 | 8.1 | 8.6 | 5.1 | 4.1 |
CIGARETTES | 17.5 | 11.2 | 7.7 | 8.1 | 4.9 | 3.9 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 3,378 | 2,817 | 842 | 983 | 331 | 246 |
NO OTHER ILLICIT DRUG USE3 | 1,080 | 794 | 44 | 93 | 11 | 33 |
ANY OTHER ILLICIT DRUG USE4 | 2,298 | 2,023 | 797 | 889 | 320 | 213 |
ANY NONPSYCHOTHERAPEUTIC5 | 2,298 | 1,915 | 746 | 833 | 314 | 182 |
Marijuana or Hashish | 1,873 | 1,576 | 681 | 712 | 290 | 137 |
Cocaine | 475 | 415 | 270 | 271 | 168 | 58 |
Crack | 123 | 104 | 77 | 83 | 65 | 20 |
Heroin | 71 | 61 | 45 | 47 | 32 | 13 |
Hallucinogens | 876 | 757 | 429 | 438 | 219 | 96 |
LSD | 357 | 323 | 207 | 199 | 120 | 54 |
PCP | 158 | 138 | 93 | 100 | 68 | 32 |
Ecstasy | 474 | 411 | 267 | 244 | 137 | 54 |
Inhalants | 1,114 | 936 | 377 | 454 | 176 | 129 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 1,040 | 706 | 669 | 250 | 182 |
Pain Relievers | N/A | N/A | 667 | 628 | 240 | 165 |
Tranquilizers | N/A | 667 | N/A | 337 | 147 | 109 |
Any Stimulants | N/A | 628 | 337 | N/A | N/A | 105 |
Methamphetamine | N/A | 240 | 147 | N/A | N/A | 46 |
Sedatives | N/A | 165 | 109 | 105 | 46 | N/A |
ALCOHOL | 2,684 | 2,245 | 774 | 885 | 317 | 191 |
CIGARETTES | 2,261 | 1,886 | 728 | 798 | 299 | 164 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 13.5 | 11.3 | 3.4 | 3.9 | 1.3 | 1.0 |
NO OTHER ILLICIT DRUG USE3 | 4.3 | 3.2 | 0.2 | 0.4 | 0.0 | 0.1 |
ANY OTHER ILLICIT DRUG USE4 | 9.2 | 8.1 | 3.2 | 3.6 | 1.3 | 0.9 |
ANY NONPSYCHOTHERAPEUTIC5 | 9.2 | 7.7 | 3.0 | 3.3 | 1.3 | 0.7 |
Marijuana or Hashish | 7.5 | 6.3 | 2.7 | 2.9 | 1.2 | 0.5 |
Cocaine | 1.9 | 1.7 | 1.1 | 1.1 | 0.7 | 0.2 |
Crack | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.1 |
Heroin | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
Hallucinogens | 3.5 | 3.0 | 1.7 | 1.8 | 0.9 | 0.4 |
LSD | 1.4 | 1.3 | 0.8 | 0.8 | 0.5 | 0.2 |
PCP | 0.6 | 0.6 | 0.4 | 0.4 | 0.3 | 0.1 |
Ecstasy | 1.9 | 1.6 | 1.1 | 1.0 | 0.5 | 0.2 |
Inhalants | 4.5 | 3.7 | 1.5 | 1.8 | 0.7 | 0.5 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 4.2 | 2.8 | 2.7 | 1.0 | 0.7 |
Pain Relievers | N/A | N/A | 2.7 | 2.5 | 1.0 | 0.7 |
Tranquilizers | N/A | 2.7 | N/A | 1.3 | 0.6 | 0.4 |
Any Stimulants | N/A | 2.5 | 1.3 | N/A | N/A | 0.4 |
Methamphetamine | N/A | 1.0 | 0.6 | N/A | N/A | 0.2 |
Sedatives | N/A | 0.7 | 0.4 | 0.4 | 0.2 | N/A |
ALCOHOL | 10.7 | 9.0 | 3.1 | 3.5 | 1.3 | 0.8 |
CIGARETTES | 9.0 | 7.5 | 2.9 | 3.2 | 1.2 | 0.7 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 9,063 | 7,393 | 3,763 | 3,395 | 1,698 | 613 |
NO OTHER ILLICIT DRUG USE3 | 1,260 | 871 | 100 | 108 | 11 | 16 |
ANY OTHER ILLICIT DRUG USE4 | 7,803 | 6,522 | 3,664 | 3,287 | 1,688 | 597 |
ANY NONPSYCHOTHERAPEUTIC5 | 7,803 | 6,371 | 3,554 | 3,222 | 1,675 | 566 |
Marijuana or Hashish | 7,556 | 6,175 | 3,481 | 3,173 | 1,662 | 552 |
Cocaine | 3,683 | 3,132 | 2,165 | 2,069 | 1,314 | 407 |
Crack | 986 | 851 | 637 | 682 | 539 | 187 |
Heroin | 455 | 414 | 345 | 316 | 226 | 118 |
Hallucinogens | 4,967 | 4,182 | 2,738 | 2,456 | 1,412 | 475 |
LSD | 3,342 | 2,851 | 2,018 | 1,818 | 1,126 | 379 |
PCP | 698 | 623 | 471 | 454 | 307 | 149 |
Ecstasy | 3,330 | 2,859 | 2,014 | 1,729 | 970 | 371 |
Inhalants | 3,301 | 2,841 | 1,853 | 1,743 | 959 | 379 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 3,959 | 3,189 | 2,520 | 1,316 | 562 |
Pain Relievers | N/A | N/A | 3,033 | 2,369 | 1,237 | 523 |
Tranquilizers | N/A | 3,033 | N/A | 1,642 | 919 | 453 |
Any Stimulants | N/A | 2,369 | 1,642 | N/A | N/A | 385 |
Methamphetamine | N/A | 1,237 | 919 | N/A | N/A | 251 |
Sedatives | N/A | 523 | 453 | 385 | 251 | N/A |
ALCOHOL | 8,764 | 7,149 | 3,716 | 3,358 | 1,688 | 605 |
CIGARETTES | 8,091 | 6,592 | 3,559 | 3,227 | 1,652 | 577 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 28.6 | 23.4 | 11.9 | 10.7 | 5.4 | 1.9 |
NO OTHER ILLICIT DRUG USE3 | 4.0 | 2.8 | 0.3 | 0.3 | 0.0 | 0.1 |
ANY OTHER ILLICIT DRUG USE4 | 24.7 | 20.6 | 11.6 | 10.4 | 5.3 | 1.9 |
ANY NONPSYCHOTHERAPEUTIC5 | 24.7 | 20.1 | 11.2 | 10.2 | 5.3 | 1.8 |
Marijuana or Hashish | 23.9 | 19.5 | 11.0 | 10.0 | 5.3 | 1.7 |
Cocaine | 11.6 | 9.9 | 6.8 | 6.5 | 4.2 | 1.3 |
Crack | 3.1 | 2.7 | 2.0 | 2.2 | 1.7 | 0.6 |
Heroin | 1.4 | 1.3 | 1.1 | 1.0 | 0.7 | 0.4 |
Hallucinogens | 15.7 | 13.2 | 8.7 | 7.8 | 4.5 | 1.5 |
LSD | 10.6 | 9.0 | 6.4 | 5.7 | 3.6 | 1.2 |
PCP | 2.2 | 2.0 | 1.5 | 1.4 | 1.0 | 0.5 |
Ecstasy | 10.5 | 9.0 | 6.4 | 5.5 | 3.1 | 1.2 |
Inhalants | 10.4 | 9.0 | 5.9 | 5.5 | 3.0 | 1.2 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 12.5 | 10.1 | 8.0 | 4.2 | 1.8 |
Pain Relievers | N/A | N/A | 9.6 | 7.5 | 3.9 | 1.7 |
Tranquilizers | N/A | 9.6 | N/A | 5.2 | 2.9 | 1.4 |
Any Stimulants | N/A | 7.5 | 5.2 | N/A | N/A | 1.2 |
Methamphetamine | N/A | 3.9 | 2.9 | N/A | N/A | 0.8 |
Sedatives | N/A | 1.7 | 1.4 | 1.2 | 0.8 | N/A |
ALCOHOL | 27.7 | 22.6 | 11.7 | 10.6 | 5.3 | 1.9 |
CIGARETTES | 25.6 | 20.8 | 11.2 | 10.2 | 5.2 | 1.8 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 35,043 | 20,652 | 15,175 | 16,239 | 10,109 | 8,928 |
NO OTHER ILLICIT DRUG USE3 | 6,282 | 3,290 | 1,065 | 719 | 138 | 240 |
ANY OTHER ILLICIT DRUG USE4 | 28,761 | 17,362 | 14,110 | 15,521 | 9,971 | 8,687 |
ANY NONPSYCHOTHERAPEUTIC5 | 28,761 | 16,536 | 13,393 | 15,195 | 9,904 | 8,491 |
Marijuana or Hashish | 28,028 | 16,012 | 13,121 | 15,024 | 9,812 | 8,392 |
Cocaine | 17,578 | 10,180 | 9,397 | 10,962 | 7,984 | 6,807 |
Crack | 4,884 | 3,490 | 3,187 | 3,233 | 2,657 | 1,997 |
Heroin | 2,372 | 1,833 | 1,740 | 1,688 | 1,349 | 1,467 |
Hallucinogens | 17,097 | 10,181 | 9,236 | 10,655 | 7,652 | 6,805 |
LSD | 13,648 | 8,284 | 7,699 | 8,966 | 6,607 | 5,938 |
PCP | 4,833 | 3,164 | 3,133 | 3,514 | 2,713 | 2,896 |
Ecstasy | 3,919 | 2,819 | 2,550 | 2,216 | 1,690 | 1,224 |
Inhalants | 10,414 | 6,661 | 6,032 | 6,463 | 4,558 | 4,360 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 12,113 | 11,661 | 10,351 | 6,692 | 7,521 |
Pain Relievers | N/A | N/A | 9,139 | 7,459 | 4,971 | 5,062 |
Tranquilizers | N/A | 9,139 | N/A | 6,744 | 4,516 | 5,404 |
Any Stimulants | N/A | 7,459 | 6,744 | N/A | N/A | 5,394 |
Methamphetamine | N/A | 4,971 | 4,516 | N/A | N/A | 3,656 |
Sedatives | N/A | 5,062 | 5,404 | 5,394 | 3,656 | N/A |
ALCOHOL | 34,034 | 19,928 | 14,877 | 16,108 | 10,052 | 8,856 |
CIGARETTES | 31,173 | 18,160 | 13,961 | 15,183 | 9,620 | 8,429 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other lifetime illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 19.3 | 11.4 | 8.4 | 9.0 | 5.6 | 4.9 |
NO OTHER ILLICIT DRUG USE3 | 3.5 | 1.8 | 0.6 | 0.4 | 0.1 | 0.1 |
ANY OTHER ILLICIT DRUG USE4 | 15.9 | 9.6 | 7.8 | 8.6 | 5.5 | 4.8 |
ANY NONPSYCHOTHERAPEUTIC5 | 15.9 | 9.1 | 7.4 | 8.4 | 5.5 | 4.7 |
Marijuana or Hashish | 15.5 | 8.8 | 7.2 | 8.3 | 5.4 | 4.6 |
Cocaine | 9.7 | 5.6 | 5.2 | 6.1 | 4.4 | 3.8 |
Crack | 2.7 | 1.9 | 1.8 | 1.8 | 1.5 | 1.1 |
Heroin | 1.3 | 1.0 | 1.0 | 0.9 | 0.7 | 0.8 |
Hallucinogens | 9.4 | 5.6 | 5.1 | 5.9 | 4.2 | 3.8 |
LSD | 7.5 | 4.6 | 4.3 | 4.9 | 3.6 | 3.3 |
PCP | 2.7 | 1.7 | 1.7 | 1.9 | 1.5 | 1.6 |
Ecstasy | 2.2 | 1.6 | 1.4 | 1.2 | 0.9 | 0.7 |
Inhalants | 5.7 | 3.7 | 3.3 | 3.6 | 2.5 | 2.4 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 6.7 | 6.4 | 5.7 | 3.7 | 4.2 |
Pain Relievers | N/A | N/A | 5.0 | 4.1 | 2.7 | 2.8 |
Tranquilizers | N/A | 5.0 | N/A | 3.7 | 2.5 | 3.0 |
Any Stimulants | N/A | 4.1 | 3.7 | N/A | N/A | 3.0 |
Methamphetamine | N/A | 2.7 | 2.5 | N/A | N/A | 2.0 |
Sedatives | N/A | 2.8 | 3.0 | 3.0 | 2.0 | N/A |
ALCOHOL | 18.8 | 11.0 | 8.2 | 8.9 | 5.5 | 4.9 |
CIGARETTES | 17.2 | 10.0 | 7.7 | 8.4 | 5.3 | 4.7 |
60315
Other Substance Use in Past Year | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other past year illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and past year use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Past year use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Past year use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 14,769 | 11,306 | 4,989 | 2,950 | 1,432 | 850 |
NO OTHER ILLICIT DRUG USE3 | 6,816 | 4,216 | 960 | 490 | 139 | 211 |
ANY OTHER ILLICIT DRUG USE4 | 7,954 | 7,090 | 4,030 | 2,460 | 1,293 | 639 |
ANY NONPSYCHOTHERAPEUTIC5 | 7,954 | 6,199 | 3,277 | 2,274 | 1,240 | 475 |
Marijuana or Hashish | 7,282 | 5,716 | 3,057 | 2,081 | 1,128 | 434 |
Cocaine | 2,882 | 2,311 | 1,465 | 1,105 | 681 | 245 |
Crack | 640 | 507 | 367 | 298 | 213 | 98 |
Heroin | 239 | 203 | 140 | 89 | 62 | 46 |
Hallucinogens | 2,309 | 1,906 | 1,194 | 873 | 476 | 168 |
LSD | 505 | 450 | 298 | 229 | 133 | 62 |
PCP | 147 | 130 | 81 | 74 | 45 | 25 |
Ecstasy | 1,370 | 1,134 | 733 | 524 | 306 | 84 |
Inhalants | 989 | 809 | 437 | 384 | 169 | 89 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 3,889 | 3,290 | 1,664 | 799 | 585 |
Pain Relievers | N/A | N/A | 3,095 | 1,512 | 733 | 496 |
Tranquilizers | N/A | 3,095 | N/A | 952 | 496 | 433 |
Any Stimulants | N/A | 1,512 | 952 | N/A | N/A | 250 |
Methamphetamine | N/A | 733 | 496 | N/A | N/A | 126 |
Sedatives | N/A | 496 | 433 | 250 | 126 | N/A |
ALCOHOL | 12,780 | 9,783 | 4,534 | 2,734 | 1,343 | 735 |
CIGARETTES | 9,081 | 7,018 | 3,514 | 2,222 | 1,197 | 545 |
60315
Other Substance Use in Past Year | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||
---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||
Any Stimulant | Metham- phetamine |
|||||
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column, with or without other past year illicit or nonmedical use of other drugs. 3 Never used marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants. Except for the "Any Prescription-Type Psychotherapeutic Drug" column, never used any prescription-type psychotherapeutic drug other than the drug category specified in a given column. 4 Nonmedical use of the prescription drug specified in the column and past year use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 5 Past year use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 6 Past year use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||
TOTAL2 | 6.2 | 4.8 | 2.1 | 1.2 | 0.6 | 0.4 |
NO OTHER ILLICIT DRUG USE3 | 2.9 | 1.8 | 0.4 | 0.2 | 0.1 | 0.1 |
ANY OTHER ILLICIT DRUG USE4 | 3.3 | 3.0 | 1.7 | 1.0 | 0.5 | 0.3 |
ANY NONPSYCHOTHERAPEUTIC5 | 3.3 | 2.6 | 1.4 | 1.0 | 0.5 | 0.2 |
Marijuana or Hashish | 3.1 | 2.4 | 1.3 | 0.9 | 0.5 | 0.2 |
Cocaine | 1.2 | 1.0 | 0.6 | 0.5 | 0.3 | 0.1 |
Crack | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 |
Heroin | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Hallucinogens | 1.0 | 0.8 | 0.5 | 0.4 | 0.2 | 0.1 |
LSD | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 |
PCP | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Ecstasy | 0.6 | 0.5 | 0.3 | 0.2 | 0.1 | 0.0 |
Inhalants | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 |
ANY OTHER PSYCHOTHERAPEUTICS6 | N/A | 1.6 | 1.4 | 0.7 | 0.3 | 0.2 |
Pain Relievers | N/A | N/A | 1.3 | 0.6 | 0.3 | 0.2 |
Tranquilizers | N/A | 1.3 | N/A | 0.4 | 0.2 | 0.2 |
Any Stimulants | N/A | 0.6 | 0.4 | N/A | N/A | 0.1 |
Methamphetamine | N/A | 0.3 | 0.2 | N/A | N/A | 0.1 |
Sedatives | N/A | 0.2 | 0.2 | 0.1 | 0.1 | N/A |
ALCOHOL | 5.4 | 4.1 | 1.9 | 1.1 | 0.6 | 0.3 |
CIGARETTES | 3.8 | 3.0 | 1.5 | 0.9 | 0.5 | 0.2 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||||||||
Any Stimulant | Metham- phetamine |
|||||||||||
Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | |
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 3 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 4 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
ANY OTHER ILLICIT DRUG USE2 | 38,863 | 62,021 | 25,907 | 78,643 | 18,571 | 89,726 | 19,697 | 88,888 | 11,979 | 96,606 | 9,498 | 99,718 |
ANY NONPSYCHOTHERAPEUTIC3 | 38,863 | 62,021 | 24,821 | 76,063 | 17,693 | 83,191 | 19,250 | 81,634 | 11,893 | 88,991 | 9,240 | 91,645 |
Marijuana or Hashish | 37,458 | 58,652 | 23,763 | 72,346 | 17,283 | 78,827 | 18,909 | 77,200 | 11,764 | 84,346 | 9,081 | 87,029 |
Cocaine | 21,736 | 12,581 | 13,727 | 20,590 | 11,832 | 22,486 | 13,302 | 21,016 | 9,466 | 24,852 | 7,272 | 27,045 |
Crack | 5,993 | 2,071 | 4,444 | 3,619 | 3,901 | 4,163 | 3,998 | 4,065 | 3,261 | 4,803 | 2,205 | 5,859 |
Heroin | 2,898 | 621 | 2,308 | 1,211 | 2,130 | 1,389 | 2,051 | 1,468 | 1,607 | 1,912 | 1,599 | 1,920 |
Hallucinogens | 22,940 | 11,397 | 15,119 | 19,218 | 12,403 | 21,934 | 13,549 | 20,788 | 9,283 | 25,054 | 7,377 | 26,959 |
LSD | 17,347 | 6,765 | 11,458 | 12,655 | 9,924 | 14,189 | 10,983 | 13,130 | 7,853 | 16,260 | 6,371 | 17,742 |
PCP | 5,688 | 1,407 | 3,924 | 3,171 | 3,698 | 3,398 | 4,069 | 3,027 | 3,089 | 4,007 | 3,077 | 4,019 |
Ecstasy | 7,723 | 3,005 | 6,089 | 4,639 | 4,831 | 5,897 | 4,189 | 6,539 | 2,796 | 7,932 | 1,649 | 9,079 |
Inhalants | 14,830 | 8,058 | 10,438 | 12,450 | 8,262 | 14,627 | 8,660 | 14,228 | 5,694 | 17,194 | 4,868 | 18,020 |
ANY OTHER PSYCHOTHERAPEUTICS4 | N/A | N/A | 17,111 | 16,622 | 15,556 | 27,704 | 13,539 | 26,867 | 8,259 | 32,148 | 8,265 | 37,697 |
Pain Relievers | N/A | N/A | N/A | N/A | 12,839 | 18,023 | 10,456 | 20,406 | 6,447 | 24,415 | 5,750 | 25,112 |
Tranquilizers | N/A | N/A | 12,839 | 6,941 | N/A | N/A | 8,723 | 11,057 | 5,581 | 14,198 | 5,967 | 13,813 |
Any Stimulants | N/A | N/A | 10,456 | 10,161 | 8,723 | 11,894 | N/A | N/A | N/A | N/A | 5,883 | 14,734 |
Methamphetamine | N/A | N/A | 6,447 | 5,690 | 5,581 | 6,556 | N/A | N/A | N/A | N/A | 3,953 | 8,184 |
Sedatives | N/A | N/A | 5,750 | 4,037 | 5,967 | 3,821 | 5,883 | 3,905 | 3,953 | 5,834 | N/A | N/A |
ALCOHOL | 45,482 | 151,586 | 29,322 | 167,746 | 19,367 | 177,701 | 20,351 | 176,717 | 12,057 | 185,012 | 9,652 | 187,416 |
CIGARETTES | 41,525 | 121,020 | 26,638 | 135,907 | 18,249 | 144,296 | 19,208 | 143,337 | 11,571 | 150,974 | 9,170 | 153,375 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||||||||
Any Stimulant | Metham- phetamine |
|||||||||||
Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | Ever Used | Never Used | |
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 3 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 4 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
ANY OTHER ILLICIT DRUG USE2 | 81.8 | 32.6 | 83.9 | 38.0 | 93.9 | 41.2 | 95.5 | 40.9 | 98.7 | 42.8 | 97.0 | 43.7 |
ANY NONPSYCHOTHERAPEUTIC3 | 81.8 | 32.6 | 80.4 | 36.8 | 89.4 | 38.2 | 93.4 | 37.6 | 98.0 | 39.4 | 94.4 | 40.2 |
Marijuana or Hashish | 78.9 | 30.8 | 77.0 | 35.0 | 87.4 | 36.2 | 91.7 | 35.5 | 96.9 | 37.4 | 92.8 | 38.2 |
Cocaine | 45.8 | 6.6 | 44.5 | 10.0 | 59.8 | 10.3 | 64.5 | 9.7 | 78.0 | 11.0 | 74.3 | 11.9 |
Crack | 12.6 | 1.1 | 14.4 | 1.7 | 19.7 | 1.9 | 19.4 | 1.9 | 26.9 | 2.1 | 22.5 | 2.6 |
Heroin | 6.1 | 0.3 | 7.5 | 0.6 | 10.8 | 0.6 | 9.9 | 0.7 | 13.2 | 0.8 | 16.3 | 0.8 |
Hallucinogens | 48.3 | 6.0 | 49.0 | 9.3 | 62.7 | 10.1 | 65.7 | 9.6 | 76.5 | 11.1 | 75.4 | 11.8 |
LSD | 36.5 | 3.6 | 37.1 | 6.1 | 50.2 | 6.5 | 53.3 | 6.0 | 64.7 | 7.2 | 65.1 | 7.8 |
PCP | 12.0 | 0.7 | 12.7 | 1.5 | 18.7 | 1.6 | 19.7 | 1.4 | 25.5 | 1.8 | 31.4 | 1.8 |
Ecstasy | 16.3 | 1.6 | 19.7 | 2.2 | 24.4 | 2.7 | 20.3 | 3.0 | 23.0 | 3.5 | 16.9 | 4.0 |
Inhalants | 31.2 | 4.2 | 33.8 | 6.0 | 41.8 | 6.7 | 42.0 | 6.6 | 46.9 | 7.6 | 49.7 | 7.9 |
ANY OTHER PSYCHOTHERAPEUTICS4 | N/A | N/A | 55.4 | 8.0 | 78.6 | 12.7 | 65.7 | 12.4 | 68.0 | 14.2 | 84.4 | 16.5 |
Pain Relievers | N/A | N/A | N/A | N/A | 64.9 | 8.3 | 50.7 | 9.4 | 53.1 | 10.8 | 58.7 | 11.0 |
Tranquilizers | N/A | N/A | 41.6 | 3.4 | N/A | N/A | 42.3 | 5.1 | 46.0 | 6.3 | 61.0 | 6.1 |
Any Stimulants | N/A | N/A | 33.9 | 4.9 | 44.1 | 5.5 | N/A | N/A | N/A | N/A | 60.1 | 6.5 |
Methamphetamine | N/A | N/A | 20.9 | 2.8 | 28.2 | 3.0 | N/A | N/A | N/A | N/A | 40.4 | 3.6 |
Sedatives | N/A | N/A | 18.6 | 2.0 | 30.2 | 1.8 | 28.5 | 1.8 | 32.6 | 2.6 | N/A | N/A |
ALCOHOL | 95.8 | 79.7 | 95.0 | 81.1 | 97.9 | 81.5 | 98.7 | 81.4 | 99.3 | 82.0 | 98.6 | 82.2 |
CIGARETTES | 87.4 | 63.6 | 86.3 | 65.7 | 92.3 | 66.2 | 93.2 | 66.0 | 95.3 | 66.9 | 93.7 | 67.3 |
60315
Other Substance Use in Past Year | Any Prescription- Type Psycho- therapeutic Drug,1 Past Year |
PRESCRIPTION DRUG TYPE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain Relievers, Past Year | Tranquilizers, Past Year | Stimulants, Past Year | Sedatives, Past Year | |||||||||
Any Stimulant | Metham- phetamine |
|||||||||||
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
|
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column and past year use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 3 Past year use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 4 Past year use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
ANY OTHER ILLICIT DRUG USE2 | 7,954 | 20,208 | 7,090 | 23,671 | 4,030 | 29,988 | 2,460 | 32,027 | 1,293 | 33,194 | 639 | 34,127 |
ANY NONPSYCHOTHERAPEUTIC3 | 7,954 | 20,208 | 6,199 | 21,963 | 3,277 | 24,884 | 2,274 | 25,888 | 1,240 | 26,921 | 475 | 27,686 |
Marijuana or Hashish | 7,282 | 18,197 | 5,716 | 19,763 | 3,057 | 22,422 | 2,081 | 23,398 | 1,128 | 24,351 | 434 | 25,045 |
Cocaine | 2,882 | 2,941 | 2,311 | 3,512 | 1,465 | 4,357 | 1,105 | 4,718 | 681 | 5,141 | 245 | 5,578 |
Crack | 640 | 781 | 507 | 915 | 367 | 1,054 | 298 | 1,123 | 213 | 1,208 | 98 | 1,323 |
Heroin | 239 | 133 | 203 | 169 | 140 | 232 | 89 | 283 | 62 | 310 | 46 | 326 |
Hallucinogens | 2,309 | 1,879 | 1,906 | 2,282 | 1,194 | 2,994 | 873 | 3,315 | 476 | 3,712 | 168 | 4,020 |
LSD | 505 | 212 | 450 | 267 | 298 | 418 | 229 | 487 | 133 | 583 | 62 | 654 |
PCP | 147 | 75 | 130 | 92 | 81 | 141 | 74 | 147 | 45 | 176 | 25 | 197 |
Ecstasy | 1,370 | 1,031 | 1,134 | 1,266 | 733 | 1,667 | 524 | 1,876 | 306 | 2,094 | 84 | 2,317 |
Inhalants | 989 | 1,149 | 809 | 1,329 | 437 | 1,701 | 384 | 1,754 | 169 | 1,969 | 89 | 2,049 |
ANY OTHER PSYCHOTHERAPEUTICS4 | N/A | N/A | 3,889 | 3,464 | 3,290 | 9,780 | 1,664 | 11,819 | 799 | 12,684 | 585 | 13,920 |
Pain Relievers | N/A | N/A | N/A | N/A | 3,095 | 8,211 | 1,512 | 9,794 | 733 | 10,572 | 496 | 10,810 |
Tranquilizers | N/A | N/A | 3,095 | 1,895 | N/A | N/A | 952 | 4,037 | 496 | 4,494 | 433 | 4,557 |
Any Stimulants | N/A | N/A | 1,512 | 1,438 | 952 | 1,998 | N/A | N/A | N/A | N/A | 250 | 2,700 |
Methamphetamine | N/A | N/A | 733 | 698 | 496 | 936 | N/A | N/A | N/A | N/A | 126 | 1,305 |
Sedatives | N/A | N/A | 496 | 354 | 433 | 417 | 250 | 599 | 126 | 723 | N/A | N/A |
ALCOHOL | 12,780 | 142,788 | 9,783 | 145,784 | 4,534 | 151,034 | 2,734 | 152,834 | 1,343 | 154,225 | 735 | 154,833 |
CIGARETTES | 9,081 | 61,277 | 7,018 | 63,339 | 3,514 | 66,843 | 2,222 | 68,136 | 1,197 | 69,160 | 545 | 69,813 |
60315
Other Substance Use in Past Year | Any Prescription- Type Psycho- therapeutic Drug,1 Past Year |
PRESCRIPTION DRUG TYPE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain Relievers, Past Year | Tranquilizers, Past Year | Stimulants, Past Year | Sedatives, Past Year | |||||||||
Any Stimulant | Metham- phetamine |
|||||||||||
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
Used | Did Not Use |
|
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column and past year use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 3 Past year use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 4 Past year use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
ANY OTHER ILLICIT DRUG USE2 | 53.9 | 9.1 | 62.7 | 10.5 | 80.8 | 12.9 | 83.4 | 13.6 | 90.3 | 14.0 | 75.2 | 14.4 |
ANY NONPSYCHOTHERAPEUTIC3 | 53.9 | 9.1 | 54.8 | 9.7 | 65.7 | 10.7 | 77.1 | 11.0 | 86.6 | 11.4 | 55.9 | 11.7 |
Marijuana or Hashish | 49.3 | 8.2 | 50.6 | 8.7 | 61.3 | 9.6 | 70.6 | 10.0 | 78.8 | 10.3 | 51.0 | 10.6 |
Cocaine | 19.5 | 1.3 | 20.4 | 1.6 | 29.4 | 1.9 | 37.4 | 2.0 | 47.6 | 2.2 | 28.8 | 2.4 |
Crack | 4.3 | 0.4 | 4.5 | 0.4 | 7.4 | 0.5 | 10.1 | 0.5 | 14.9 | 0.5 | 11.6 | 0.6 |
Heroin | 1.6 | 0.1 | 1.8 | 0.1 | 2.8 | 0.1 | 3.0 | 0.1 | 4.3 | 0.1 | 5.4 | 0.1 |
Hallucinogens | 15.6 | 0.8 | 16.9 | 1.0 | 23.9 | 1.3 | 29.6 | 1.4 | 33.2 | 1.6 | 19.8 | 1.7 |
LSD | 3.4 | 0.1 | 4.0 | 0.1 | 6.0 | 0.2 | 7.8 | 0.2 | 9.3 | 0.2 | 7.4 | 0.3 |
PCP | 1.0 | 0.0 | 1.1 | 0.0 | 1.6 | 0.1 | 2.5 | 0.1 | 3.2 | 0.1 | 2.9 | 0.1 |
Ecstasy | 9.3 | 0.5 | 10.0 | 0.6 | 14.7 | 0.7 | 17.8 | 0.8 | 21.4 | 0.9 | 9.8 | 1.0 |
Inhalants | 6.7 | 0.5 | 7.2 | 0.6 | 8.8 | 0.7 | 13.0 | 0.7 | 11.8 | 0.8 | 10.5 | 0.9 |
ANY OTHER PSYCHOTHERAPEUTICS4 | N/A | N/A | 34.4 | 1.5 | 65.9 | 4.2 | 56.4 | 5.0 | 55.8 | 5.4 | 68.8 | 5.9 |
Pain Relievers | N/A | N/A | N/A | N/A | 62.0 | 3.5 | 51.3 | 4.2 | 51.2 | 4.5 | 58.4 | 4.6 |
Tranquilizers | N/A | N/A | 27.4 | 0.8 | N/A | N/A | 32.3 | 1.7 | 34.6 | 1.9 | 50.9 | 1.9 |
Any Stimulants | N/A | N/A | 13.4 | 0.6 | 19.1 | 0.9 | N/A | N/A | N/A | N/A | 29.5 | 1.1 |
Methamphetamine | N/A | N/A | 6.5 | 0.3 | 9.9 | 0.4 | N/A | N/A | N/A | N/A | 14.9 | 0.6 |
Sedatives | N/A | N/A | 4.4 | 0.2 | 8.7 | 0.2 | 8.5 | 0.3 | 8.8 | 0.3 | N/A | N/A |
ALCOHOL | 86.5 | 64.0 | 86.5 | 64.4 | 90.9 | 64.9 | 92.7 | 65.1 | 93.8 | 65.3 | 86.5 | 65.3 |
CIGARETTES | 61.5 | 27.5 | 62.1 | 28.0 | 70.4 | 28.7 | 75.3 | 29.0 | 83.6 | 29.3 | 64.1 | 29.5 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||||||||
Any Stimulant | Metham- phetamine |
|||||||||||
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
|
*Low precision; no estimate reported. N/A: Not applicable. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 3 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 4 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
ANY OTHER ILLICIT DRUG USE2 | 4,455 | 29,041 | 2,313 | 20,825 | 750 | 15,942 | 1,535 | 15,332 | 477 | 10,024 | 304 | 7,813 |
ANY NON-PSYCHOTHERAPEUTIC3 | 4,455 | 29,041 | 2,314 | 20,183 | 968 | 15,314 | 1,613 | 14,878 | 512 | 9,862 | 476 | 7,583 |
Marijuana or Hashish | 4,708 | 27,321 | 2,335 | 19,082 | 1,087 | 14,687 | 1,856 | 14,200 | 667 | 9,500 | 570 | 7,259 |
Cocaine | 11,999 | 5,793 | 5,456 | 5,938 | 4,516 | 5,155 | 7,009 | 3,516 | 4,292 | 2,988 | 3,867 | 1,831 |
Crack | 4,609 | 749 | 2,921 | 980 | 2,544 | 848 | 2,957 | 521 | 2,232 | 503 | 1,797 | 226 |
Heroin | 2,118 | 385 | 1,444 | 511 | 1,235 | 558 | 1,455 | 302 | 1,047 | 316 | 1,062 | 267 |
Hallucinogens | 7,600 | 9,015 | 3,483 | 8,396 | 2,301 | 7,506 | 3,987 | 5,571 | 2,103 | 4,478 | 1,732 | 3,413 |
LSD | 6,107 | 6,484 | 2,677 | 6,361 | 1,970 | 5,875 | 3,517 | 4,238 | 1,961 | 3,564 | 1,727 | 2,730 |
PCP | 2,920 | 1,356 | 1,468 | 1,608 | 1,293 | 1,541 | 1,890 | 1,081 | 1,186 | 1,028 | 1,420 | 840 |
Ecstasy | 4,821 | 1,510 | 3,170 | 1,698 | 2,419 | 1,503 | 2,513 | 844 | 1,612 | 588 | 1,099 | 294 |
Inhalants | 4,730 | 7,082 | 2,399 | 6,201 | 1,618 | 5,175 | 2,638 | 4,196 | 1,460 | 3,035 | 1,376 | 2,396 |
ANY OTHER PSYCHOTHERAPEUTICS4 | N/A | N/A | 4,112 | 6,999 | 2,067 | 7,749 | 4,765 | 4,281 | 2,590 | 3,287 | 1,488 | 3,234 |
Pain Relievers | N/A | N/A | N/A | N/A | 2,701 | 4,488 | 4,789 | 2,857 | 2,679 | 2,239 | 2,166 | 1,599 |
Tranquilizers | N/A | N/A | 4,488 | 2,701 | N/A | N/A | 4,177 | 1,902 | 2,391 | 1,739 | 2,192 | 1,329 |
Any Stimulants | N/A | N/A | 2,857 | 4,789 | 1,902 | 4,177 | N/A | N/A | N/A | N/A | 1,263 | 1,945 |
Methamphetamine | N/A | N/A | 2,239 | 2,679 | 1,739 | 2,391 | N/A | N/A | N/A | N/A | 1,241 | 1,041 |
Sedatives | N/A | N/A | 1,599 | 2,166 | 1,329 | 2,192 | 1,945 | 1,263 | 1,041 | 1,241 | N/A | N/A |
ALCOHOL | 3,926 | 37,620 | 2,482 | 24,887 | 714 | 17,598 | 1,054 | 17,536 | 386 | 10,722 | 474 | 8,409 |
CIGARETTES | 3,170 | 35,474 | 1,833 | 23,339 | 673 | 16,762 | 1,111 | 16,868 | 520 | 10,433 | 473 | 8,119 |
60315
Other Substance Use in Lifetime | Any Prescription- Type Psycho- therapeutic Drug1 |
PRESCRIPTION DRUG TYPE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | |||||||||
Any Stimulant | Metham- phetamine |
|||||||||||
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
Drug in Column Used First |
Drug in Row Used First |
|
*Low precision; no estimate reported. N/A: Not applicable. NOTE: Cell entries are percentages of lifetime users of both row and column drugs classified according to the age at which the first used each of the two. Percentages do not sum to 100 because of persons who began using the two drugs at the same age. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. 2 Nonmedical use of the prescription drug specified in the column and lifetime use of marijuana or hashish, cocaine, heroin, hallucinogens, or inhalants, or nonmedical use of any other prescription-type psychotherapeutic drug. 3 Lifetime use of both the prescription drug specified in the column and any of the following drugs: marijuana or hashish, cocaine, crack cocaine, heroin, hallucinogens, LSD, PCP, Ecstasy, or inhalants. 4 Lifetime use of prescription drug specified in column and any other prescription drug shown in the indented stub immediately below. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||
ANY OTHER ILLICIT DRUG USE2 | 11.5 | 74.7 | 8.9 | 80.4 | 4.0 | 85.8 | 7.8 | 77.8 | 4.0 | 83.7 | 3.2 | 82.3 |
ANY NON-PSYCHOTHERAPEUTIC3 | 11.5 | 74.7 | 9.3 | 81.3 | 5.5 | 86.6 | 8.4 | 77.3 | 4.3 | 82.9 | 5.2 | 82.1 |
Marijuana or Hashish | 12.6 | 72.9 | 9.8 | 80.3 | 6.3 | 85.0 | 9.8 | 75.1 | 5.7 | 80.8 | 6.3 | 79.9 |
Cocaine | 55.2 | 26.7 | 39.7 | 43.3 | 38.2 | 43.6 | 52.7 | 26.4 | 45.3 | 31.6 | 53.2 | 25.2 |
Crack | 76.9 | 12.5 | 65.7 | 22.1 | 65.2 | 21.8 | 74.0 | 13.0 | 68.4 | 15.4 | 81.5 | 10.3 |
Heroin | 73.1 | 13.3 | 62.6 | 22.1 | 58.0 | 26.2 | 71.0 | 14.7 | 65.1 | 19.6 | 66.4 | 16.7 |
Hallucinogens | 33.1 | 39.3 | 23.0 | 55.5 | 18.6 | 60.5 | 29.4 | 41.1 | 22.7 | 48.2 | 23.5 | 46.3 |
LSD | 35.2 | 37.4 | 23.4 | 55.5 | 19.9 | 59.2 | 32.0 | 38.6 | 25.0 | 45.4 | 27.1 | 42.9 |
PCP | 51.3 | 23.8 | 37.4 | 41.0 | 35.0 | 41.7 | 46.4 | 26.6 | 38.4 | 33.3 | 46.2 | 27.3 |
Ecstasy | 62.4 | 19.5 | 52.1 | 27.9 | 50.1 | 31.1 | 60.0 | 20.1 | 57.6 | 21.0 | 66.7 | 17.8 |
Inhalants | 31.9 | 47.8 | 23.0 | 59.4 | 19.6 | 62.6 | 30.5 | 48.5 | 25.6 | 53.3 | 28.3 | 49.2 |
ANY OTHER PSYCHOTHERAPEUTICS4 | N/A | N/A | 24.0 | 40.9 | 13.3 | 49.8 | 35.2 | 31.6 | 31.4 | 39.8 | 18.0 | 39.1 |
Pain Relievers | N/A | N/A | N/A | N/A | 21.0 | 35.0 | 45.8 | 27.3 | 41.5 | 34.7 | 37.7 | 27.8 |
Tranquilizers | N/A | N/A | 35.0 | 21.0 | N/A | N/A | 47.9 | 21.8 | 42.8 | 31.1 | 36.7 | 22.3 |
Any Stimulants | N/A | N/A | 27.3 | 45.8 | 21.8 | 47.9 | N/A | N/A | N/A | N/A | 21.5 | 33.1 |
Methamphetamine | N/A | N/A | 34.7 | 41.5 | 31.1 | 42.8 | N/A | N/A | N/A | N/A | 31.4 | 26.3 |
Sedatives | N/A | N/A | 27.8 | 37.7 | 22.3 | 36.7 | 33.1 | 21.5 | 26.3 | 31.4 | N/A | N/A |
ALCOHOL | 8.6 | 82.7 | 8.5 | 84.9 | 3.7 | 90.9 | 5.2 | 86.2 | 3.2 | 88.9 | 4.9 | 87.1 |
CIGARETTES | 7.6 | 85.4 | 6.9 | 87.6 | 3.7 | 91.9 | 5.8 | 87.8 | 4.5 | 90.2 | 5.2 | 88.5 |
60124
Drug of Past Year Dependence or Abuse | Total | AGE GROUP | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||||||||
2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | 2002 | 2003 | 2004 | |||
Numbers in Thousands | ||||||||||||||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). a Difference between estimate and 2004 estimate is statistically significant at the .05 level. b Difference between estimate and 2004 estimate is statistically significant at the .01 level. 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||||||||
Nonmedical Use of Psychotherapeutics1 | 2,018 | 1,923 | 2,048 | 333 | 361 | 388 | 587 | 516b | 652 | 1,098 | 1,046 | 1,008 | ||
Pain Relievers | 1,509 | 1,424 | 1,388 | 237a | 281 | 309 | 419 | 350a | 454 | 853 | 793 | 624 | ||
Tranquilizers | 509 | 435 | 573 | 87 | 96 | 75 | 144 | 147 | 154 | 278 | 192 | 344 | ||
Stimulants | 436 | 378 | 470 | 98 | 98 | 86 | 137 | 142 | 172 | 202 | 138 | 212 | ||
Sedatives | 154 | 158 | 128 | 28 | 40 | 22 | 26 | 20 | 24 | 100 | 99 | 82 | ||
Drug of Past Year Dependence or Abuse | Percentages | |||||||||||||
Nonmedical Use of Psychotherapeutics1 | 0.9 | 0.8 | 0.9 | 1.3 | 1.4 | 1.5 | 1.9 | 1.6a | 2.0 | 0.6 | 0.6 | 0.6 | ||
Pain Relievers | 0.6 | 0.6 | 0.6 | 1.0a | 1.1 | 1.2 | 1.4 | 1.1a | 1.4 | 0.5 | 0.4 | 0.3 | ||
Tranquilizers | 0.2 | 0.2 | 0.2 | 0.4 | 0.4 | 0.3 | 0.5 | 0.5 | 0.5 | 0.2 | 0.1 | 0.2 | ||
Stimulants | 0.2 | 0.2 | 0.2 | 0.4 | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | 0.1 | 0.1 | 0.1 | ||
Sedatives | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
60209
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 1,996 | 1,440 | 505 | 428 | 147 |
AGE | |||||
12-17 | 361 | 275 | 86 | 94 | 30 |
18-25 | 585 | 408 | 148 | 150 | 23 |
26 or Older | 1,050 | 757 | 271 | 184 | 93 |
26-34 | 339 | 237 | 74 | 72 | 14 |
35-49 | 532 | 394 | 122 | 91 | 51 |
50 or Older | 180 | 127 | 75 | 21 | 29 |
GENDER | |||||
Male | 978 | 739 | 240 | 219 | 75 |
12-17 | 137 | 102 | 32 | 35 | 12 |
18-25 | 309 | 228 | 79 | 76 | 11 |
26 or Older | 531 | 409 | 129 | 109 | 52 |
Female | 1,018 | 701 | 265 | 209 | 72 |
12-17 | 223 | 174 | 54 | 59 | 18 |
18-25 | 276 | 180 | 69 | 75 | 12 |
26 or Older | 519 | 348 | 143 | 75 | 42 |
HISPANIC ORIGIN AND RACE | |||||
Not Hispanic or Latino | 1,745 | 1,248 | 442 | 402 | 135 |
White | 1,496 | 1,071 | 379 | 360 | 115 |
Black or African American | 139 | 110 | 20 | 17 | 13 |
American Indian or Alaska Native | 27 | 16 | 12 | 8 | 2 |
Native Hawaiian or Other Pacific Islander | 10 | 3 | 0 | 8 | 1 |
Asian | 47 | 28 | 20 | 4 | 2 |
Two or More Races | 27 | 21 | 10 | 6 | 2 |
Hispanic or Latino | 251 | 192 | 63 | 26 | 11 |
60209
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 0.8 | 0.6 | 0.2 | 0.2 | 0.1 |
AGE | |||||
12-17 | 1.4 | 1.1 | 0.3 | 0.4 | 0.1 |
18-25 | 1.8 | 1.3 | 0.5 | 0.5 | 0.1 |
26 or Older | 0.6 | 0.4 | 0.1 | 0.1 | 0.1 |
26-34 | 1.0 | 0.7 | 0.2 | 0.2 | 0.0 |
35-49 | 0.8 | 0.6 | 0.2 | 0.1 | 0.1 |
50 or Older | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 |
GENDER | |||||
Male | 0.9 | 0.6 | 0.2 | 0.2 | 0.1 |
12-17 | 1.1 | 0.8 | 0.3 | 0.3 | 0.1 |
18-25 | 1.9 | 1.4 | 0.5 | 0.5 | 0.1 |
26 or Older | 0.6 | 0.5 | 0.1 | 0.1 | 0.1 |
Female | 0.8 | 0.6 | 0.2 | 0.2 | 0.1 |
12-17 | 1.8 | 1.4 | 0.4 | 0.5 | 0.2 |
18-25 | 1.7 | 1.1 | 0.4 | 0.5 | 0.1 |
26 or Older | 0.5 | 0.4 | 0.2 | 0.1 | 0.0 |
HISPANIC ORIGIN AND RACE | |||||
Not Hispanic or Latino | 0.8 | 0.6 | 0.2 | 0.2 | 0.1 |
White | 0.9 | 0.6 | 0.2 | 0.2 | 0.1 |
Black or African American | 0.5 | 0.4 | 0.1 | 0.1 | 0.0 |
American Indian or Alaska Native | 2.0 | 1.2 | 0.9 | 0.6 | 0.2 |
Native Hawaiian or Other Pacific Islander | 1.6 | 0.4 | 0.0 | 1.2 | 0.2 |
Asian | 0.5 | 0.3 | 0.2 | 0.0 | 0.0 |
Two or More Races | 1.1 | 0.8 | 0.4 | 0.3 | 0.1 |
Hispanic or Latino | 0.8 | 0.6 | 0.2 | 0.1 | 0.0 |
60206
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 1,996 | 1,440 | 505 | 428 | 147 |
GEOGRAPHIC DIVISION | |||||
Northeast | 328 | 252 | 88 | 61 | 41 |
New England | 127 | 104 | 36 | 35 | 23 |
Middle Atlantic | 202 | 148 | 53 | 26 | 18 |
Midwest | 358 | 252 | 83 | 89 | 32 |
East North Central | 266 | 201 | 69 | 53 | 21 |
West North Central | 93 | 51 | 14 | 36 | 11 |
South | 794 | 588 | 238 | 145 | 54 |
South Atlantic | 360 | 267 | 112 | 68 | 23 |
East South Central | 177 | 142 | 52 | 26 | 12 |
West South Central | 256 | 179 | 74 | 50 | 18 |
West | 516 | 348 | 95 | 134 | 20 |
Mountain | 143 | 96 | 30 | 37 | 7 |
Pacific | 373 | 252 | 65 | 97 | 13 |
COUNTY TYPE | |||||
Large Metro | 967 | 678 | 250 | 173 | 67 |
Small Metro | 684 | 521 | 176 | 157 | 58 |
250K – 1 Mil. Pop. | 401 | 294 | 85 | 87 | 15 |
< 250K Pop. | 283 | 227 | 91 | 70 | 43 |
Nonmetro | 345 | 241 | 80 | 98 | 22 |
Urbanized | 155 | 112 | 32 | 38 | 7 |
Less Urbanized | 165 | 115 | 41 | 52 | 14 |
Completely Rural | 25 | 15 | 7 | 8 | 2 |
60206
Geographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 0.8 | 0.6 | 0.2 | 0.2 | 0.1 |
GEOGRAPHIC DIVISION | |||||
Northeast | 0.7 | 0.6 | 0.2 | 0.1 | 0.1 |
New England | 1.1 | 0.9 | 0.3 | 0.3 | 0.2 |
Middle Atlantic | 0.6 | 0.4 | 0.2 | 0.1 | 0.1 |
Midwest | 0.7 | 0.5 | 0.2 | 0.2 | 0.1 |
East North Central | 0.7 | 0.5 | 0.2 | 0.1 | 0.1 |
West North Central | 0.6 | 0.3 | 0.1 | 0.2 | 0.1 |
South | 0.9 | 0.7 | 0.3 | 0.2 | 0.1 |
South Atlantic | 0.8 | 0.6 | 0.3 | 0.2 | 0.1 |
East South Central | 1.2 | 1.0 | 0.4 | 0.2 | 0.1 |
West South Central | 1.0 | 0.7 | 0.3 | 0.2 | 0.1 |
West | 1.0 | 0.6 | 0.2 | 0.2 | 0.0 |
Mountain | 0.9 | 0.6 | 0.2 | 0.2 | 0.0 |
Pacific | 1.0 | 0.7 | 0.2 | 0.3 | 0.0 |
COUNTY TYPE | |||||
Large Metro | 0.8 | 0.5 | 0.2 | 0.1 | 0.1 |
Small Metro | 1.0 | 0.7 | 0.2 | 0.2 | 0.1 |
250K – 1 Mil. Pop. | 0.9 | 0.6 | 0.2 | 0.2 | 0.0 |
< 250K Pop. | 1.2 | 0.9 | 0.4 | 0.3 | 0.2 |
Nonmetro | 0.9 | 0.6 | 0.2 | 0.2 | 0.1 |
Urbanized | 0.9 | 0.7 | 0.2 | 0.2 | 0.0 |
Less Urbanized | 0.9 | 0.6 | 0.2 | 0.3 | 0.1 |
Completely Rural | 0.6 | 0.4 | 0.2 | 0.2 | 0.1 |
60206
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 1,995 | 1,440 | 505 | 424 | 147 |
AGE | |||||
12-17 | 361 | 275 | 86 | 94 | 30 |
18-25 | 584 | 408 | 148 | 146 | 23 |
26 or Older | 1,050 | 757 | 271 | 184 | 93 |
GENDER | |||||
Male | 977 | 739 | 240 | 216 | 75 |
Female | 1,018 | 701 | 265 | 208 | 72 |
60206
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 13.5 | 12.7 | 10.1 | 14.4 | 17.3 |
AGE | |||||
12-17 | 15.9 | 14.6 | 15.3 | 16.4 | 22.3 |
18-25 | 12.7 | 10.9 | 9.2 | 12.8 | 14.5 |
26 or Older | 13.3 | 13.3 | 9.7 | 14.9 | 16.8 |
GENDER | |||||
Male | 13.0 | 12.4 | 9.9 | 14.0 | 19.8 |
Female | 14.0 | 13.2 | 10.4 | 14.8 | 15.3 |
60209
Age at First Use | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
Past Year Substance Dependence or Abuse among Lifetime Users Aged 18 or Older | |||||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 1,635 | 1,165 | 420 | 334 | 117 |
Under 16 Years | 500 | 269 | 99 | 117 | 33 |
16 Years or Older | 1,135 | 896 | 321 | 217 | 83 |
16 to 20 Years | 652 | 414 | 150 | 134 | 55 |
21 to 25 Years | 254 | 234 | 53 | 31 | 9 |
26 Years or Older | 230 | 248 | 118 | 52 | 20 |
Age at First Use | Past Year Substance Dependence or Abuse among Lifetime Users Aged 18 to 25 | ||||
TOTAL | 585 | 408 | 148 | 150 | 23 |
Under 16 Years | 209 | 117 | 42 | 50 | 9 |
16 Years or Older | 376 | 291 | 106 | 100 | 15 |
16 to 20 Years | 340 | 244 | 90 | 93 | 11 |
21 to 25 Years | 36 | 47 | 17 | 7 | 4 |
Age at First Use | Past Year Substance Dependence or Abuse among Lifetime Users Aged 26 or Older | ||||
TOTAL | 1,050 | 757 | 271 | 184 | 93 |
Under 16 Years | 291 | 151 | 57 | 67 | 25 |
16 Years or Older | 759 | 605 | 214 | 117 | 69 |
16 to 20 Years | 312 | 170 | 60 | 41 | 44 |
21 to 25 Years | 218 | 187 | 36 | 24 | 5 |
26 Years or Older | 230 | 248 | 118 | 52 | 20 |
60209
Age at First Use | Any Prescription- Type Psycho- therapeutic Drug |
PRESCRIPTION DRUG TYPE | |||
---|---|---|---|---|---|
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
Past Year Substance Dependence or Abuse among Lifetime Users Aged 18 or Older | |||||
*Low precision; no estimate reported. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 3.7 | 4.2 | 2.2 | 1.7 | 1.2 |
Under 16 Years | 7.5 | 7.4 | 5.1 | 3.9 | 2.3 |
16 Years or Older | 3.0 | 3.7 | 1.9 | 1.3 | 1.0 |
16 to 20 Years | 3.3 | 3.7 | 2.1 | 1.3 | 1.1 |
21 to 25 Years | 2.8 | 3.8 | 1.2 | 0.8 | 0.5 |
26 Years or Older | 2.6 | 3.5 | 2.2 | 2.1 | 1.4 |
Age at First Use | Past Year Substance Dependence or Abuse among Lifetime Users Aged 18 to 25 | ||||
TOTAL | 6.5 | 5.5 | 3.9 | 4.4 | 3.8 |
Under 16 Years | 10.4 | 8.5 | 7.2 | 6.3 | 6.2 |
16 Years or Older | 5.3 | 4.8 | 3.3 | 3.8 | 3.1 |
16 to 20 Years | 5.7 | 4.8 | 3.5 | 4.1 | 2.8 |
21 to 25 Years | 3.5 | 4.9 | 2.9 | 2.2 | 4.7 |
Age at First Use | Past Year Substance Dependence or Abuse among Lifetime Users Aged 26 or Older | ||||
TOTAL | 3.0 | 3.7 | 1.8 | 1.1 | 1.0 |
Under 16 Years | 6.2 | 6.6 | 4.2 | 3.0 | 1.9 |
16 Years or Older | 2.5 | 3.3 | 1.6 | 0.8 | 0.9 |
16 to 20 Years | 2.3 | 2.8 | 1.3 | 0.5 | 1.0 |
21 to 25 Years | 2.7 | 3.6 | 0.9 | 0.7 | 0.3 |
26 Years or Older | 2.6 | 3.5 | 2.2 | 2.1 | 1.4 |
60213
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug1 |
Past Year Drug Dependence or Abuse and Receiving Treatment for Any Illicit Drug in Past Year | |||
---|---|---|---|---|---|
Prescription Drug Type | |||||
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
Numbers in Thousands | |||||
*Low precision; no estimate reported. NOTE: Received treatment for use of illicit drug at any facility refers to treatment received in order to reduce or stop use of any illicit drug, or for medical problems associated with illicit drug use. It includes treatment received at any location, such as hospital, a rehabilitation facility (impatient or outpatient), mental health center, emergency room, private doctor's office, self-help group, or prison/jail. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 290 | 210 | 106 | 104 | 39 |
AGE GROUP | |||||
12 to 17 | 41 | 31 | 15 | 18 | 6 |
18 to 25 | 90 | 59 | 23 | 38 | 4 |
26 or Older | 159 | 120 | 69 | 48 | 29 |
GENDER | |||||
Male | 145 | 108 | 56 | 52 | 31 |
Female | 145 | 102 | 51 | 51 | 8 |
Demographic Characteristic | Percentage among Persons Aged 12 or Older | ||||
TOTAL | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
AGE GROUP | |||||
12 to 17 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 |
18 to 25 | 0.3 | 0.2 | 0.1 | 0.1 | 0.0 |
26 or Older | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
GENDER | |||||
Male | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Female | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Demographic Characteristic | Percentage among Persons Aged 12 or Older Dependent on or Abusing Relevant Drug in the Past Year | ||||
TOTAL | 14.5 | 14.6 | 21.1 | 24.2 | * |
AGE GROUP | |||||
12 to 17 | 11.3 | 11.2 | 17.0 | 19.3 | * |
18 to 25 | 15.4 | 14.5 | 15.6 | 25.1 | * |
26 or Older | 15.1 | 15.9 | * | * | * |
GENDER | |||||
Male | 14.8 | 14.6 | * | * | * |
Female | 14.3 | 14.6 | 19.1 | 24.6 | * |
60209
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug1 |
Past Year Drug Dependence or Abuse and Receiving Treatment for Any Illicit Drug in Past Year | |||
---|---|---|---|---|---|
Prescription Drug Type | |||||
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
Numbers in Thousands | |||||
*Low precision; no estimate reported. NOTE: Received treatment for use of any illicit drug at a specialty facility refers to treatment received at a hospital (inpatient), a rehabilitation facility (inpatient or outpatient), or mental health center in order to reduce or stop illicit drug use, or for medical problems associated with illicit drug use. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 249 | 186 | 98 | 87 | 38 |
AGE GROUP | |||||
12 to 17 | 29 | 22 | 13 | 13 | 5 |
18 to 25 | 74 | 49 | 21 | 31 | 4 |
26 or Older | 146 | 114 | 64 | 43 | 29 |
GENDER | |||||
Male | 130 | 98 | 55 | 46 | 30 |
Female | 119 | 88 | 43 | 42 | 8 |
Demographic Characteristic | Percentage among Persons Aged 12 or Older | ||||
TOTAL | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
AGE GROUP | |||||
12 to 17 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
18 to 25 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 |
26 or Older | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
GENDER | |||||
Male | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Female | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Demographic Characteristic | Percentage among Persons Aged 12 or Older Dependent on or Abusing Relevant Drug in the Past Year | ||||
TOTAL | 12.5 | 12.9 | 19.3 | 20.4 | * |
AGE GROUP | |||||
12 to 17 | 7.9 | 8.1 | 15.0 | 13.7 | * |
18 to 25 | 12.7 | 12.1 | 14.0 | 20.8 | * |
26 or Older | 13.9 | 15.1 | * | * | * |
GENDER | |||||
Male | 13.3 | 13.3 | * | * | * |
Female | 11.7 | 12.5 | 16.0 | 19.9 | * |
60213
Demographic Characteristic | Any Prescription- Type Psycho- therapeutic Drug1 |
Drug for which Last or Current Treatment in the Past Year Was Received and That Individual was Dependent on or Abusing in the Past Year | |||
---|---|---|---|---|---|
Prescription Drug Type | |||||
Pain Relievers | Tranquilizers | Stimulants | Sedatives | ||
Numbers in Thousands | |||||
*Low precision; no estimate reported. NOTE: If respondents reported that they were currently receiving treatment, they were asked questions regarding specific substances for their current treatment; otherwise, questions pertained to the last treatment they received. Only persons who received treatment in the past year are included. NOTE: Received treatment for use of illicit drug at any facility refers to treatment received in order to reduce or stop use of any illicit drug, or for medical problems associated with illicit drug use. It includes treatment received at any location, such as hospital, a rehabilitation facility (impatient or outpatient), mental health center, emergency room, private doctor's office, self-help group, or prison/jail. NOTE: Dependence or abuse is based on definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 1 Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
|||||
TOTAL | 209 | 135 | 50 | 64 | 34 |
AGE GROUP | |||||
12 to 17 | 24 | 20 | 8 | 9 | 4 |
18 to 25 | 68 | 42 | 15 | 29 | 3 |
26 or Older | 117 | 74 | 27 | 26 | 27 |
GENDER | |||||
Male | 101 | 59 | 20 | 25 | 27 |
Female | 108 | 76 | 30 | 39 | 7 |
Demographic Characteristic | Percentage among Persons Aged 12 or Older | ||||
TOTAL | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
AGE GROUP | |||||
12 to 17 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
18 to 25 | 0.2 | 0.1 | 0.0 | 0.1 | 0.0 |
26 or Older | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
GENDER | |||||
Male | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Female | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Demographic Characteristic | Percentage among Persons Aged 12 or Older Dependent on or Abusing Relevant Drug in the Past Year | ||||
TOTAL | 10.5 | 9.4 | 9.8 | 15.0 | * |
AGE GROUP | |||||
12 to 17 | 6.5 | 7.1 | 9.4 | 10.0 | * |
18 to 25 | 11.6 | 10.4 | 10.0 | 19.0 | * |
26 or Older | 11.2 | 9.7 | 9.8 | * | * |
GENDER | |||||
Male | 10.3 | 8.0 | 8.3 | 11.3 | * |
Female | 10.6 | 10.8 | 11.2 | 18.8 | * |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 14,769 | (14,303 - 15,250) | 2,266 | (2,190 - 2,344) | 4,587 | (4,455 - 4,721) | 7,917 | (7,504 - 8,352) |
Alabama | 242 | (190 - 307) | 36 | (28 - 46) | 83 | (71 - 98) | 123 | (82 - 183) |
Alaska | 32 | (26 - 40) | 6 | (5 - 7) | 10 | (9 - 12) | 16 | (10 - 25) |
Arizona | 339 | (279 - 411) | 52 | (37 - 72) | 94 | (74 - 120) | 193 | (149 - 249) |
Arkansas | 159 | (130 - 194) | 26 | (21 - 32) | 58 | (49 - 68) | 76 | (57 - 100) |
California | 2,038 | (1,821 - 2,278) | 289 | (264 - 317) | 491 | (439 - 548) | 1,258 | (1,058 - 1,492) |
Colorado | 289 | (222 - 374) | 39 | (31 - 49) | 87 | (75 - 101) | 163 | (110 - 239) |
Connecticut | 165 | (134 - 203) | 20 | (15 - 27) | 51 | (41 - 64) | 94 | (62 - 140) |
Delaware | 41 | (35 - 49) | 6 | (5 - 8) | 16 | (13 - 19) | 20 | (15 - 26) |
District of Columbia | 24 | (18 - 31) | 2 | (1 - 3) | 7 | (5 - 9) | 15 | (10 - 22) |
Florida | 910 | (826 - 1,001) | 123 | (108 - 140) | 252 | (231 - 274) | 535 | (463 - 617) |
Georgia | 484 | (367 - 634) | 72 | (54 - 94) | 115 | (90 - 144) | 297 | (200 - 438) |
Hawaii | 49 | (41 - 59) | 10 | (8 - 12) | 14 | (12 - 17) | 25 | (19 - 34) |
Idaho | 84 | (70 - 100) | 13 | (10 - 16) | 26 | (22 - 31) | 45 | (33 - 61) |
Illinois | 502 | (441 - 572) | 83 | (72 - 95) | 171 | (156 - 187) | 249 | (196 - 316) |
Indiana | 383 | (313 - 468) | 52 | (39 - 67) | 126 | (107 - 147) | 206 | (151 - 278) |
Iowa | 109 | (89 - 133) | 18 | (12 - 27) | 38 | (28 - 50) | 54 | (40 - 72) |
Kansas | 130 | (101 - 166) | 17 | (14 - 22) | 40 | (29 - 55) | 72 | (51 - 103) |
Kentucky | 290 | (256 - 328) | 42 | (35 - 50) | 89 | (77 - 101) | 160 | (127 - 200) |
Louisiana | 250 | (210 - 298) | 35 | (27 - 44) | 105 | (88 - 124) | 110 | (81 - 149) |
Maine | 63 | (48 - 81) | 9 | (6 - 12) | 23 | (20 - 26) | 31 | (19 - 50) |
Maryland | 226 | (161 - 314) | 32 | (22 - 45) | 60 | (49 - 74) | 134 | (78 - 226) |
Massachusetts | 396 | (304 - 512) | 56 | (48 - 66) | 121 | (91 - 158) | 219 | (142 - 333) |
Michigan | 534 | (486 - 587) | 104 | (93 - 115) | 162 | (151 - 175) | 268 | (227 - 315) |
Minnesota | 211 | (169 - 263) | 35 | (23 - 51) | 71 | (59 - 85) | 105 | (74 - 148) |
Mississippi | 117 | (102 - 135) | 27 | (20 - 35) | 40 | (32 - 50) | 50 | (36 - 71) |
Missouri | 322 | (265 - 389) | 50 | (40 - 62) | 97 | (77 - 121) | 175 | (127 - 239) |
Montana | 47 | (38 - 59) | 9 | (7 - 12) | 15 | (13 - 17) | 23 | (16 - 34) |
Nebraska | 64 | (48 - 83) | 13 | (10 - 16) | 24 | (18 - 32) | 27 | (19 - 39) |
Nevada | 148 | (123 - 178) | 17 | (14 - 21) | 36 | (29 - 45) | 95 | (75 - 120) |
New Hampshire | 62 | (50 - 78) | 9 | (6 - 14) | 25 | (21 - 30) | 28 | (20 - 38) |
New Jersey | 295 | (224 - 387) | 56 | (39 - 80) | 91 | (76 - 109) | 147 | (96 - 226) |
New Mexico | 117 | (96 - 141) | 18 | (14 - 22) | 34 | (27 - 41) | 66 | (47 - 91) |
New York | 778 | (671 - 901) | 108 | (95 - 122) | 262 | (231 - 297) | 408 | (319 - 521) |
North Carolina | 398 | (326 - 485) | 77 | (58 - 101) | 125 | (98 - 157) | 196 | (127 - 299) |
North Dakota | 25 | (21 - 30) | 4 | (3 - 5) | 9 | (7 - 12) | 12 | (8 - 18) |
Ohio | 569 | (523 - 619) | 82 | (72 - 93) | 192 | (175 - 210) | 295 | (255 - 342) |
Oklahoma | 202 | (162 - 250) | 34 | (26 - 44) | 82 | (70 - 96) | 85 | (55 - 130) |
Oregon | 228 | (172 - 299) | 34 | (28 - 43) | 64 | (53 - 78) | 129 | (85 - 194) |
Pennsylvania | 505 | (453 - 563) | 78 | (69 - 87) | 184 | (167 - 203) | 243 | (198 - 298) |
Rhode Island | 69 | (57 - 84) | 8 | (6 - 11) | 30 | (25 - 35) | 32 | (23 - 44) |
South Carolina | 233 | (193 - 279) | 31 | (25 - 38) | 75 | (58 - 96) | 127 | (91 - 176) |
South Dakota | 25 | (21 - 30) | 7 | (5 - 9) | 9 | (7 - 11) | 9 | (6 - 14) |
Tennessee | 318 | (266 - 379) | 50 | (39 - 64) | 102 | (83 - 124) | 166 | (127 - 215) |
Texas | 1,081 | (965 - 1,211) | 176 | (157 - 198) | 352 | (313 - 396) | 553 | (458 - 667) |
Utah | 142 | (124 - 162) | 19 | (15 - 23) | 55 | (46 - 66) | 68 | (52 - 89) |
Vermont | 33 | (27 - 41) | 6 | (4 - 8) | 12 | (10 - 15) | 15 | (11 - 22) |
Virginia | 286 | (251 - 325) | 53 | (43 - 65) | 105 | (85 - 128) | 128 | (90 - 182) |
Washington | 376 | (294 - 480) | 64 | (54 - 76) | 111 | (92 - 133) | 201 | (136 - 295) |
West Virginia | 102 | (81 - 128) | 13 | (10 - 17) | 38 | (29 - 49) | 52 | (38 - 69) |
Wisconsin | 250 | (205 - 303) | 44 | (35 - 56) | 96 | (75 - 122) | 109 | (75 - 160) |
Wyoming | 27 | (23 - 30) | 4 | (3 - 5) | 10 | (8 - 11) | 13 | (10 - 16) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. NOTE: Nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, or sedatives; does not include over-the-counter drugs. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 6.2 | (6.0 - 6.4) | 9.1 | (8.8 - 9.4) | 14.5 | (14.1 - 14.9) | 4.4 | (4.1 - 4.6) |
Alabama | 6.5 | (5.1 - 8.3) | 9.4 | (7.3 - 12.2) | 16.6 | (14.1 - 19.4) | 4.4 | (2.9 - 6.5) |
Alaska | 6.4 | (5.1 - 7.9) | 8.6 | (6.7 - 10.9) | 15.9 | (13.3 - 18.8) | 4.3 | (2.7 - 6.7) |
Arizona | 7.6 | (6.2 - 9.2) | 10.6 | (7.5 - 14.7) | 15.4 | (12.0 - 19.5) | 5.7 | (4.4 - 7.4) |
Arkansas | 7.1 | (5.8 - 8.7) | 11.2 | (8.9 - 13.9) | 19.0 | (16.1 - 22.3) | 4.4 | (3.4 - 5.9) |
California | 7.1 | (6.4 - 8.0) | 9.1 | (8.3 - 10.0) | 12.5 | (11.1 - 13.9) | 5.8 | (4.9 - 6.9) |
Colorado | 7.8 | (6.0 - 10.1) | 10.0 | (8.0 - 12.5) | 17.6 | (15.1 - 20.4) | 5.8 | (3.9 - 8.5) |
Connecticut | 5.8 | (4.7 - 7.1) | 6.7 | (4.9 - 9.2) | 15.6 | (12.3 - 19.5) | 4.2 | (2.8 - 6.3) |
Delaware | 6.1 | (5.1 - 7.3) | 9.3 | (7.3 - 11.8) | 17.4 | (14.6 - 20.8) | 3.8 | (2.8 - 5.0) |
District of Columbia | 5.0 | (3.8 - 6.5) | 5.5 | (4.0 - 7.5) | 9.5 | (6.8 - 13.1) | 4.1 | (2.8 - 5.8) |
Florida | 6.4 | (5.8 - 7.1) | 9.1 | (8.0 - 10.3) | 15.6 | (14.3 - 17.0) | 4.8 | (4.1 - 5.5) |
Georgia | 7.0 | (5.3 - 9.1) | 9.5 | (7.2 - 12.4) | 12.0 | (9.5 - 15.1) | 5.7 | (3.8 - 8.4) |
Hawaii | 4.9 | (4.1 - 5.9) | 9.5 | (7.5 - 11.8) | 11.6 | (9.6 - 14.0) | 3.3 | (2.4 - 4.4) |
Idaho | 7.6 | (6.4 - 9.1) | 10.1 | (7.9 - 12.8) | 15.6 | (13.2 - 18.4) | 5.6 | (4.1 - 7.5) |
Illinois | 4.9 | (4.3 - 5.5) | 7.6 | (6.6 - 8.7) | 12.3 | (11.2 - 13.5) | 3.2 | (2.5 - 4.0) |
Indiana | 7.6 | (6.2 - 9.2) | 9.5 | (7.2 - 12.4) | 17.8 | (15.2 - 20.7) | 5.4 | (4.0 - 7.3) |
Iowa | 4.4 | (3.6 - 5.4) | 7.3 | (4.8 - 11.0) | 10.7 | (8.0 - 14.1) | 2.9 | (2.2 - 3.9) |
Kansas | 5.9 | (4.6 - 7.5) | 7.2 | (5.7 - 9.2) | 12.6 | (9.1 - 17.2) | 4.4 | (3.1 - 6.2) |
Kentucky | 8.5 | (7.5 - 9.7) | 12.7 | (10.6 - 15.3) | 19.5 | (17.0 - 22.3) | 6.1 | (4.8 - 7.7) |
Louisiana | 6.9 | (5.8 - 8.2) | 8.6 | (6.8 - 10.9) | 19.5 | (16.4 - 23.0) | 4.1 | (3.0 - 5.6) |
Maine | 5.6 | (4.3 - 7.3) | 8.2 | (5.9 - 11.3) | 17.3 | (14.9 - 19.9) | 3.5 | (2.2 - 5.8) |
Maryland | 5.0 | (3.6 - 7.0) | 6.6 | (4.6 - 9.4) | 11.1 | (9.0 - 13.5) | 3.8 | (2.2 - 6.5) |
Massachusetts | 7.4 | (5.7 - 9.5) | 11.0 | (9.3 - 13.0) | 17.9 | (13.5 - 23.5) | 5.2 | (3.4 - 7.9) |
Michigan | 6.4 | (5.8 - 7.1) | 11.5 | (10.4 - 12.8) | 14.8 | (13.7 - 15.9) | 4.2 | (3.6 - 5.0) |
Minnesota | 5.0 | (4.0 - 6.3) | 7.8 | (5.2 - 11.5) | 12.3 | (10.2 - 14.6) | 3.3 | (2.3 - 4.7) |
Mississippi | 5.1 | (4.4 - 5.8) | 10.4 | (7.9 - 13.5) | 11.5 | (9.2 - 14.4) | 2.9 | (2.1 - 4.1) |
Missouri | 6.8 | (5.6 - 8.3) | 10.2 | (8.2 - 12.6) | 15.2 | (12.0 - 19.0) | 4.9 | (3.6 - 6.7) |
Montana | 6.2 | (4.9 - 7.7) | 11.3 | (8.8 - 14.5) | 14.3 | (12.5 - 16.3) | 4.0 | (2.7 - 5.9) |
Nebraska | 4.5 | (3.4 - 5.9) | 8.4 | (6.5 - 10.7) | 11.6 | (8.6 - 15.4) | 2.5 | (1.8 - 3.6) |
Nevada | 8.1 | (6.7 - 9.8) | 9.1 | (7.5 - 11.1) | 16.2 | (12.9 - 20.2) | 6.7 | (5.3 - 8.5) |
New Hampshire | 5.8 | (4.6 - 7.2) | 8.3 | (5.6 - 12.0) | 19.3 | (16.3 - 22.7) | 3.3 | (2.4 - 4.5) |
New Jersey | 4.1 | (3.1 - 5.4) | 7.7 | (5.4 - 11.0) | 11.4 | (9.5 - 13.6) | 2.6 | (1.7 - 4.0) |
New Mexico | 7.7 | (6.3 - 9.3) | 10.1 | (8.0 - 12.7) | 15.6 | (12.6 - 19.2) | 5.8 | (4.2 - 8.0) |
New York | 4.9 | (4.2 - 5.7) | 6.9 | (6.0 - 7.8) | 12.9 | (11.3 - 14.6) | 3.3 | (2.6 - 4.2) |
North Carolina | 5.8 | (4.8 - 7.1) | 11.1 | (8.4 - 14.6) | 14.2 | (11.1 - 17.8) | 3.7 | (2.4 - 5.7) |
North Dakota | 4.8 | (4.0 - 5.7) | 8.0 | (6.5 - 9.8) | 10.6 | (8.0 - 14.0) | 3.1 | (2.1 - 4.5) |
Ohio | 6.0 | (5.5 - 6.6) | 8.3 | (7.3 - 9.4) | 15.4 | (14.1 - 16.9) | 4.1 | (3.5 - 4.8) |
Oklahoma | 7.1 | (5.7 - 8.8) | 11.4 | (8.7 - 14.7) | 19.9 | (16.9 - 23.2) | 4.0 | (2.6 - 6.1) |
Oregon | 7.7 | (5.8 - 10.1) | 11.5 | (9.3 - 14.3) | 16.6 | (13.6 - 20.1) | 5.7 | (3.7 - 8.5) |
Pennsylvania | 4.9 | (4.4 - 5.4) | 7.5 | (6.7 - 8.5) | 14.2 | (12.9 - 15.6) | 3.0 | (2.5 - 3.7) |
Rhode Island | 7.7 | (6.4 - 9.3) | 9.1 | (6.6 - 12.4) | 23.4 | (19.8 - 27.5) | 4.6 | (3.4 - 6.3) |
South Carolina | 6.8 | (5.7 - 8.2) | 8.7 | (7.0 - 10.8) | 16.3 | (12.5 - 20.9) | 4.9 | (3.5 - 6.8) |
South Dakota | 4.0 | (3.4 - 4.8) | 9.9 | (7.3 - 13.4) | 10.0 | (8.1 - 12.3) | 2.0 | (1.3 - 3.1) |
Tennessee | 6.6 | (5.5 - 7.9) | 10.5 | (8.1 - 13.5) | 16.2 | (13.3 - 19.7) | 4.5 | (3.4 - 5.8) |
Texas | 6.2 | (5.5 - 6.9) | 8.7 | (7.7 - 9.7) | 13.8 | (12.3 - 15.6) | 4.3 | (3.5 - 5.2) |
Utah | 7.8 | (6.8 - 8.9) | 8.1 | (6.6 - 9.9) | 15.4 | (12.9 - 18.4) | 5.5 | (4.2 - 7.2) |
Vermont | 6.2 | (5.1 - 7.7) | 10.8 | (7.6 - 15.0) | 17.5 | (14.1 - 21.4) | 3.7 | (2.6 - 5.3) |
Virginia | 4.8 | (4.2 - 5.5) | 8.7 | (7.0 - 10.7) | 14.0 | (11.4 - 17.1) | 2.8 | (2.0 - 4.0) |
Washington | 7.5 | (5.8 - 9.5) | 12.2 | (10.2 - 14.5) | 16.8 | (13.9 - 20.0) | 5.2 | (3.5 - 7.6) |
West Virginia | 6.7 | (5.3 - 8.3) | 9.3 | (7.1 - 12.1) | 19.5 | (14.9 - 25.1) | 4.3 | (3.2 - 5.7) |
Wisconsin | 5.5 | (4.5 - 6.7) | 9.2 | (7.2 - 11.6) | 15.3 | (11.9 - 19.5) | 3.2 | (2.2 - 4.6) |
Wyoming | 6.3 | (5.5 - 7.3) | 9.4 | (7.3 - 12.0) | 15.9 | (13.1 - 19.1) | 4.1 | (3.2 - 5.2) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 11,306 | (10,918 - 11,707) | 1,884 | (1,814 - 1,956) | 3,726 | (3,612 - 3,842) | 5,696 | (5,352 - 6,062) |
Alabama | 184 | (146 - 231) | 32 | (24 - 42) | 71 | (63 - 80) | 81 | (52 - 125) |
Alaska | 28 | (24 - 32) | 5 | (4 - 7) | 9 | (8 - 11) | 13 | (9 - 19) |
Arizona | 264 | (212 - 327) | 43 | (29 - 62) | 75 | (55 - 100) | 146 | (106 - 200) |
Arkansas | 114 | (92 - 141) | 21 | (15 - 29) | 43 | (36 - 53) | 50 | (37 - 66) |
California | 1,483 | (1,308 - 1,678) | 249 | (224 - 276) | 390 | (346 - 439) | 843 | (685 - 1,036) |
Colorado | 246 | (187 - 323) | 34 | (27 - 43) | 72 | (60 - 86) | 141 | (92 - 213) |
Connecticut | 112 | (87 - 144) | 17 | (12 - 23) | 40 | (31 - 53) | 55 | (34 - 90) |
Delaware | 33 | (27 - 41) | 5 | (4 - 6) | 13 | (10 - 16) | 15 | (11 - 22) |
District of Columbia | 12 | (10 - 16) | 1 | (1 - 2) | 4 | (3 - 5) | 7 | (4 - 12) |
Florida | 691 | (612 - 780) | 94 | (82 - 107) | 205 | (185 - 226) | 392 | (324 - 474) |
Georgia | 394 | (285 - 541) | 59 | (43 - 80) | 97 | (77 - 121) | 239 | (147 - 383) |
Hawaii | 38 | (29 - 50) | 8 | (6 - 11) | 10 | (8 - 13) | 20 | (13 - 31) |
Idaho | 64 | (50 - 81) | 11 | (8 - 14) | 22 | (18 - 27) | 31 | (21 - 45) |
Illinois | 387 | (343 - 436) | 69 | (60 - 80) | 144 | (130 - 160) | 173 | (135 - 222) |
Indiana | 306 | (245 - 380) | 45 | (33 - 63) | 111 | (93 - 131) | 150 | (105 - 213) |
Iowa | 64 | (46 - 90) | 13 | (8 - 19) | 28 | (20 - 38) | 24 | (15 - 40) |
Kansas | 93 | (65 - 133) | 13 | (10 - 17) | 32 | (23 - 44) | 48 | (28 - 82) |
Kentucky | 238 | (214 - 264) | 34 | (27 - 41) | 79 | (68 - 91) | 126 | (105 - 150) |
Louisiana | 179 | (148 - 215) | 28 | (22 - 36) | 79 | (65 - 94) | 72 | (49 - 105) |
Maine | 49 | (38 - 63) | 7 | (5 - 11) | 20 | (17 - 23) | 22 | (13 - 36) |
Maryland | 161 | (120 - 216) | 21 | (15 - 30) | 56 | (45 - 68) | 84 | (48 - 147) |
Massachusetts | 261 | (198 - 345) | 46 | (36 - 57) | 100 | (79 - 124) | 116 | (63 - 212) |
Michigan | 450 | (410 - 495) | 89 | (79 - 99) | 136 | (125 - 148) | 225 | (190 - 267) |
Minnesota | 152 | (123 - 186) | 25 | (16 - 39) | 49 | (41 - 58) | 77 | (58 - 103) |
Mississippi | 84 | (71 - 101) | 21 | (15 - 30) | 33 | (26 - 42) | 30 | (19 - 48) |
Missouri | 239 | (194 - 295) | 39 | (28 - 53) | 76 | (58 - 98) | 125 | (90 - 171) |
Montana | 31 | (24 - 40) | 7 | (6 - 9) | 11 | (9 - 13) | 13 | (7 - 22) |
Nebraska | 40 | (31 - 52) | 10 | (8 - 13) | 18 | (13 - 25) | 12 | (7 - 20) |
Nevada | 110 | (88 - 137) | 15 | (11 - 19) | 29 | (22 - 37) | 67 | (50 - 88) |
New Hampshire | 52 | (40 - 68) | 8 | (6 - 12) | 21 | (18 - 25) | 23 | (16 - 34) |
New Jersey | 226 | (173 - 295) | 45 | (29 - 70) | 80 | (65 - 98) | 101 | (68 - 148) |
New Mexico | 81 | (63 - 103) | 15 | (12 - 19) | 26 | (20 - 33) | 40 | (24 - 66) |
New York | 626 | (532 - 736) | 96 | (83 - 110) | 209 | (183 - 239) | 321 | (240 - 429) |
North Carolina | 313 | (259 - 378) | 66 | (51 - 85) | 106 | (83 - 134) | 141 | (90 - 221) |
North Dakota | 19 | (16 - 22) | 3 | (2 - 5) | 6 | (4 - 8) | 9 | (7 - 14) |
Ohio | 448 | (405 - 496) | 70 | (61 - 81) | 162 | (145 - 180) | 216 | (181 - 258) |
Oklahoma | 153 | (128 - 183) | 30 | (23 - 37) | 63 | (51 - 78) | 60 | (38 - 94) |
Oregon | 177 | (124 - 249) | 30 | (24 - 37) | 55 | (44 - 69) | 92 | (51 - 161) |
Pennsylvania | 414 | (369 - 464) | 64 | (55 - 73) | 152 | (138 - 167) | 198 | (161 - 245) |
Rhode Island | 55 | (47 - 64) | 7 | (5 - 10) | 23 | (18 - 29) | 25 | (19 - 33) |
South Carolina | 168 | (134 - 210) | 26 | (21 - 32) | 58 | (47 - 70) | 84 | (56 - 126) |
South Dakota | 17 | (14 - 20) | 5 | (3 - 7) | 6 | (5 - 7) | 6 | (3 - 10) |
Tennessee | 231 | (185 - 288) | 42 | (33 - 53) | 72 | (59 - 86) | 117 | (80 - 170) |
Texas | 818 | (716 - 934) | 143 | (125 - 162) | 275 | (241 - 314) | 400 | (315 - 507) |
Utah | 111 | (91 - 134) | 15 | (11 - 19) | 46 | (39 - 54) | 50 | (32 - 75) |
Vermont | 27 | (22 - 33) | 5 | (3 - 7) | 10 | (8 - 12) | 13 | (9 - 18) |
Virginia | 243 | (209 - 281) | 48 | (37 - 61) | 85 | (69 - 104) | 110 | (75 - 162) |
Washington | 315 | (252 - 392) | 57 | (47 - 68) | 99 | (82 - 118) | 160 | (108 - 235) |
West Virginia | 83 | (66 - 104) | 11 | (9 - 14) | 31 | (24 - 41) | 40 | (30 - 53) |
Wisconsin | 200 | (164 - 243) | 36 | (26 - 48) | 83 | (63 - 109) | 81 | (58 - 115) |
Wyoming | 21 | (17 - 24) | 4 | (3 - 5) | 7 | (6 - 9) | 10 | (8 - 13) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 4.8 | (4.6 - 4.9) | 7.5 | (7.3 - 7.8) | 11.8 | (11.4 - 12.1) | 3.1 | (3.0 - 3.3) |
Alabama | 5.0 | (3.9 - 6.2) | 8.4 | (6.4 - 11.1) | 14.1 | (12.6 - 15.8) | 2.9 | (1.8 - 4.4) |
Alaska | 5.5 | (4.7 - 6.4) | 7.6 | (5.6 - 10.1) | 13.9 | (11.5 - 16.6) | 3.6 | (2.5 - 5.1) |
Arizona | 5.9 | (4.7 - 7.3) | 8.7 | (6.0 - 12.5) | 12.2 | (9.1 - 16.3) | 4.3 | (3.1 - 5.9) |
Arkansas | 5.1 | (4.1 - 6.3) | 9.0 | (6.6 - 12.3) | 14.3 | (11.7 - 17.3) | 2.9 | (2.2 - 3.9) |
California | 5.2 | (4.6 - 5.9) | 7.8 | (7.1 - 8.7) | 9.9 | (8.8 - 11.2) | 3.9 | (3.2 - 4.8) |
Colorado | 6.7 | (5.0 - 8.7) | 8.7 | (6.8 - 11.0) | 14.4 | (12.0 - 17.2) | 5.0 | (3.3 - 7.6) |
Connecticut | 3.9 | (3.0 - 5.0) | 5.6 | (4.0 - 7.8) | 12.3 | (9.3 - 16.0) | 2.5 | (1.5 - 4.0) |
Delaware | 4.9 | (4.0 - 6.0) | 7.3 | (5.7 - 9.2) | 14.2 | (11.6 - 17.4) | 3.0 | (2.1 - 4.2) |
District of Columbia | 2.6 | (2.0 - 3.4) | 4.3 | (2.9 - 6.3) | 5.3 | (3.8 - 7.4) | 1.9 | (1.1 - 3.3) |
Florida | 4.9 | (4.3 - 5.5) | 6.9 | (6.1 - 7.9) | 12.7 | (11.5 - 14.0) | 3.5 | (2.9 - 4.2) |
Georgia | 5.7 | (4.1 - 7.8) | 7.8 | (5.7 - 10.5) | 10.1 | (8.0 - 12.7) | 4.6 | (2.8 - 7.3) |
Hawaii | 3.8 | (3.0 - 5.0) | 7.7 | (5.5 - 10.9) | 8.3 | (6.5 - 10.4) | 2.6 | (1.7 - 4.0) |
Idaho | 5.8 | (4.5 - 7.3) | 8.4 | (6.3 - 11.0) | 13.3 | (10.6 - 16.5) | 3.8 | (2.6 - 5.6) |
Illinois | 3.7 | (3.3 - 4.2) | 6.4 | (5.5 - 7.4) | 10.4 | (9.3 - 11.6) | 2.2 | (1.7 - 2.8) |
Indiana | 6.1 | (4.9 - 7.5) | 8.4 | (6.0 - 11.5) | 15.6 | (13.1 - 18.5) | 3.9 | (2.8 - 5.6) |
Iowa | 2.6 | (1.9 - 3.7) | 5.1 | (3.4 - 7.6) | 7.8 | (5.6 - 10.8) | 1.3 | (0.8 - 2.1) |
Kansas | 4.2 | (3.0 - 6.0) | 5.4 | (4.2 - 7.0) | 10.0 | (7.2 - 13.8) | 2.9 | (1.7 - 5.0) |
Kentucky | 7.0 | (6.3 - 7.8) | 10.2 | (8.2 - 12.5) | 17.3 | (14.9 - 20.0) | 4.8 | (4.0 - 5.8) |
Louisiana | 4.9 | (4.1 - 5.9) | 7.0 | (5.5 - 8.8) | 14.6 | (12.1 - 17.4) | 2.7 | (1.8 - 3.9) |
Maine | 4.4 | (3.4 - 5.6) | 6.7 | (4.6 - 9.8) | 14.8 | (12.6 - 17.3) | 2.5 | (1.5 - 4.2) |
Maryland | 3.6 | (2.7 - 4.8) | 4.4 | (3.1 - 6.1) | 10.2 | (8.2 - 12.5) | 2.4 | (1.4 - 4.2) |
Massachusetts | 4.9 | (3.7 - 6.4) | 9.0 | (7.1 - 11.2) | 14.8 | (11.7 - 18.4) | 2.8 | (1.5 - 5.1) |
Michigan | 5.4 | (4.9 - 6.0) | 9.9 | (8.8 - 11.1) | 12.4 | (11.4 - 13.5) | 3.6 | (3.0 - 4.2) |
Minnesota | 3.6 | (2.9 - 4.4) | 5.7 | (3.7 - 8.7) | 8.4 | (7.1 - 10.1) | 2.4 | (1.8 - 3.2) |
Mississippi | 3.6 | (3.0 - 4.4) | 8.1 | (5.7 - 11.6) | 9.6 | (7.5 - 12.1) | 1.8 | (1.1 - 2.8) |
Missouri | 5.1 | (4.1 - 6.3) | 7.9 | (5.7 - 10.8) | 12.0 | (9.2 - 15.4) | 3.5 | (2.5 - 4.8) |
Montana | 4.0 | (3.1 - 5.3) | 9.0 | (6.9 - 11.8) | 10.5 | (8.7 - 12.7) | 2.2 | (1.3 - 3.7) |
Nebraska | 2.8 | (2.2 - 3.6) | 6.5 | (5.0 - 8.4) | 8.7 | (6.1 - 12.3) | 1.1 | (0.7 - 1.9) |
Nevada | 6.1 | (4.8 - 7.5) | 7.8 | (6.0 - 9.9) | 13.0 | (10.1 - 16.6) | 4.7 | (3.6 - 6.2) |
New Hampshire | 4.8 | (3.7 - 6.3) | 7.2 | (5.0 - 10.3) | 15.8 | (13.3 - 18.6) | 2.8 | (1.9 - 4.1) |
New Jersey | 3.2 | (2.4 - 4.1) | 6.2 | (4.0 - 9.7) | 9.9 | (8.1 - 12.2) | 1.8 | (1.2 - 2.7) |
New Mexico | 5.3 | (4.1 - 6.8) | 8.6 | (6.7 - 11.0) | 12.0 | (9.4 - 15.2) | 3.5 | (2.1 - 5.8) |
New York | 3.9 | (3.3 - 4.6) | 6.1 | (5.3 - 7.0) | 10.3 | (9.0 - 11.7) | 2.6 | (1.9 - 3.5) |
North Carolina | 4.6 | (3.8 - 5.5) | 9.6 | (7.4 - 12.3) | 12.0 | (9.4 - 15.2) | 2.7 | (1.7 - 4.2) |
North Dakota | 3.6 | (3.0 - 4.3) | 6.2 | (4.5 - 8.5) | 7.4 | (5.3 - 10.1) | 2.4 | (1.7 - 3.5) |
Ohio | 4.8 | (4.3 - 5.3) | 7.1 | (6.1 - 8.2) | 13.0 | (11.7 - 14.5) | 3.0 | (2.5 - 3.6) |
Oklahoma | 5.4 | (4.5 - 6.4) | 9.9 | (7.8 - 12.5) | 15.3 | (12.4 - 18.8) | 2.8 | (1.8 - 4.4) |
Oregon | 6.0 | (4.2 - 8.4) | 10.0 | (8.0 - 12.3) | 14.3 | (11.4 - 17.8) | 4.0 | (2.3 - 7.1) |
Pennsylvania | 4.0 | (3.6 - 4.5) | 6.2 | (5.4 - 7.1) | 11.7 | (10.6 - 12.9) | 2.5 | (2.0 - 3.0) |
Rhode Island | 6.1 | (5.2 - 7.1) | 7.8 | (5.4 - 11.1) | 18.3 | (14.5 - 22.8) | 3.6 | (2.7 - 4.8) |
South Carolina | 4.9 | (3.9 - 6.2) | 7.5 | (6.0 - 9.2) | 12.5 | (10.2 - 15.3) | 3.3 | (2.2 - 4.8) |
South Dakota | 2.7 | (2.2 - 3.2) | 7.1 | (5.0 - 10.0) | 6.7 | (5.6 - 7.9) | 1.2 | (0.7 - 2.2) |
Tennessee | 4.8 | (3.8 - 6.0) | 8.9 | (7.0 - 11.3) | 11.4 | (9.4 - 13.7) | 3.1 | (2.2 - 4.6) |
Texas | 4.7 | (4.1 - 5.3) | 7.0 | (6.2 - 8.0) | 10.8 | (9.5 - 12.4) | 3.1 | (2.4 - 3.9) |
Utah | 6.1 | (5.0 - 7.3) | 6.5 | (5.0 - 8.5) | 12.9 | (11.0 - 15.2) | 4.0 | (2.6 - 6.1) |
Vermont | 5.2 | (4.2 - 6.3) | 8.8 | (6.0 - 12.9) | 14.4 | (11.6 - 17.7) | 3.1 | (2.1 - 4.5) |
Virginia | 4.1 | (3.5 - 4.7) | 7.8 | (6.0 - 10.0) | 11.3 | (9.2 - 13.9) | 2.4 | (1.6 - 3.5) |
Washington | 6.2 | (5.0 - 7.8) | 10.7 | (8.9 - 12.9) | 14.9 | (12.3 - 17.8) | 4.1 | (2.8 - 6.1) |
West Virginia | 5.4 | (4.3 - 6.7) | 8.0 | (6.2 - 10.2) | 16.2 | (12.3 - 21.0) | 3.3 | (2.5 - 4.4) |
Wisconsin | 4.4 | (3.6 - 5.3) | 7.4 | (5.4 - 10.1) | 13.2 | (10.0 - 17.4) | 2.4 | (1.7 - 3.3) |
Wyoming | 4.9 | (4.2 - 5.8) | 8.1 | (6.2 - 10.5) | 11.6 | (9.3 - 14.4) | 3.2 | (2.5 - 4.1) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 4,989 | (4,727 - 5,266) | 562 | (525 - 601) | 1,616 | (1,538 - 1,698) | 2,811 | (2,578 - 3,064) |
Alabama | 105 | (79 - 139) | 11 | (6 - 18) | 40 | (31 - 51) | 54 | (32 - 91) |
Alaska | 9 | (7 - 13) | 1 | (0 - 3) | 2 | (1 - 4) | 6 | (3 - 11) |
Arizona | 94 | (54 - 165) | 14 | (9 - 22) | 36 | (21 - 62) | 44 | (19 - 103) |
Arkansas | 69 | (56 - 84) | 9 | (6 - 13) | 29 | (21 - 38) | 31 | (20 - 47) |
California | 513 | (415 - 633) | 66 | (54 - 79) | 122 | (97 - 151) | 326 | (243 - 436) |
Colorado | 85 | (60 - 120) | 8 | (6 - 12) | 27 | (16 - 45) | 50 | (28 - 89) |
Connecticut | 46 | (30 - 69) | 2 | (1 - 5) | 13 | (9 - 19) | 30 | (17 - 53) |
Delaware | 14 | (11 - 19) | 2 | (1 - 3) | 5 | (4 - 7) | 7 | (4 - 12) |
District of Columbia | 9 | (6 - 14) | 0 | (0 - 0) | 2 | (1 - 4) | 7 | (4 - 12) |
Florida | 431 | (363 - 510) | 48 | (38 - 60) | 124 | (109 - 141) | 259 | (201 - 332) |
Georgia | 156 | (100 - 242) | 17 | (11 - 26) | 40 | (24 - 65) | 100 | (52 - 191) |
Hawaii | 10 | (7 - 15) | 1 | (1 - 3) | 3 | (2 - 5) | 6 | (3 - 11) |
Idaho | 20 | (14 - 29) | 3 | (2 - 5) | 5 | (3 - 7) | 12 | (8 - 20) |
Illinois | 160 | (122 - 209) | 15 | (11 - 20) | 38 | (31 - 47) | 107 | (74 - 155) |
Indiana | 142 | (103 - 195) | 15 | (10 - 22) | 48 | (36 - 66) | 78 | (48 - 127) |
Iowa | 27 | (16 - 45) | 3 | (1 - 9) | 7 | (6 - 10) | 17 | (8 - 34) |
Kansas | 42 | (29 - 60) | 4 | (2 - 7) | 13 | (8 - 21) | 25 | (15 - 41) |
Kentucky | 158 | (137 - 182) | 16 | (13 - 19) | 50 | (44 - 57) | 91 | (68 - 123) |
Louisiana | 125 | (98 - 159) | 15 | (11 - 19) | 53 | (45 - 62) | 58 | (37 - 90) |
Maine | 21 | (16 - 26) | 2 | (2 - 2) | 11 | (8 - 15) | 8 | (4 - 15) |
Maryland | 84 | (48 - 145) | 6 | (3 - 13) | 21 | (14 - 31) | 57 | (24 - 131) |
Massachusetts | 158 | (97 - 257) | 16 | (13 - 20) | 38 | (27 - 53) | 105 | (54 - 201) |
Michigan | 132 | (108 - 161) | 17 | (13 - 22) | 45 | (39 - 52) | 71 | (51 - 98) |
Minnesota | 34 | (23 - 50) | 5 | (2 - 13) | 14 | (10 - 19) | 15 | (7 - 32) |
Mississippi | 56 | (42 - 74) | 8 | (4 - 16) | 20 | (14 - 27) | 28 | (19 - 42) |
Missouri | 120 | (87 - 164) | 14 | (9 - 23) | 43 | (33 - 56) | 62 | (32 - 119) |
Montana | 11 | (7 - 18) | 2 | (1 - 3) | 4 | (2 - 5) | 6 | (2 - 14) |
Nebraska | 14 | (9 - 20) | 2 | (1 - 4) | 6 | (4 - 9) | 5 | (2 - 11) |
Nevada | 47 | (33 - 67) | 4 | (2 - 8) | 12 | (9 - 17) | 31 | (17 - 54) |
New Hampshire | 20 | (14 - 26) | 2 | (1 - 4) | 8 | (6 - 10) | 10 | (5 - 18) |
New Jersey | 128 | (88 - 187) | 11 | (5 - 25) | 36 | (26 - 48) | 81 | (45 - 146) |
New Mexico | 37 | (25 - 53) | 1 | (1 - 3) | 9 | (6 - 13) | 26 | (15 - 46) |
New York | 245 | (188 - 317) | 18 | (14 - 25) | 70 | (57 - 85) | 156 | (105 - 232) |
North Carolina | 152 | (104 - 219) | 27 | (16 - 44) | 53 | (37 - 77) | 71 | (39 - 129) |
North Dakota | 4 | (3 - 6) | 1 | (1 - 1) | 1 | (1 - 2) | 2 | (1 - 4) |
Ohio | 196 | (165 - 232) | 17 | (14 - 22) | 79 | (69 - 91) | 99 | (72 - 137) |
Oklahoma | 80 | (61 - 106) | 9 | (6 - 15) | 37 | (30 - 47) | 34 | (21 - 53) |
Oregon | 59 | (35 - 96) | 5 | (3 - 9) | 17 | (11 - 26) | 37 | (19 - 72) |
Pennsylvania | 183 | (151 - 222) | 19 | (15 - 24) | 67 | (56 - 78) | 98 | (69 - 138) |
Rhode Island | 22 | (17 - 28) | 2 | (1 - 4) | 9 | (6 - 14) | 11 | (7 - 17) |
South Carolina | 122 | (97 - 154) | 12 | (8 - 19) | 30 | (21 - 42) | 80 | (56 - 114) |
South Dakota | 4 | (2 - 6) | 1 | (1 - 2) | 1 | (0 - 2) | 2 | (1 - 4) |
Tennessee | 146 | (112 - 190) | 18 | (11 - 28) | 59 | (43 - 80) | 69 | (41 - 114) |
Texas | 329 | (277 - 389) | 57 | (47 - 69) | 136 | (114 - 163) | 136 | (100 - 184) |
Utah | 41 | (30 - 55) | 3 | (2 - 6) | 18 | (14 - 24) | 19 | (10 - 36) |
Vermont | 9 | (6 - 14) | 1 | (1 - 3) | 4 | (2 - 6) | 4 | (2 - 8) |
Virginia | 101 | (72 - 143) | 13 | (9 - 18) | 29 | (20 - 41) | 60 | (33 - 110) |
Washington | 91 | (66 - 124) | 7 | (3 - 17) | 32 | (20 - 50) | 52 | (32 - 83) |
West Virginia | 41 | (31 - 55) | 5 | (3 - 7) | 20 | (15 - 27) | 17 | (10 - 27) |
Wisconsin | 83 | (47 - 144) | 7 | (3 - 16) | 27 | (14 - 50) | 48 | (20 - 115) |
Wyoming | 8 | (6 - 11) | 1 | (0 - 1) | 2 | (1 - 3) | 5 | (3 - 8) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 2.1 | (2.0 - 2.2) | 2.2 | (2.1 - 2.4) | 5.1 | (4.9 - 5.4) | 1.6 | (1.4 - 1.7) |
Alabama | 2.8 | (2.1 - 3.7) | 2.8 | (1.6 - 4.7) | 8.0 | (6.2 - 10.2) | 1.9 | (1.1 - 3.2) |
Alaska | 1.8 | (1.3 - 2.6) | 1.6 | (0.7 - 3.9) | 3.7 | (2.3 - 5.9) | 1.6 | (0.8 - 3.1) |
Arizona | 2.1 | (1.2 - 3.7) | 2.8 | (1.8 - 4.4) | 6.0 | (3.4 - 10.2) | 1.3 | (0.6 - 3.0) |
Arkansas | 3.1 | (2.5 - 3.8) | 3.9 | (2.6 - 5.7) | 9.4 | (7.0 - 12.5) | 1.8 | (1.2 - 2.7) |
California | 1.8 | (1.4 - 2.2) | 2.1 | (1.7 - 2.5) | 3.1 | (2.5 - 3.8) | 1.5 | (1.1 - 2.0) |
Colorado | 2.3 | (1.6 - 3.2) | 2.1 | (1.4 - 3.0) | 5.4 | (3.2 - 9.1) | 1.8 | (1.0 - 3.2) |
Connecticut | 1.6 | (1.0 - 2.4) | 0.8 | (0.4 - 1.6) | 4.0 | (2.8 - 5.7) | 1.3 | (0.8 - 2.4) |
Delaware | 2.1 | (1.6 - 2.7) | 2.7 | (1.4 - 5.1) | 5.8 | (4.5 - 7.3) | 1.4 | (0.8 - 2.3) |
District of Columbia | 2.0 | (1.3 - 2.9) | 0.1 | (0.0 - 0.8) | 2.8 | (1.5 - 5.1) | 2.0 | (1.2 - 3.2) |
Florida | 3.0 | (2.6 - 3.6) | 3.5 | (2.8 - 4.4) | 7.7 | (6.8 - 8.7) | 2.3 | (1.8 - 3.0) |
Georgia | 2.2 | (1.4 - 3.5) | 2.2 | (1.4 - 3.4) | 4.1 | (2.5 - 6.8) | 1.9 | (1.0 - 3.6) |
Hawaii | 1.0 | (0.7 - 1.5) | 1.4 | (0.8 - 2.5) | 2.6 | (1.7 - 3.9) | 0.7 | (0.4 - 1.4) |
Idaho | 1.8 | (1.3 - 2.6) | 2.4 | (1.4 - 4.1) | 2.8 | (1.8 - 4.4) | 1.5 | (1.0 - 2.4) |
Illinois | 1.5 | (1.2 - 2.0) | 1.3 | (1.0 - 1.9) | 2.7 | (2.2 - 3.4) | 1.4 | (0.9 - 2.0) |
Indiana | 2.8 | (2.0 - 3.9) | 2.7 | (1.8 - 4.1) | 6.9 | (5.0 - 9.3) | 2.1 | (1.3 - 3.3) |
Iowa | 1.1 | (0.7 - 1.9) | 1.3 | (0.4 - 3.5) | 2.1 | (1.6 - 2.8) | 0.9 | (0.4 - 1.8) |
Kansas | 1.9 | (1.3 - 2.7) | 1.6 | (0.9 - 3.0) | 4.1 | (2.5 - 6.6) | 1.5 | (0.9 - 2.5) |
Kentucky | 4.6 | (4.0 - 5.3) | 4.9 | (4.1 - 5.8) | 11.1 | (9.7 - 12.6) | 3.5 | (2.6 - 4.7) |
Louisiana | 3.5 | (2.7 - 4.4) | 3.6 | (2.7 - 4.7) | 9.8 | (8.3 - 11.6) | 2.2 | (1.4 - 3.4) |
Maine | 1.9 | (1.4 - 2.4) | 1.8 | (1.5 - 2.2) | 8.2 | (6.0 - 11.2) | 0.9 | (0.5 - 1.7) |
Maryland | 1.9 | (1.1 - 3.2) | 1.2 | (0.6 - 2.8) | 3.8 | (2.6 - 5.6) | 1.6 | (0.7 - 3.8) |
Massachusetts | 2.9 | (1.8 - 4.8) | 3.1 | (2.5 - 3.9) | 5.6 | (4.0 - 7.9) | 2.5 | (1.3 - 4.8) |
Michigan | 1.6 | (1.3 - 1.9) | 1.9 | (1.4 - 2.4) | 4.1 | (3.5 - 4.7) | 1.1 | (0.8 - 1.5) |
Minnesota | 0.8 | (0.5 - 1.2) | 1.0 | (0.4 - 2.9) | 2.4 | (1.7 - 3.4) | 0.5 | (0.2 - 1.0) |
Mississippi | 2.4 | (1.8 - 3.2) | 3.1 | (1.5 - 6.3) | 5.6 | (4.1 - 7.7) | 1.7 | (1.1 - 2.5) |
Missouri | 2.5 | (1.8 - 3.5) | 3.0 | (1.9 - 4.6) | 6.8 | (5.3 - 8.8) | 1.7 | (0.9 - 3.3) |
Montana | 1.4 | (0.9 - 2.3) | 2.1 | (1.2 - 3.7) | 3.4 | (2.4 - 5.0) | 1.0 | (0.4 - 2.5) |
Nebraska | 1.0 | (0.7 - 1.4) | 1.4 | (0.8 - 2.6) | 3.0 | (2.1 - 4.4) | 0.5 | (0.2 - 1.1) |
Nevada | 2.6 | (1.8 - 3.7) | 1.9 | (0.9 - 4.2) | 5.5 | (4.0 - 7.6) | 2.2 | (1.2 - 3.8) |
New Hampshire | 1.8 | (1.3 - 2.4) | 1.7 | (0.9 - 3.1) | 6.0 | (4.6 - 7.8) | 1.2 | (0.6 - 2.1) |
New Jersey | 1.8 | (1.2 - 2.6) | 1.5 | (0.7 - 3.5) | 4.5 | (3.3 - 6.0) | 1.5 | (0.8 - 2.6) |
New Mexico | 2.4 | (1.7 - 3.5) | 0.8 | (0.4 - 1.6) | 4.2 | (2.9 - 6.1) | 2.3 | (1.3 - 4.0) |
New York | 1.5 | (1.2 - 2.0) | 1.2 | (0.9 - 1.6) | 3.4 | (2.8 - 4.2) | 1.3 | (0.9 - 1.9) |
North Carolina | 2.2 | (1.5 - 3.2) | 3.9 | (2.4 - 6.3) | 6.1 | (4.2 - 8.7) | 1.4 | (0.7 - 2.5) |
North Dakota | 0.8 | (0.5 - 1.1) | 1.5 | (1.1 - 2.1) | 1.3 | (0.7 - 2.5) | 0.5 | (0.3 - 1.0) |
Ohio | 2.1 | (1.8 - 2.5) | 1.8 | (1.4 - 2.3) | 6.4 | (5.6 - 7.4) | 1.4 | (1.0 - 1.9) |
Oklahoma | 2.8 | (2.1 - 3.7) | 3.0 | (1.9 - 4.9) | 9.0 | (7.2 - 11.3) | 1.6 | (1.0 - 2.5) |
Oregon | 2.0 | (1.2 - 3.2) | 1.6 | (0.9 - 2.9) | 4.3 | (2.7 - 6.6) | 1.6 | (0.8 - 3.2) |
Pennsylvania | 1.8 | (1.5 - 2.1) | 1.8 | (1.5 - 2.3) | 5.1 | (4.3 - 6.0) | 1.2 | (0.9 - 1.7) |
Rhode Island | 2.4 | (1.9 - 3.1) | 2.2 | (1.2 - 4.2) | 7.4 | (5.0 - 10.8) | 1.5 | (1.0 - 2.4) |
South Carolina | 3.6 | (2.9 - 4.5) | 3.5 | (2.3 - 5.4) | 6.5 | (4.6 - 9.1) | 3.1 | (2.2 - 4.4) |
South Dakota | 0.6 | (0.4 - 1.0) | 1.7 | (0.8 - 3.5) | 0.9 | (0.5 - 1.7) | 0.4 | (0.2 - 0.9) |
Tennessee | 3.0 | (2.3 - 3.9) | 3.8 | (2.4 - 6.0) | 9.5 | (6.9 - 12.8) | 1.8 | (1.1 - 3.1) |
Texas | 1.9 | (1.6 - 2.2) | 2.8 | (2.3 - 3.4) | 5.4 | (4.5 - 6.4) | 1.1 | (0.8 - 1.4) |
Utah | 2.2 | (1.7 - 3.0) | 1.5 | (0.8 - 2.7) | 5.0 | (3.8 - 6.6) | 1.5 | (0.8 - 2.9) |
Vermont | 1.7 | (1.1 - 2.7) | 2.5 | (1.2 - 4.9) | 5.5 | (3.5 - 8.6) | 0.9 | (0.4 - 2.0) |
Virginia | 1.7 | (1.2 - 2.4) | 2.1 | (1.5 - 3.0) | 3.8 | (2.7 - 5.5) | 1.3 | (0.7 - 2.4) |
Washington | 1.8 | (1.3 - 2.5) | 1.4 | (0.6 - 3.3) | 4.8 | (3.0 - 7.5) | 1.3 | (0.8 - 2.1) |
West Virginia | 2.7 | (2.0 - 3.6) | 3.3 | (2.1 - 5.1) | 10.3 | (7.5 - 13.9) | 1.4 | (0.8 - 2.2) |
Wisconsin | 1.8 | (1.0 - 3.2) | 1.5 | (0.7 - 3.4) | 4.3 | (2.3 - 8.0) | 1.4 | (0.6 - 3.3) |
Wyoming | 1.9 | (1.3 - 2.7) | 1.8 | (1.1 - 3.0) | 3.5 | (2.4 - 5.1) | 1.6 | (1.0 - 2.6) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 2,950 | (2,774 - 3,137) | 571 | (532 - 613) | 1,147 | (1,072 - 1,226) | 1,232 | (1,091 - 1,391) |
Alabama | 55 | (41 - 75) | 10 | (7 - 14) | 23 | (15 - 35) | 22 | (13 - 37) |
Alaska | 6 | (4 - 8) | 1 | (1 - 2) | 3 | (2 - 4) | 2 | (1 - 4) |
Arizona | 74 | (53 - 105) | 14 | (9 - 22) | 22 | (12 - 40) | 38 | (23 - 62) |
Arkansas | 41 | (30 - 55) | 8 | (4 - 13) | 20 | (14 - 28) | 14 | (8 - 24) |
California | 457 | (370 - 563) | 61 | (46 - 80) | 133 | (106 - 165) | 264 | (189 - 366) |
Colorado | 51 | (29 - 88) | 12 | (8 - 17) | 21 | (14 - 30) | 18 | (4 - 73) |
Connecticut | 20 | (15 - 26) | 5 | (3 - 8) | 13 | (9 - 19) | 2 | (0 - 13) |
Delaware | 9 | (7 - 13) | 2 | (1 - 2) | 5 | (3 - 7) | 3 | (1 - 6) |
District of Columbia | 7 | (4 - 12) | 0 | (0 - 1) | 3 | (2 - 6) | 3 | (1 - 7) |
Florida | 101 | (77 - 133) | 26 | (19 - 36) | 40 | (34 - 49) | 35 | (19 - 64) |
Georgia | 79 | (50 - 122) | 18 | (12 - 27) | 23 | (12 - 45) | 38 | (20 - 69) |
Hawaii | 15 | (11 - 21) | 3 | (2 - 4) | 5 | (3 - 8) | 8 | (5 - 13) |
Idaho | 20 | (15 - 26) | 4 | (2 - 7) | 6 | (5 - 8) | 9 | (5 - 17) |
Illinois | 80 | (64 - 102) | 20 | (15 - 27) | 33 | (25 - 44) | 27 | (16 - 47) |
Indiana | 84 | (58 - 122) | 13 | (9 - 20) | 27 | (17 - 43) | 44 | (26 - 75) |
Iowa | 42 | (28 - 60) | 7 | (4 - 12) | 15 | (11 - 22) | 19 | (10 - 38) |
Kansas | 37 | (28 - 48) | 5 | (3 - 8) | 12 | (6 - 20) | 20 | (12 - 33) |
Kentucky | 69 | (47 - 101) | 10 | (7 - 14) | 16 | (10 - 25) | 43 | (26 - 73) |
Louisiana | 50 | (34 - 74) | 9 | (6 - 13) | 26 | (17 - 41) | 14 | (7 - 29) |
Maine | 16 | (8 - 31) | 2 | (1 - 4) | 5 | (4 - 7) | 8 | (2 - 28) |
Maryland | 44 | (26 - 74) | 10 | (4 - 22) | 14 | (10 - 20) | 20 | (7 - 60) |
Massachusetts | 101 | (63 - 163) | 17 | (11 - 26) | 48 | (29 - 80) | 36 | (11 - 113) |
Michigan | 103 | (85 - 125) | 29 | (24 - 34) | 40 | (32 - 49) | 35 | (22 - 56) |
Minnesota | 65 | (49 - 85) | 15 | (9 - 25) | 29 | (20 - 40) | 21 | (10 - 45) |
Mississippi | 28 | (17 - 48) | 7 | (3 - 13) | 10 | (6 - 17) | 11 | (3 - 36) |
Missouri | 85 | (60 - 121) | 12 | (8 - 17) | 31 | (20 - 47) | 42 | (25 - 71) |
Montana | 18 | (15 - 23) | 4 | (3 - 5) | 6 | (4 - 7) | 9 | (6 - 13) |
Nebraska | 24 | (16 - 37) | 4 | (3 - 7) | 9 | (7 - 11) | 11 | (6 - 23) |
Nevada | 48 | (34 - 68) | 5 | (3 - 8) | 11 | (7 - 18) | 33 | (20 - 53) |
New Hampshire | 11 | (8 - 15) | 3 | (2 - 5) | 7 | (5 - 11) | 0 | (0 - 1) |
New Jersey | 36 | (22 - 57) | 15 | (8 - 27) | 18 | (11 - 29) | 3 | (0 - 27) |
New Mexico | 25 | (14 - 44) | 3 | (2 - 5) | 9 | (6 - 13) | 13 | (5 - 34) |
New York | 111 | (80 - 152) | 21 | (16 - 27) | 62 | (47 - 81) | 28 | (12 - 65) |
North Carolina | 30 | (17 - 53) | 12 | (5 - 28) | 12 | (6 - 24) | 5 | (1 - 47) |
North Dakota | 8 | (5 - 13) | 2 | (1 - 3) | 3 | (2 - 5) | 3 | (1 - 7) |
Ohio | 93 | (76 - 114) | 21 | (16 - 27) | 42 | (33 - 54) | 30 | (18 - 52) |
Oklahoma | 51 | (34 - 75) | 10 | (5 - 18) | 22 | (16 - 31) | 19 | (10 - 33) |
Oregon | 55 | (38 - 80) | 5 | (2 - 11) | 18 | (13 - 25) | 32 | (17 - 59) |
Pennsylvania | 91 | (73 - 114) | 21 | (16 - 28) | 45 | (35 - 57) | 26 | (14 - 48) |
Rhode Island | 16 | (10 - 25) | 3 | (2 - 4) | 10 | (7 - 15) | 3 | (1 - 11) |
South Carolina | 53 | (37 - 76) | 8 | (5 - 13) | 26 | (16 - 42) | 19 | (8 - 41) |
South Dakota | 11 | (9 - 14) | 3 | (2 - 4) | 4 | (3 - 6) | 4 | (3 - 7) |
Tennessee | 40 | (30 - 53) | 8 | (4 - 15) | 20 | (12 - 31) | 12 | (4 - 33) |
Texas | 240 | (199 - 288) | 48 | (37 - 61) | 91 | (69 - 120) | 101 | (71 - 143) |
Utah | 28 | (21 - 38) | 4 | (2 - 7) | 11 | (6 - 18) | 14 | (7 - 26) |
Vermont | 8 | (6 - 11) | 1 | (1 - 2) | 5 | (4 - 7) | 1 | (1 - 4) |
Virginia | 46 | (31 - 68) | 13 | (7 - 23) | 28 | (16 - 49) | 5 | (1 - 23) |
Washington | 96 | (59 - 155) | 16 | (9 - 26) | 30 | (19 - 48) | 50 | (24 - 103) |
West Virginia | 19 | (10 - 35) | 3 | (2 - 5) | 10 | (6 - 15) | 6 | (2 - 21) |
Wisconsin | 43 | (31 - 58) | 16 | (11 - 24) | 20 | (13 - 29) | 7 | (1 - 34) |
Wyoming | 9 | (7 - 11) | 1 | (1 - 2) | 4 | (4 - 5) | 3 | (2 - 6) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 1.2 | (1.2 - 1.3) | 2.3 | (2.1 - 2.5) | 3.6 | (3.4 - 3.9) | 0.7 | (0.6 - 0.8) |
Alabama | 1.5 | (1.1 - 2.0) | 2.7 | (1.9 - 3.7) | 4.6 | (3.1 - 6.9) | 0.8 | (0.5 - 1.3) |
Alaska | 1.2 | (0.8 - 1.7) | 2.0 | (1.2 - 3.3) | 3.9 | (2.4 - 6.2) | 0.5 | (0.2 - 1.2) |
Arizona | 1.7 | (1.2 - 2.3) | 2.9 | (1.9 - 4.4) | 3.6 | (2.0 - 6.6) | 1.1 | (0.7 - 1.8) |
Arkansas | 1.8 | (1.3 - 2.5) | 3.2 | (1.9 - 5.5) | 6.5 | (4.5 - 9.2) | 0.8 | (0.4 - 1.4) |
California | 1.6 | (1.3 - 2.0) | 1.9 | (1.4 - 2.5) | 3.4 | (2.7 - 4.2) | 1.2 | (0.9 - 1.7) |
Colorado | 1.4 | (0.8 - 2.4) | 3.1 | (2.1 - 4.3) | 4.2 | (2.9 - 6.0) | 0.6 | (0.2 - 2.6) |
Connecticut | 0.7 | (0.5 - 0.9) | 1.8 | (1.2 - 2.9) | 3.9 | (2.6 - 5.8) | 0.1 | (0.0 - 0.6) |
Delaware | 1.4 | (1.0 - 1.9) | 2.4 | (1.6 - 3.6) | 5.4 | (3.6 - 8.2) | 0.5 | (0.2 - 1.2) |
District of Columbia | 1.5 | (0.9 - 2.5) | 1.2 | (0.7 - 2.2) | 4.9 | (3.0 - 7.8) | 0.9 | (0.4 - 2.0) |
Florida | 0.7 | (0.5 - 0.9) | 1.9 | (1.4 - 2.6) | 2.5 | (2.1 - 3.0) | 0.3 | (0.2 - 0.6) |
Georgia | 1.1 | (0.7 - 1.8) | 2.4 | (1.6 - 3.6) | 2.4 | (1.2 - 4.7) | 0.7 | (0.4 - 1.3) |
Hawaii | 1.5 | (1.1 - 2.1) | 2.5 | (1.7 - 3.5) | 3.8 | (2.1 - 6.6) | 1.1 | (0.7 - 1.7) |
Idaho | 1.8 | (1.3 - 2.4) | 3.2 | (1.9 - 5.3) | 3.9 | (3.0 - 4.9) | 1.1 | (0.6 - 2.2) |
Illinois | 0.8 | (0.6 - 1.0) | 1.9 | (1.4 - 2.5) | 2.4 | (1.8 - 3.1) | 0.3 | (0.2 - 0.6) |
Indiana | 1.7 | (1.1 - 2.4) | 2.4 | (1.6 - 3.6) | 3.8 | (2.3 - 6.1) | 1.2 | (0.7 - 2.0) |
Iowa | 1.7 | (1.2 - 2.5) | 2.9 | (1.7 - 5.1) | 4.3 | (3.0 - 6.2) | 1.0 | (0.5 - 2.0) |
Kansas | 1.7 | (1.3 - 2.1) | 2.2 | (1.4 - 3.4) | 3.6 | (2.0 - 6.4) | 1.2 | (0.7 - 2.0) |
Kentucky | 2.0 | (1.4 - 3.0) | 2.9 | (2.0 - 4.2) | 3.5 | (2.2 - 5.4) | 1.7 | (1.0 - 2.8) |
Louisiana | 1.4 | (0.9 - 2.0) | 2.2 | (1.5 - 3.3) | 4.9 | (3.1 - 7.6) | 0.5 | (0.3 - 1.1) |
Maine | 1.4 | (0.7 - 2.7) | 2.2 | (1.4 - 3.5) | 4.0 | (3.0 - 5.3) | 0.9 | (0.3 - 3.3) |
Maryland | 1.0 | (0.6 - 1.6) | 2.1 | (0.9 - 4.6) | 2.5 | (1.8 - 3.6) | 0.6 | (0.2 - 1.7) |
Massachusetts | 1.9 | (1.2 - 3.0) | 3.4 | (2.2 - 5.0) | 7.2 | (4.2 - 11.8) | 0.9 | (0.3 - 2.7) |
Michigan | 1.2 | (1.0 - 1.5) | 3.2 | (2.6 - 3.8) | 3.6 | (2.9 - 4.4) | 0.6 | (0.3 - 0.9) |
Minnesota | 1.5 | (1.2 - 2.0) | 3.4 | (2.0 - 5.7) | 4.9 | (3.5 - 7.0) | 0.7 | (0.3 - 1.4) |
Mississippi | 1.2 | (0.7 - 2.1) | 2.6 | (1.3 - 5.2) | 3.0 | (1.8 - 4.9) | 0.7 | (0.2 - 2.1) |
Missouri | 1.8 | (1.3 - 2.6) | 2.4 | (1.7 - 3.4) | 4.9 | (3.2 - 7.5) | 1.2 | (0.7 - 2.0) |
Montana | 2.4 | (1.9 - 3.0) | 4.8 | (3.7 - 6.2) | 5.5 | (4.2 - 7.1) | 1.5 | (1.1 - 2.2) |
Nebraska | 1.7 | (1.1 - 2.6) | 2.9 | (1.8 - 4.6) | 4.3 | (3.3 - 5.5) | 1.1 | (0.5 - 2.1) |
Nevada | 2.7 | (1.9 - 3.8) | 2.6 | (1.6 - 4.1) | 4.9 | (2.9 - 8.1) | 2.3 | (1.4 - 3.8) |
New Hampshire | 1.0 | (0.7 - 1.4) | 2.7 | (1.6 - 4.6) | 5.7 | (3.8 - 8.3) | 0.0 | (0.0 - 0.2) |
New Jersey | 0.5 | (0.3 - 0.8) | 2.0 | (1.1 - 3.7) | 2.2 | (1.3 - 3.6) | 0.1 | (0.0 - 0.5) |
New Mexico | 1.6 | (0.9 - 2.9) | 1.7 | (1.0 - 3.0) | 4.2 | (2.9 - 6.0) | 1.1 | (0.4 - 3.0) |
New York | 0.7 | (0.5 - 1.0) | 1.3 | (1.0 - 1.7) | 3.0 | (2.3 - 4.0) | 0.2 | (0.1 - 0.5) |
North Carolina | 0.4 | (0.2 - 0.8) | 1.8 | (0.8 - 4.0) | 1.4 | (0.7 - 2.7) | 0.1 | (0.0 - 0.9) |
North Dakota | 1.6 | (1.0 - 2.4) | 3.5 | (2.3 - 5.4) | 3.8 | (2.3 - 6.3) | 0.8 | (0.4 - 1.8) |
Ohio | 1.0 | (0.8 - 1.2) | 2.1 | (1.6 - 2.7) | 3.4 | (2.7 - 4.3) | 0.4 | (0.2 - 0.7) |
Oklahoma | 1.8 | (1.2 - 2.6) | 3.3 | (1.8 - 5.9) | 5.4 | (3.9 - 7.5) | 0.9 | (0.5 - 1.6) |
Oregon | 1.9 | (1.3 - 2.7) | 1.8 | (0.8 - 3.8) | 4.6 | (3.3 - 6.4) | 1.4 | (0.8 - 2.6) |
Pennsylvania | 0.9 | (0.7 - 1.1) | 2.0 | (1.5 - 2.7) | 3.4 | (2.7 - 4.4) | 0.3 | (0.2 - 0.6) |
Rhode Island | 1.8 | (1.1 - 2.8) | 3.1 | (2.0 - 4.9) | 8.1 | (5.6 - 11.6) | 0.5 | (0.1 - 1.5) |
South Carolina | 1.6 | (1.1 - 2.2) | 2.4 | (1.5 - 3.8) | 5.7 | (3.5 - 9.2) | 0.7 | (0.3 - 1.6) |
South Dakota | 1.8 | (1.4 - 2.3) | 4.0 | (3.0 - 5.4) | 4.5 | (3.0 - 6.7) | 0.9 | (0.6 - 1.5) |
Tennessee | 0.8 | (0.6 - 1.1) | 1.8 | (0.9 - 3.2) | 3.1 | (2.0 - 4.9) | 0.3 | (0.1 - 0.9) |
Texas | 1.4 | (1.1 - 1.6) | 2.4 | (1.8 - 3.0) | 3.6 | (2.7 - 4.7) | 0.8 | (0.5 - 1.1) |
Utah | 1.5 | (1.1 - 2.1) | 1.6 | (0.8 - 3.0) | 3.0 | (1.8 - 5.0) | 1.1 | (0.6 - 2.1) |
Vermont | 1.5 | (1.1 - 2.1) | 2.8 | (1.9 - 4.0) | 7.4 | (5.8 - 9.3) | 0.4 | (0.1 - 1.0) |
Virginia | 0.8 | (0.5 - 1.1) | 2.2 | (1.2 - 3.8) | 3.8 | (2.2 - 6.5) | 0.1 | (0.0 - 0.5) |
Washington | 1.9 | (1.2 - 3.1) | 3.0 | (1.8 - 4.9) | 4.6 | (2.9 - 7.2) | 1.3 | (0.6 - 2.7) |
West Virginia | 1.2 | (0.7 - 2.3) | 2.4 | (1.5 - 3.7) | 4.9 | (3.0 - 7.9) | 0.5 | (0.2 - 1.8) |
Wisconsin | 0.9 | (0.7 - 1.3) | 3.4 | (2.3 - 4.9) | 3.1 | (2.1 - 4.6) | 0.2 | (0.0 - 1.0) |
Wyoming | 2.1 | (1.6 - 2.7) | 2.4 | (1.5 - 3.7) | 7.1 | (5.9 - 8.6) | 1.1 | (0.6 - 1.9) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 1,432 | (1,310 - 1,564) | 187 | (165 - 212) | 516 | (469 - 566) | 729 | (624 - 851) |
Alabama | 28 | (16 - 50) | 3 | (1 - 5) | 14 | (8 - 23) | 12 | (4 - 36) |
Alaska | 3 | (2 - 5) | 1 | (0 - 2) | 2 | (1 - 3) | 1 | (0 - 3) |
Arizona | 58 | (38 - 86) | 6 | (3 - 14) | 14 | (7 - 26) | 38 | (23 - 62) |
Arkansas | 28 | (20 - 38) | 3 | (2 - 7) | 14 | (10 - 20) | 10 | (5 - 21) |
California | 338 | (270 - 422) | 30 | (22 - 41) | 104 | (80 - 134) | 204 | (143 - 289) |
Colorado | 41 | (19 - 84) | 5 | (3 - 11) | 17 | (10 - 28) | 18 | (4 - 73) |
Connecticut | 1 | (0 - 6) | 0 | (0 - 2) | 1 | (0 - 7) | * | (* - *) |
Delaware | 2 | (1 - 4) | 1 | (0 - 1) | 1 | (0 - 2) | 0 | (0 - 3) |
District of Columbia | 2 | (1 - 7) | 0 | (0 - 0) | 1 | (0 - 2) | 1 | (0 - 6) |
Florida | 52 | (32 - 83) | 7 | (4 - 13) | 12 | (8 - 17) | 33 | (17 - 61) |
Georgia | 33 | (16 - 67) | 7 | (2 - 19) | 9 | (3 - 24) | 17 | (7 - 41) |
Hawaii | 11 | (8 - 16) | 1 | (1 - 2) | 3 | (1 - 6) | 7 | (4 - 12) |
Idaho | 13 | (10 - 18) | 2 | (1 - 3) | 4 | (3 - 7) | 7 | (4 - 12) |
Illinois | 23 | (14 - 37) | 5 | (3 - 8) | 9 | (6 - 12) | 10 | (3 - 28) |
Indiana | 40 | (27 - 60) | 5 | (3 - 10) | 13 | (7 - 22) | 22 | (12 - 39) |
Iowa | 28 | (18 - 43) | 3 | (1 - 5) | 8 | (5 - 15) | 17 | (8 - 35) |
Kansas | 19 | (12 - 32) | 3 | (2 - 6) | 5 | (3 - 11) | 10 | (5 - 23) |
Kentucky | 32 | (19 - 55) | 2 | (1 - 7) | 7 | (4 - 12) | 23 | (11 - 48) |
Louisiana | 17 | (11 - 26) | 4 | (1 - 12) | 9 | (4 - 18) | 4 | (1 - 18) |
Maine | 2 | (1 - 2) | 0 | (0 - 1) | 1 | (1 - 2) | * | (* - *) |
Maryland | 7 | (4 - 14) | 1 | (0 - 5) | 4 | (2 - 9) | 2 | (0 - 17) |
Massachusetts | 9 | (4 - 17) | 3 | (1 - 7) | 6 | (2 - 16) | * | (* - *) |
Michigan | 33 | (22 - 51) | 5 | (3 - 8) | 12 | (9 - 17) | 16 | (7 - 35) |
Minnesota | 41 | (28 - 60) | 5 | (3 - 9) | 22 | (14 - 36) | 14 | (4 - 45) |
Mississippi | 21 | (11 - 39) | 3 | (2 - 7) | 8 | (5 - 15) | 9 | (3 - 35) |
Missouri | 44 | (28 - 68) | 2 | (1 - 4) | 17 | (10 - 29) | 25 | (12 - 52) |
Montana | 11 | (7 - 17) | 2 | (1 - 3) | 4 | (2 - 6) | 6 | (3 - 11) |
Nebraska | 18 | (11 - 30) | 2 | (1 - 5) | 6 | (4 - 9) | 10 | (5 - 22) |
Nevada | 40 | (27 - 61) | 3 | (2 - 6) | 10 | (6 - 16) | 28 | (15 - 50) |
New Hampshire | 2 | (1 - 2) | 1 | (0 - 1) | 1 | (0 - 2) | 0 | (0 - 1) |
New Jersey | 9 | (4 - 20) | 3 | (1 - 6) | 7 | (3 - 16) | * | (* - *) |
New Mexico | 20 | (10 - 40) | 1 | (1 - 3) | 7 | (5 - 9) | 12 | (4 - 36) |
New York | 18 | (9 - 39) | 3 | (1 - 6) | 5 | (3 - 10) | 10 | (3 - 35) |
North Carolina | 8 | (4 - 18) | 4 | (1 - 13) | 4 | (1 - 10) | * | (* - *) |
North Dakota | 6 | (4 - 10) | 1 | (1 - 2) | 2 | (1 - 4) | 3 | (1 - 7) |
Ohio | 25 | (17 - 35) | 6 | (3 - 10) | 14 | (10 - 20) | 5 | (2 - 17) |
Oklahoma | 27 | (17 - 42) | 3 | (1 - 8) | 15 | (9 - 25) | 9 | (3 - 27) |
Oregon | 31 | (22 - 45) | 3 | (1 - 7) | 10 | (5 - 17) | 19 | (11 - 34) |
Pennsylvania | 14 | (8 - 23) | 3 | (1 - 6) | 7 | (4 - 12) | 4 | (1 - 16) |
Rhode Island | 2 | (1 - 6) | 1 | (0 - 2) | 1 | (0 - 3) | 1 | (0 - 7) |
South Carolina | 20 | (10 - 38) | 3 | (1 - 7) | 9 | (6 - 12) | 8 | (2 - 32) |
South Dakota | 8 | (6 - 10) | 2 | (1 - 3) | 3 | (2 - 4) | 4 | (2 - 7) |
Tennessee | 12 | (7 - 23) | 2 | (1 - 6) | 5 | (2 - 10) | 5 | (1 - 30) |
Texas | 115 | (89 - 150) | 16 | (10 - 25) | 44 | (32 - 61) | 55 | (34 - 92) |
Utah | 18 | (11 - 29) | 1 | (0 - 3) | 7 | (4 - 13) | 9 | (4 - 24) |
Vermont | 1 | (0 - 3) | 0 | (0 - 1) | 0 | (0 - 1) | 1 | (0 - 5) |
Virginia | 15 | (9 - 27) | 8 | (4 - 18) | 7 | (3 - 15) | * | (* - *) |
Washington | 58 | (32 - 104) | 8 | (4 - 16) | 20 | (11 - 37) | 30 | (12 - 70) |
West Virginia | 7 | (4 - 11) | 1 | (1 - 3) | 4 | (2 - 8) | 1 | (0 - 7) |
Wisconsin | 14 | (6 - 33) | 2 | (1 - 4) | 6 | (2 - 14) | 7 | (1 - 34) |
Wyoming | 6 | (4 - 9) | 1 | (0 - 1) | 3 | (2 - 4) | 2 | (1 - 5) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 0.6 | (0.6 - 0.7) | 0.7 | (0.7 - 0.8) | 1.6 | (1.5 - 1.8) | 0.4 | (0.3 - 0.5) |
Alabama | 0.8 | (0.4 - 1.4) | 0.7 | (0.3 - 1.4) | 2.8 | (1.7 - 4.6) | 0.4 | (0.1 - 1.3) |
Alaska | 0.6 | (0.4 - 1.0) | 1.0 | (0.4 - 2.2) | 2.5 | (1.4 - 4.5) | 0.2 | (0.1 - 0.9) |
Arizona | 1.3 | (0.9 - 1.9) | 1.3 | (0.6 - 2.8) | 2.2 | (1.2 - 4.2) | 1.1 | (0.7 - 1.8) |
Arkansas | 1.2 | (0.9 - 1.7) | 1.4 | (0.7 - 2.8) | 4.6 | (3.2 - 6.5) | 0.6 | (0.3 - 1.2) |
California | 1.2 | (0.9 - 1.5) | 1.0 | (0.7 - 1.3) | 2.6 | (2.0 - 3.4) | 0.9 | (0.7 - 1.3) |
Colorado | 1.1 | (0.5 - 2.3) | 1.4 | (0.7 - 2.7) | 3.4 | (2.0 - 5.7) | 0.6 | (0.2 - 2.6) |
Connecticut | 0.0 | (0.0 - 0.2) | 0.1 | (0.0 - 0.7) | 0.3 | (0.0 - 2.2) | * | (* - *) |
Delaware | 0.3 | (0.1 - 0.5) | 0.8 | (0.5 - 1.5) | 1.0 | (0.4 - 2.4) | 0.1 | (0.0 - 0.5) |
District of Columbia | 0.4 | (0.1 - 1.4) | 0.1 | (0.0 - 0.9) | 0.8 | (0.3 - 2.2) | 0.4 | (0.1 - 1.7) |
Florida | 0.4 | (0.2 - 0.6) | 0.5 | (0.3 - 1.0) | 0.7 | (0.5 - 1.1) | 0.3 | (0.2 - 0.5) |
Georgia | 0.5 | (0.2 - 1.0) | 0.9 | (0.3 - 2.5) | 0.9 | (0.3 - 2.5) | 0.3 | (0.1 - 0.8) |
Hawaii | 1.1 | (0.8 - 1.6) | 1.2 | (0.7 - 2.0) | 2.3 | (1.1 - 5.0) | 0.9 | (0.5 - 1.5) |
Idaho | 1.2 | (0.9 - 1.6) | 1.4 | (0.8 - 2.6) | 2.7 | (1.7 - 4.0) | 0.8 | (0.5 - 1.5) |
Illinois | 0.2 | (0.1 - 0.4) | 0.4 | (0.3 - 0.7) | 0.6 | (0.4 - 0.9) | 0.1 | (0.0 - 0.4) |
Indiana | 0.8 | (0.5 - 1.2) | 1.0 | (0.5 - 1.9) | 1.8 | (1.0 - 3.1) | 0.6 | (0.3 - 1.0) |
Iowa | 1.1 | (0.7 - 1.8) | 1.0 | (0.5 - 2.2) | 2.4 | (1.3 - 4.3) | 0.9 | (0.4 - 1.9) |
Kansas | 0.9 | (0.5 - 1.5) | 1.4 | (0.7 - 2.7) | 1.7 | (0.8 - 3.4) | 0.6 | (0.3 - 1.4) |
Kentucky | 0.9 | (0.5 - 1.6) | 0.7 | (0.3 - 2.0) | 1.5 | (0.8 - 2.6) | 0.9 | (0.4 - 1.8) |
Louisiana | 0.5 | (0.3 - 0.7) | 1.0 | (0.3 - 3.1) | 1.7 | (0.8 - 3.3) | 0.1 | (0.0 - 0.7) |
Maine | 0.1 | (0.1 - 0.2) | 0.4 | (0.1 - 1.3) | 0.8 | (0.4 - 1.7) | * | (* - *) |
Maryland | 0.2 | (0.1 - 0.3) | 0.3 | (0.1 - 1.1) | 0.8 | (0.4 - 1.6) | 0.1 | (0.0 - 0.5) |
Massachusetts | 0.2 | (0.1 - 0.3) | 0.6 | (0.3 - 1.4) | 0.8 | (0.3 - 2.4) | * | (* - *) |
Michigan | 0.4 | (0.3 - 0.6) | 0.6 | (0.3 - 0.9) | 1.1 | (0.8 - 1.6) | 0.3 | (0.1 - 0.6) |
Minnesota | 1.0 | (0.7 - 1.4) | 1.1 | (0.6 - 2.1) | 3.9 | (2.4 - 6.2) | 0.4 | (0.1 - 1.4) |
Mississippi | 0.9 | (0.5 - 1.7) | 1.3 | (0.6 - 2.7) | 2.4 | (1.4 - 4.2) | 0.6 | (0.1 - 2.1) |
Missouri | 0.9 | (0.6 - 1.4) | 0.4 | (0.2 - 0.9) | 2.7 | (1.6 - 4.6) | 0.7 | (0.3 - 1.5) |
Montana | 1.5 | (1.0 - 2.2) | 2.3 | (1.4 - 3.6) | 3.4 | (2.2 - 5.2) | 1.0 | (0.5 - 1.9) |
Nebraska | 1.3 | (0.8 - 2.1) | 1.3 | (0.5 - 3.3) | 2.9 | (2.0 - 4.2) | 1.0 | (0.5 - 2.0) |
Nevada | 2.2 | (1.5 - 3.3) | 1.6 | (0.8 - 3.2) | 4.3 | (2.5 - 7.3) | 2.0 | (1.1 - 3.6) |
New Hampshire | 0.2 | (0.1 - 0.2) | 0.6 | (0.3 - 1.1) | 0.6 | (0.2 - 1.6) | 0.0 | (0.0 - 0.2) |
New Jersey | 0.1 | (0.1 - 0.3) | 0.4 | (0.2 - 0.8) | 0.8 | (0.3 - 2.0) | * | (* - *) |
New Mexico | 1.3 | (0.7 - 2.6) | 0.8 | (0.4 - 1.6) | 3.1 | (2.1 - 4.4) | 1.1 | (0.4 - 3.1) |
New York | 0.1 | (0.1 - 0.2) | 0.2 | (0.1 - 0.4) | 0.3 | (0.1 - 0.5) | 0.1 | (0.0 - 0.3) |
North Carolina | 0.1 | (0.1 - 0.3) | 0.6 | (0.2 - 1.9) | 0.4 | (0.2 - 1.2) | * | (* - *) |
North Dakota | 1.2 | (0.7 - 2.0) | 1.7 | (1.0 - 2.9) | 3.0 | (1.7 - 5.2) | 0.8 | (0.3 - 1.8) |
Ohio | 0.3 | (0.2 - 0.4) | 0.6 | (0.3 - 1.0) | 1.1 | (0.8 - 1.6) | 0.1 | (0.0 - 0.2) |
Oklahoma | 0.9 | (0.6 - 1.5) | 1.0 | (0.3 - 2.8) | 3.6 | (2.1 - 6.0) | 0.4 | (0.1 - 1.3) |
Oregon | 1.1 | (0.7 - 1.5) | 0.9 | (0.3 - 2.4) | 2.5 | (1.4 - 4.5) | 0.8 | (0.5 - 1.5) |
Pennsylvania | 0.1 | (0.1 - 0.2) | 0.3 | (0.1 - 0.6) | 0.5 | (0.3 - 0.9) | 0.0 | (0.0 - 0.2) |
Rhode Island | 0.3 | (0.1 - 0.7) | 0.6 | (0.2 - 2.3) | 0.8 | (0.3 - 2.1) | 0.1 | (0.0 - 1.1) |
South Carolina | 0.6 | (0.3 - 1.1) | 0.8 | (0.3 - 2.0) | 1.9 | (1.4 - 2.5) | 0.3 | (0.1 - 1.2) |
South Dakota | 1.3 | (1.0 - 1.7) | 2.4 | (1.4 - 4.1) | 3.0 | (2.0 - 4.6) | 0.8 | (0.4 - 1.5) |
Tennessee | 0.3 | (0.1 - 0.5) | 0.5 | (0.2 - 1.3) | 0.8 | (0.4 - 1.6) | 0.1 | (0.0 - 0.8) |
Texas | 0.7 | (0.5 - 0.9) | 0.8 | (0.5 - 1.2) | 1.7 | (1.3 - 2.4) | 0.4 | (0.3 - 0.7) |
Utah | 1.0 | (0.6 - 1.6) | 0.4 | (0.1 - 1.2) | 2.1 | (1.2 - 3.5) | 0.8 | (0.3 - 1.9) |
Vermont | 0.2 | (0.1 - 0.6) | 0.4 | (0.1 - 1.3) | 0.4 | (0.1 - 1.4) | 0.1 | (0.0 - 1.2) |
Virginia | 0.3 | (0.1 - 0.5) | 1.3 | (0.6 - 3.0) | 1.0 | (0.4 - 2.0) | * | (* - *) |
Washington | 1.1 | (0.6 - 2.1) | 1.6 | (0.8 - 3.0) | 3.0 | (1.7 - 5.5) | 0.8 | (0.3 - 1.8) |
West Virginia | 0.4 | (0.2 - 0.7) | 0.9 | (0.4 - 2.0) | 2.3 | (1.2 - 4.2) | 0.1 | (0.0 - 0.6) |
Wisconsin | 0.3 | (0.1 - 0.7) | 0.4 | (0.2 - 0.8) | 0.9 | (0.4 - 2.3) | 0.2 | (0.0 - 1.0) |
Wyoming | 1.5 | (1.0 - 2.2) | 1.6 | (0.8 - 2.9) | 5.3 | (4.0 - 7.0) | 0.8 | (0.4 - 1.5) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 850 | (741 - 975) | 134 | (115 - 157) | 160 | (140 - 184) | 555 | (453 - 681) |
Alabama | 17 | (8 - 39) | 1 | (0 - 5) | 4 | (2 - 10) | 12 | (3 - 39) |
Alaska | 2 | (1 - 2) | 1 | (0 - 2) | 0 | (0 - 1) | 1 | (0 - 1) |
Arizona | 10 | (5 - 22) | 2 | (1 - 9) | 3 | (2 - 8) | 5 | (1 - 22) |
Arkansas | 11 | (5 - 25) | 2 | (1 - 4) | 5 | (3 - 9) | 4 | (0 - 32) |
California | 90 | (59 - 138) | 17 | (9 - 32) | 12 | (6 - 24) | 61 | (34 - 109) |
Colorado | 12 | (4 - 35) | 1 | (0 - 5) | 4 | (1 - 10) | 7 | (1 - 40) |
Connecticut | 19 | (6 - 59) | 2 | (0 - 5) | 3 | (1 - 7) | 14 | (3 - 66) |
Delaware | 1 | (1 - 2) | 0 | (0 - 1) | 1 | (0 - 1) | * | (* - *) |
District of Columbia | 3 | (2 - 7) | 0 | (0 - 1) | 1 | (0 - 2) | 3 | (1 - 6) |
Florida | 58 | (41 - 82) | 9 | (5 - 16) | 10 | (7 - 16) | 39 | (23 - 66) |
Georgia | 21 | (8 - 60) | 6 | (2 - 15) | 2 | (0 - 10) | 14 | (4 - 49) |
Hawaii | 1 | (0 - 4) | 0 | (0 - 1) | 0 | (0 - 1) | 1 | (0 - 4) |
Idaho | 8 | (5 - 12) | 1 | (0 - 2) | 1 | (1 - 3) | 6 | (3 - 10) |
Illinois | 18 | (11 - 32) | 7 | (4 - 12) | 3 | (2 - 6) | 9 | (3 - 25) |
Indiana | 20 | (8 - 50) | 1 | (0 - 5) | 4 | (2 - 9) | 16 | (5 - 51) |
Iowa | 14 | (6 - 32) | 1 | (0 - 3) | 0 | (0 - 3) | 12 | (5 - 30) |
Kansas | 7 | (2 - 24) | 1 | (0 - 4) | 2 | (1 - 7) | 4 | (0 - 34) |
Kentucky | 20 | (10 - 39) | 3 | (2 - 5) | 1 | (0 - 6) | 16 | (7 - 34) |
Louisiana | 16 | (8 - 31) | 2 | (0 - 6) | 3 | (1 - 5) | 11 | (4 - 30) |
Maine | 6 | (1 - 28) | 0 | (0 - 1) | 1 | (0 - 2) | 5 | (1 - 33) |
Maryland | 24 | (6 - 92) | 3 | (1 - 7) | 3 | (1 - 9) | 18 | (3 - 108) |
Massachusetts | 52 | (17 - 154) | 5 | (1 - 15) | 1 | (0 - 5) | 46 | (13 - 155) |
Michigan | 25 | (16 - 40) | 7 | (4 - 11) | 7 | (4 - 10) | 12 | (5 - 28) |
Minnesota | 15 | (5 - 44) | 2 | (0 - 11) | 1 | (0 - 9) | 12 | (4 - 37) |
Mississippi | 10 | (7 - 14) | 1 | (0 - 4) | 2 | (1 - 4) | 7 | (5 - 11) |
Missouri | 29 | (13 - 65) | 3 | (1 - 7) | 5 | (2 - 12) | 21 | (7 - 62) |
Montana | 2 | (1 - 3) | 0 | (0 - 1) | 1 | (0 - 2) | 0 | (0 - 4) |
Nebraska | 1 | (0 - 4) | 1 | (0 - 2) | 1 | (0 - 4) | * | (* - *) |
Nevada | 6 | (3 - 11) | 2 | (1 - 4) | 2 | (1 - 4) | 2 | (0 - 8) |
New Hampshire | 5 | (2 - 14) | 0 | (0 - 1) | 1 | (1 - 3) | 4 | (1 - 15) |
New Jersey | 21 | (11 - 42) | 3 | (1 - 9) | 3 | (1 - 10) | 15 | (7 - 35) |
New Mexico | 7 | (3 - 17) | 1 | (0 - 2) | 2 | (1 - 4) | 5 | (2 - 14) |
New York | 51 | (34 - 78) | 7 | (4 - 12) | 10 | (6 - 16) | 34 | (18 - 65) |
North Carolina | 24 | (9 - 60) | 4 | (1 - 10) | 3 | (1 - 13) | 17 | (5 - 65) |
North Dakota | 0 | (0 - 2) | 0 | (0 - 1) | * | (* - *) | * | (* - *) |
Ohio | 32 | (20 - 49) | 4 | (2 - 7) | 6 | (3 - 10) | 22 | (12 - 41) |
Oklahoma | 10 | (4 - 28) | 3 | (1 - 8) | 2 | (1 - 7) | 5 | (1 - 25) |
Oregon | 12 | (4 - 31) | 1 | (0 - 4) | 2 | (1 - 4) | 8 | (2 - 33) |
Pennsylvania | 23 | (16 - 34) | 5 | (3 - 8) | 9 | (6 - 14) | 9 | (4 - 25) |
Rhode Island | 6 | (2 - 18) | 0 | (0 - 1) | 1 | (1 - 2) | 5 | (1 - 20) |
South Carolina | 16 | (7 - 35) | 0 | (0 - 2) | 3 | (1 - 7) | 12 | (4 - 34) |
South Dakota | 1 | (0 - 1) | 0 | (0 - 1) | 0 | (0 - 1) | 0 | (0 - 1) |
Tennessee | 11 | (6 - 20) | 5 | (3 - 9) | 3 | (2 - 4) | 3 | (0 - 24) |
Texas | 41 | (26 - 64) | 12 | (8 - 17) | 12 | (7 - 20) | 18 | (7 - 42) |
Utah | 9 | (4 - 18) | 1 | (0 - 4) | 3 | (1 - 6) | 5 | (1 - 16) |
Vermont | 1 | (0 - 3) | 0 | (0 - 1) | 0 | (0 - 1) | 0 | (0 - 3) |
Virginia | 10 | (6 - 17) | 4 | (2 - 10) | 6 | (2 - 15) | * | (* - *) |
Washington | 36 | (16 - 82) | 1 | (0 - 6) | 3 | (1 - 6) | 32 | (13 - 82) |
West Virginia | 7 | (3 - 16) | 0 | (0 - 1) | 2 | (1 - 5) | 4 | (1 - 16) |
Wisconsin | 6 | (2 - 18) | 2 | (0 - 6) | 4 | (1 - 15) | * | (* - *) |
Wyoming | 2 | (1 - 3) | 0 | (0 - 1) | 1 | (0 - 2) | 1 | (1 - 2) |
60406
State | Total | AGE GROUP (Years) | ||||||
---|---|---|---|---|---|---|---|---|
12-17 | 18-25 | 26 or Older | ||||||
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
Total | 95% Confidence Interval |
|
*Low precision; no estimate reported. Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002, 2003, and 2004. |
||||||||
Total | 0.4 | (0.3 - 0.4) | 0.5 | (0.5 - 0.6) | 0.5 | (0.4 - 0.6) | 0.3 | (0.2 - 0.4) |
Alabama | 0.5 | (0.2 - 1.1) | 0.4 | (0.1 - 1.3) | 0.8 | (0.3 - 2.0) | 0.4 | (0.1 - 1.4) |
Alaska | 0.3 | (0.2 - 0.5) | 0.9 | (0.3 - 3.4) | 0.7 | (0.3 - 1.8) | 0.1 | (0.1 - 0.4) |
Arizona | 0.2 | (0.1 - 0.5) | 0.5 | (0.1 - 1.8) | 0.6 | (0.2 - 1.2) | 0.1 | (0.0 - 0.6) |
Arkansas | 0.5 | (0.2 - 1.1) | 1.0 | (0.5 - 1.7) | 1.8 | (1.0 - 3.0) | 0.2 | (0.0 - 1.9) |
California | 0.3 | (0.2 - 0.5) | 0.5 | (0.3 - 1.0) | 0.3 | (0.2 - 0.6) | 0.3 | (0.2 - 0.5) |
Colorado | 0.3 | (0.1 - 0.9) | 0.4 | (0.1 - 1.2) | 0.8 | (0.3 - 2.0) | 0.3 | (0.0 - 1.4) |
Connecticut | 0.6 | (0.2 - 2.1) | 0.5 | (0.2 - 1.6) | 0.9 | (0.4 - 2.2) | 0.6 | (0.1 - 2.9) |
Delaware | 0.1 | (0.1 - 0.3) | 0.5 | (0.2 - 1.7) | 0.7 | (0.3 - 1.6) | * | (* - *) |
District of Columbia | 0.7 | (0.3 - 1.4) | 0.3 | (0.1 - 1.8) | 0.8 | (0.2 - 2.6) | 0.7 | (0.3 - 1.7) |
Florida | 0.4 | (0.3 - 0.6) | 0.6 | (0.3 - 1.2) | 0.6 | (0.4 - 1.0) | 0.4 | (0.2 - 0.6) |
Georgia | 0.3 | (0.1 - 0.9) | 0.7 | (0.3 - 2.0) | 0.2 | (0.1 - 1.0) | 0.3 | (0.1 - 0.9) |
Hawaii | 0.1 | (0.0 - 0.4) | 0.2 | (0.0 - 0.8) | 0.0 | (0.0 - 0.4) | 0.1 | (0.0 - 0.6) |
Idaho | 0.7 | (0.5 - 1.1) | 0.6 | (0.2 - 1.7) | 0.8 | (0.4 - 1.7) | 0.7 | (0.4 - 1.3) |
Illinois | 0.2 | (0.1 - 0.3) | 0.6 | (0.4 - 1.1) | 0.2 | (0.1 - 0.4) | 0.1 | (0.0 - 0.3) |
Indiana | 0.4 | (0.2 - 1.0) | 0.1 | (0.0 - 0.9) | 0.6 | (0.3 - 1.3) | 0.4 | (0.1 - 1.3) |
Iowa | 0.6 | (0.2 - 1.3) | 0.5 | (0.2 - 1.2) | 0.1 | (0.0 - 1.0) | 0.7 | (0.3 - 1.6) |
Kansas | 0.3 | (0.1 - 1.1) | 0.4 | (0.1 - 1.8) | 0.6 | (0.2 - 2.1) | 0.2 | (0.0 - 2.1) |
Kentucky | 0.6 | (0.3 - 1.1) | 0.9 | (0.5 - 1.5) | 0.3 | (0.1 - 1.3) | 0.6 | (0.3 - 1.3) |
Louisiana | 0.4 | (0.2 - 0.9) | 0.4 | (0.1 - 1.4) | 0.5 | (0.3 - 1.0) | 0.4 | (0.2 - 1.1) |
Maine | 0.5 | (0.1 - 2.5) | 0.4 | (0.1 - 1.1) | 0.5 | (0.1 - 1.6) | 0.6 | (0.1 - 3.7) |
Maryland | 0.5 | (0.1 - 2.0) | 0.6 | (0.2 - 1.5) | 0.6 | (0.2 - 1.6) | 0.5 | (0.1 - 3.1) |
Massachusetts | 1.0 | (0.3 - 2.9) | 0.9 | (0.3 - 2.9) | 0.2 | (0.0 - 0.8) | 1.1 | (0.3 - 3.7) |
Michigan | 0.3 | (0.2 - 0.5) | 0.8 | (0.4 - 1.3) | 0.6 | (0.4 - 1.0) | 0.2 | (0.1 - 0.4) |
Minnesota | 0.4 | (0.1 - 1.1) | 0.4 | (0.1 - 2.4) | 0.2 | (0.0 - 1.5) | 0.4 | (0.1 - 1.2) |
Mississippi | 0.4 | (0.3 - 0.6) | 0.3 | (0.1 - 1.6) | 0.6 | (0.3 - 1.0) | 0.4 | (0.3 - 0.7) |
Missouri | 0.6 | (0.3 - 1.4) | 0.7 | (0.3 - 1.4) | 0.8 | (0.3 - 1.9) | 0.6 | (0.2 - 1.7) |
Montana | 0.2 | (0.1 - 0.5) | 0.2 | (0.1 - 0.9) | 0.9 | (0.4 - 1.8) | 0.1 | (0.0 - 0.7) |
Nebraska | 0.1 | (0.0 - 0.3) | 0.5 | (0.2 - 1.3) | 0.3 | (0.1 - 1.8) | * | (* - *) |
Nevada | 0.3 | (0.2 - 0.6) | 0.8 | (0.3 - 2.3) | 0.9 | (0.4 - 2.0) | 0.1 | (0.0 - 0.6) |
New Hampshire | 0.5 | (0.2 - 1.3) | 0.3 | (0.1 - 1.0) | 1.0 | (0.5 - 1.9) | 0.4 | (0.1 - 1.8) |
New Jersey | 0.3 | (0.2 - 0.6) | 0.4 | (0.1 - 1.3) | 0.4 | (0.1 - 1.2) | 0.3 | (0.1 - 0.6) |
New Mexico | 0.5 | (0.2 - 1.1) | 0.4 | (0.1 - 1.4) | 0.8 | (0.3 - 1.8) | 0.4 | (0.1 - 1.3) |
New York | 0.3 | (0.2 - 0.5) | 0.5 | (0.3 - 0.8) | 0.5 | (0.3 - 0.8) | 0.3 | (0.1 - 0.5) |
North Carolina | 0.3 | (0.1 - 0.9) | 0.5 | (0.2 - 1.4) | 0.3 | (0.1 - 1.4) | 0.3 | (0.1 - 1.2) |
North Dakota | 0.1 | (0.0 - 0.4) | 0.5 | (0.2 - 1.3) | * | (* - *) | * | (* - *) |
Ohio | 0.3 | (0.2 - 0.5) | 0.4 | (0.2 - 0.7) | 0.5 | (0.3 - 0.8) | 0.3 | (0.2 - 0.6) |
Oklahoma | 0.4 | (0.1 - 1.0) | 0.9 | (0.3 - 2.8) | 0.5 | (0.1 - 1.7) | 0.3 | (0.1 - 1.2) |
Oregon | 0.4 | (0.1 - 1.1) | 0.5 | (0.2 - 1.4) | 0.5 | (0.3 - 0.9) | 0.4 | (0.1 - 1.4) |
Pennsylvania | 0.2 | (0.2 - 0.3) | 0.5 | (0.3 - 0.8) | 0.7 | (0.4 - 1.0) | 0.1 | (0.0 - 0.3) |
Rhode Island | 0.7 | (0.2 - 2.0) | 0.2 | (0.0 - 1.1) | 1.1 | (0.7 - 1.7) | 0.7 | (0.1 - 2.9) |
South Carolina | 0.5 | (0.2 - 1.0) | 0.1 | (0.0 - 0.6) | 0.7 | (0.3 - 1.6) | 0.5 | (0.2 - 1.3) |
South Dakota | 0.1 | (0.1 - 0.2) | 0.6 | (0.2 - 1.8) | 0.3 | (0.1 - 1.1) | 0.0 | (0.0 - 0.1) |
Tennessee | 0.2 | (0.1 - 0.4) | 1.0 | (0.6 - 1.9) | 0.5 | (0.3 - 0.7) | 0.1 | (0.0 - 0.6) |
Texas | 0.2 | (0.1 - 0.4) | 0.6 | (0.4 - 0.8) | 0.5 | (0.3 - 0.8) | 0.1 | (0.1 - 0.3) |
Utah | 0.5 | (0.2 - 1.0) | 0.5 | (0.1 - 1.6) | 0.8 | (0.4 - 1.7) | 0.4 | (0.1 - 1.3) |
Vermont | 0.2 | (0.1 - 0.5) | 0.9 | (0.4 - 1.8) | 0.4 | (0.1 - 1.2) | 0.1 | (0.0 - 0.8) |
Virginia | 0.2 | (0.1 - 0.3) | 0.7 | (0.3 - 1.6) | 0.8 | (0.3 - 2.0) | * | (* - *) |
Washington | 0.7 | (0.3 - 1.6) | 0.2 | (0.0 - 1.1) | 0.4 | (0.2 - 1.0) | 0.8 | (0.3 - 2.1) |
West Virginia | 0.4 | (0.2 - 1.0) | 0.3 | (0.1 - 0.8) | 1.0 | (0.5 - 2.4) | 0.3 | (0.1 - 1.3) |
Wisconsin | 0.1 | (0.0 - 0.4) | 0.3 | (0.1 - 1.2) | 0.6 | (0.2 - 2.4) | * | (* - *) |
Wyoming | 0.5 | (0.3 - 0.8) | 0.8 | (0.3 - 2.2) | 1.2 | (0.5 - 2.9) | 0.3 | (0.2 - 0.7) |
![]() This page was last updated on June 03, 2008. |
* Adobe™ PDF and MS Office™ formatted files require software viewer programs to properly read them.
Click here to download these FREE programs now
Highlights | Topics | Data | Drugs | Pubs | Short Reports | Treatment | Help | OAS |